N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase

ABSTRACT

The present invention is directed to N-hydroxyamidino compounds which are modulators of indoleamine 2,3-dioxygenase (IDO), as well as pharmaceutical compositions thereof and methods of use thereof relating to the treatment of cancer and other diseases.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. Ser. No. 11/641,284, filed Dec.19, 2006, which claims the benefit of U.S. Ser. Nos. 60/751,854, filedDec. 20, 2005; 60/801,337, filed May 18, 2006; and 60/857,558, filedNov. 8, 2006, the disclosures of each of which are incorporated hereinby reference in their entireties.

FIELD OF THE INVENTION

The present invention is directed to modulators of indoleamine2,3-dioxygenase (IDO), as well as compositions and pharmaceuticalmethods thereof.

BACKGROUND OF THE INVENTION

Tryptophan (Trp) is an essential amino acid required for thebiosynthesis of proteins, niacin and the neurotransmitter5-hydroxytryptamine (serotonin). The enzyme indoleamine 2,3-dioxygenase(also known as INDO or IDO) catalyzes the first and rate limiting stepin the degradation of L-tryptophan to N-formyl-kynurenine. In humancells, a depletion of Trp resulting from IDO activity is a prominentgamma interferon (IFN-γ) inducible antimicrobial effector mechanism.IFN-γ stimulation induces activation of IDO, which leads to a depletionof Trp, thereby arresting the growth of Trp-dependent intracellularpathogens such as Toxoplasma gondii and Chlamydia trachomatis. IDOactivity also has an antiproliferative effect on many tumor cells, andIDO induction has been observed in vivo during rejection of allogeneictumors, indicating a possible role for this enzyme in the tumorrejection process (Daubener, et al, 1999, Adv. Exp. Med. Biol., 467:517-24; Taylor, et al., 1991, FASEB J., 5: 2516-22).

It has been observed that HeLa cells co-cultured with peripheral bloodlymphocytes (PBLs) acquire an immuno-inhibitory phenotype throughup-regulation of IDO activity. A reduction in PBL proliferation upontreatment with interleukin-2 (IL2) was believed to result from IDOreleased by the tumor cells in response to IFNG secretion by the PBLs.This effect was reversed by treatment with 1-methyl-tryptophan (1MT), aspecific IDO inhibitor. It was proposed that IDO activity in tumor cellsmay serve to impair antitumor responses (Logan, et al., 2002,Immunology, 105: 478-87).

Recently, an immunoregulatory role of Trp depletion has received muchattention. Several lines of evidence suggest that IDO is involved ininduction of immune tolerance. Studies of mammalian pregnancy, tumorresistance, chronic infections and autoimmune diseases have shown thatcells expressing IDO can suppress T-cell responses and promotetolerance. Accelerated Trp catabolism has been observed in diseases anddisorders associated with cellular immune activation, such as infection,malignancy, autoimmune diseases and AIDS, as well as during pregnancy.For example, increased levels of IFNs and elevated levels of urinary Trpmetabolites have been observed in autoimmune diseases; it has beenpostulated that systemic or local depletion of Trp occurring inautoimmune diseases may relate to the degeneration and wasting symptomsof these diseases. In support of this hypothesis, high levels of IDOwere observed in cells isolated from the synovia of arthritic joints.IFNs are also elevated in human immunodeficiency virus (HIV) patientsand increasing IFN levels are associated with a worsening prognosis.Thus, it was proposed that IDO is induced chronically by HIV infection,and is further increased by opportunistic infections, and that thechronic loss of Trp initiates mechanisms responsible for cachexia,dementia and diarrhea and possibly immunosuppression of AIDS patients(Brown, et al., 1991, Adv. Exp. Med. Biol., 294: 425-35). To this end,it has recently been shown that IDO inhibition can enhance the levels ofvirus-specific T cells and, concomitantly, reduce the number ofvirally-infected macrophages in a mouse model of HIV (Portula et al.,2005, Blood, 106:2382-90).

IDO is believed to play a role in the immunosuppressive processes thatprevent fetal rejection in utero. More than 40 years ago, it wasobserved that, during pregnancy, the genetically disparate mammalianconceptus survives in spite of what would be predicted by tissuetransplantation immunology (Medawar, 1953, Symp. Soc. Exp. Biol. 7:320-38). Anatomic separation of mother and fetus and antigenicimmaturity of the fetus cannot fully explain fetal allograft survival.Recent attention has focused on immunologic tolerance of the mother.Because IDO is expressed by human syncytiotrophoblast cells and systemictryptophan concentration falls during normal pregnancy, it washypothesized that IDO expression at the maternal-fetal interface isnecessary to prevent immunologic rejection of the fetal allografts. Totest this hypothesis, pregnant mice (carrying syngeneic or allogeneicfetuses) were exposed to 1MT, and a rapid, T cell-induced rejection ofall allogeneic concept was observed. Thus, by catabolizing tryptophan,the mammalian conceptus appears to suppresses T-cell activity anddefends itself against rejection, and blocking tryptophan catabolismduring murine pregnancy allows maternal T cells to provoke fetalallograft rejection (Munn, et al., 1998, Science 281: 1191-3).

Further evidence for a tumoral immune resistance mechanism based ontryptophan degradation by IDO comes from the observation that most humantumors constitutively express IDO, and that expression of IDO byimmunogenic mouse tumor cells prevents their rejection by preimmunizedmice. This effect is accompanied by a lack of accumulation of specific Tcells at the tumor site and can be partly reverted by systemic treatmentof mice with an inhibitor of IDO, in the absence of noticeable toxicity.Thus, it was suggested that the efficacy of therapeutic vaccination ofcancer patients might be improved by concomitant administration of anIDO inhibitor (Uyttenhove et al., 2003, Nature Med., 9: 1269-74). It hasalso been shown that the IDO inhibitor, 1-MT, can synergize withchemotherapeutic agents to reduce tumor growth in mice, suggesting thatIDO inhibition may also enhance the anti-tumor activity of conventionalcytotoxic therapies (Muller et al., 2005, Nature Med., 11:312-9).

One mechanism contributing to immunologic unresponsiveness toward tumorsmay be presentation of tumor antigens by tolerogenic host APCs. A subsetof human IDO-expressing antigen-presenting cells (APCs) that coexpressedCD123 (IL3RA) and CCR6 and inhibited T-cell proliferation have also beendescribed. Both mature and immature CD123-positive dendritic cellssuppressed T-cell activity, and this IDO suppressive activity wasblocked by 1MT (Munn, et al., 2002, Science 297: 1867-70). It has alsobeen demonstrated that mouse tumor-draining lymph nodes (TDLNs) containa subset of plasmacytoid dendritic cells (pDCs) that constitutivelyexpress immunosuppressive levels of IDO. Despite comprising only 0.5% oflymph node cells, in vitro, these pDCs potently suppressed T cellresponses to antigens presented by the pDCs themselves and also, in adominant fashion, suppressed T cell responses to third-party antigenspresented by nonsuppressive APCs. Within the population of pDCs, themajority of the functional IDO-mediated suppressor activity segregatedwith a novel subset of pDCs coexpressing the B-lineage marker CD19.Thus, it was hypothesized that IDO-mediated suppression by pDCs in'TDLNscreates a local microenvironment that is potently suppressive of hostantitumor T cell responses (Munn, et al., 2004, J. Clin. Invest.,114(2): 280-90).

IDO degrades the indole moiety of tryptophan, serotonin and melatonin,and initiates the production of neuroactive and immunoregulatorymetabolites, collectively known as kynurenines. By locally depletingtryptophan and increasing proapoptotic kynurenines, IDO expressed bydendritic cells (DCs) can greatly affect T-cell proliferation andsurvival. IDO induction in DCs could be a common mechanism of deletionaltolerance driven by regulatory T cells. Because such tolerogenicresponses can be expected to operate in a variety of physiopathologicalconditions, tryptophan metabolism and kynurenine production mightrepresent a crucial interface between the immune and nervous systems(Grohmann, et al., 2003, Trends Immunol., 24: 242-8). In states ofpersistent immune activation, availability of free serum Trp isdiminished and, as a consequence of reduced serotonin production,serotonergic functions may also be affected (Wirleitner, et al., 2003,Curr. Med. Chem., 10: 1581-91).

Interestingly, administration of interferon-α has been observed toinduce neuropsychiatric side effects, such as depressive symptoms andchanges in cognitive function. Direct influence on serotonergicneurotransmission may contribute to these side effects. In addition,because IDO activation leads to reduced levels of tryptophan, theprecursor of serotonin (5-HT), IDO may play a role in theseneuropsychiatric side effects by reducing central 5-HT synthesis.Furthermore, kynurenine metabolites such as 3-hydroxy-kynurenine(3-OH-KYN) and quinolinic acid (QUIN) have toxic effects on brainfunction. 3-OH-KYN is able to produce oxidative stress by increasing theproduction of reactive oxygen species (ROS), and QUIN may produceoverstimulation of hippocampal N-methyl-D-aspartate (NMDA) receptors,which leads to apoptosis and hippocampal atrophy. Both ROSoverproduction and hippocampal atrophy caused by NMDA overstimulationhave been associated with depression (Wichers and Maes, 2004, J.Psychiatry Neurosci., 29: 11-17). Thus, IDO activity may play a role indepression.

Small molecule inhibitors of IDO are being developed to treat or preventIDO-related diseases such as those described above. For example, PCTPublication WO 99/29310 reports methods for altering T cell-mediatedimmunity comprising altering local extracellular concentrations oftryptophan and tryptophan metabolites, using an inhibitor of IDO such as1-methyl-DL-tryptophan, p-(3-benzofuranyl)-DL-alanine, p-[3benzo(b)thienyl]-DL-alanine, and 6-nitro-L-tryptophan) (Munn, 1999).Reported in WO 03/087347, also published as European Patent 1501918, aremethods of making antigen-presenting cells for enhancing or reducing Tcell tolerance (Munn, 2003). Compounds havingindoleamine-2,3-dioxygenase (IDO) inhibitory activity are furtherreported in WO 2004/094409; and U.S. Patent Application Publication No.2004/0234623 is directed to methods of treating a subject with a canceror an infection by the administration of an inhibitor ofindoleamine-2,3-dioxygenase in combination with other therapeuticmodalities.

In light of the experimental data indicating a role for IDO inimmunosuppression, tumor resistance and/or rejection, chronicinfections, HIV-infection, AIDS (including its manifestations such ascachexia, dementia and diarrhea), autoimmune diseases or disorders (suchas rheumatoid arthritis), and immunologic tolerance and prevention offetal rejection in utero, therapeutic agents aimed at suppression oftryptophan degradation by inhibiting IDO activity are desirable.Inhibitors of IDO can be used to activate T cells and therefore enhanceT cell activation when the T cells are suppressed by pregnancy,malignancy or a virus such as HIV. Inhibition of IDO may also be animportant treatment strategy for patients with neurological orneuropsychiatric diseases or disorders such as depression. Thecompounds, compositions and methods herein help meet the current needfor IDO modulators.

SUMMARY OF THE INVENTION

The present invention provides, inter alia, compounds of Formula Ia:

or pharmaceutically acceptable salts or prodrugs thereof, whereinconstituent members are provided herein.

The present invention further provides compositions comprising acompound of Formula Ia, or pharmaceutically acceptable salt thereof, andat least one pharmaceutically acceptable carrier.

The present invention further provides methods of modulating enzymeactivity of IDO comprising contacting a compound of Formula Ia, orpharmaceutically acceptable salt thereof, with IDO.

The present invention further provides methods of treatingIDO-associated diseases, including cancer, viral infection anddepression, comprising administering to a patient a therapeuticallyeffective amount of a compound of Formula Ia, or pharmaceuticallyacceptable salt thereof.

The present invention further provides methods of altering extracellulartryptophan levels in a mammal comprising administering to the mammal aneffective amount of a compound of Formula Ia, or pharmaceuticallyacceptable salt thereof.

The present invention further provides methods of inhibitingimmunosuppression, such as IDO-mediated immunosuppression, in a patientcomprising administering to the patient an effective amount of acompound of Formula Ia, or pharmaceutically acceptable salt thereof.

DETAILED DESCRIPTION

The present invention provides compounds which are modulators of IDOhaving Formula Ia:

or pharmaceutically acceptable salts or prodrugs thereof, wherein:

U is N, O, S, CR′, or NR″;

V, and W are each, independently, N, O, S, CR², or NR³, wherein thefive-membered ring containing U, V, and W is an aromatic heterocycle;

A is aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each optionallysubstituted by 1, 2, 3, 4, or 5 substituents independently selected fromhalo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆hydroxyalkyl, C₁₋₆ cyanoalkyl, halosulfanyl, Cy¹, CN, NO₂, OR^(a),SR^(a), C(O)R^(b), C(O)NR^(c)R^(d), C(O)OR^(a), OC(O)R^(b),OC(O)NR^(c)R^(d), NR^(c)R^(d)NR^(c)C(O)R^(b), NR^(e)C(O)NR^(c)R^(d),NR^(c)C(O)OR^(a), C(═NR^(i))NR^(c)R^(d), NR^(e)C(═NR^(i))NR^(c)R^(d),P(R^(f))₂, P(OR^(e))₂, P(O)R^(e)R^(f), P(O)OR^(e)OR^(f), S(O)R^(b),S(O)NR^(c)R^(d), S(O)₂R^(b), NR^(c)S(O)₂R^(b), and S(O)₂NR^(c)R^(d),wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl is optionallysubstituted with 1, 2, or 3 substitutents independently selected fromCy¹, CN, NO₂, OR^(a), SR^(a), C(O)R^(b), C(O)NR^(c)R^(d), C(O)ORB,OC(O)R^(b), OC(O)NR^(c)R^(d), NR^(c)R^(d), NR^(c)C(O)R^(b),NR^(c)C(O)NR^(c)R^(d), NR^(c)C(O)OR^(a), C(═NR^(i))NR^(c)R^(d),NR^(c)C(═NR^(i))NR^(c)R^(d), P(R^(f))₂, P(OR^(e))₂, P(O)R^(e)R^(f),P(O)OR^(e)OR^(f), S(O)R^(b), S(O)NR^(c)R^(d), S(O)₂R^(b),NR^(c)S(O)₂R^(b), and S(O)₂NR^(c)R^(d);

R is H, C(O)R⁵, C(O)OR⁶, or C(O)NR^(6a)R^(6b);

R^(A) and R^(B) are independently selected from H, F, C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, aryl, cycloalkyl, heteroaryl,heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl,heterocycloalkylalkyl, halosulfanyl, CN, NO₂, OR^(a1), SR^(a1),C(O)R^(b1), C(O)NR^(c1)R^(d1), C(O)OR^(a1), OC(O)R^(b1),OC(O)NR^(c1)R^(d1), NR^(c1)R^(d1), NR^(c1)C(O)R^(b1),NR^(c1)C(O)NR^(c1)R^(d1), NR^(c1)C(O)OR^(a1), C(═NR^(i))NR^(c1)R^(d1),NR^(c1)C(═NR^(i))NR^(c1)R^(d1), P(R^(f1))₂, P(OR^(e1))₂,P(O)R^(e1)R^(f1), P(O)OR^(e1)OR^(f1), S(O)R^(b1), S(O)NR^(c1)R^(d1),S(O)₂R^(b1), NR^(c1)S(O)₂R^(b1), and S(O)₂NR^(c1)R^(d1); wherein saidC₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, cycloalkyl, heteroaryl,heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, orheterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5substituents independently selected from halo, C₁₋₄ alkyl, C₂₋₄ alkenyl,C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₁₋₄ hydroxyalkyl, C₁₋₄ cyanoalkyl,halosulfanyl, CN, NO₂, OR^(a1), SR^(a1), C(O)R^(b1), C(O)NR^(c1)R^(d1),C(O)OR^(a1), OC(O)R^(b1), OC(O)NR^(c1)R^(d1), NR^(c1)R^(d1),NR^(c1)C(O)R^(b1), NR^(c1)C(O)NR^(c1)R^(d1), NR^(c1)C(O)OR^(a1),C(═NR^(i))NR^(c1)R^(d1), NR^(c1)C(═NR^(i))NR^(c1)R^(d1), P(R^(f1))₂,P(OR^(e1))₂, P(O)R^(e1)R^(f1), P(O)OR^(e1)OR^(f1), S(O)R^(b1),S(O)NR^(c1)R^(d1), S(O)₂R^(b1), NR^(c1)S(O)₂R^(b1), andS(O)₂NR^(c1)R^(d1);

or R^(A) and R^(B) together with the carbon atom to which they areattached form a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group or 3-,4-, 5-, 6-, or 7-membered heterocycloalkyl group, each optionallysubstituted with 1, 2, or 3 substituents independently selected fromhalo, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₁₋₄hydroxyalkyl, C₁₋₄ cyanoalkyl, halosulfanyl, CN, NO₂, OR^(a1), SR^(a1),C(O)R^(b1), C(O)NR^(c1)R^(d1), C(O)OR^(a1), OC(O)R^(b1),OC(O)NR^(c1)R^(d1), NR^(c1)R^(dl), NR^(c1)C(O)R^(b1),NR^(c1)C(O)NR^(c1)R^(d1), NR^(c1)C(O)OR^(a1), C(═NR^(i))NR^(c1)R^(d1),NR^(c1)C(═NR^(i))NR^(c1)R^(d1), P(R^(f1))₂, P(OR^(e1))₂,P(O)R^(e1)R^(f1), P(O)OR^(e1)OR^(f1), S(O)R^(b1), S(O)NR^(c1)R^(d1),S(O)₂R^(b1), NR^(c1)S(O)₂R^(b1), and S(O)₂NR^(c1)R^(d1);

-   -   or R^(A) and R^(B), together with the carbon atom to which they        are attached, form a C═CH₂ group;    -   Q is OR^(Q), OC(O)R^(Q), OC(O)NR⁴R^(Q), NR⁴R^(Q), NR⁴C(O)R^(Q),        NR⁴C(O)NR⁴R^(Q), NR⁴C(O)OR^(Q), NR⁴S(O)R^(Q), NR⁴S(O)₂R^(Q),        NR⁴C(═NR^(i))NR⁴R^(Q), SR^(Q), S(O)R^(Q), S(O)NR⁴R^(Q),        S(O)₂R^(Q), S(O)₂NR⁴R^(Q), C(O)R^(Q), cope, C(O)NR⁴R^(Q), halo,        cyano, azido, or nitro;

or Q is H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, heteroaryl,cycloalkyl, heterocycloalkyl, each optionally substituted by 1, 2, 3, 4,or 5 substituents independently selected from halo, C₁₋₄ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆cyanoalkyl, Cy, —(C₁₋₄ alkyl)-Cy, halosulfanyl, CN, NO₂, OR^(a2), —(C₁₋₄alkyl)-OR^(a2), SR^(a2), —(C₁₋₄ alkyl)-SR^(a2), C(O)R^(b2), —(C₁₋₄alkyl)-C(O)R^(b2), C(O)NR^(c2)R^(d2), —(C₁₋₄ alkyl)-C(O)NR^(c2)R^(d2),C(O)OR^(a2), —(C₁₋₄ alkyl)-C(O)OR^(a2), OC(O)R^(b2), —(C₁₋₄alkyl)-OC(O)R^(b2), OC(O)NR^(c2)R^(d2), —(C₁₋₄alkyl)-OC(O)NR^(c2)R^(d2), NR^(c2)R^(d2), —(C₁₋₄ alkyl)-NR^(c2)R^(d2),NR^(c2)C(O)R^(b2), —(C₁₋₄ alkyl)-NR^(c2)C(O)R^(b2),NR^(c2)C(O)NR^(c2)R^(d2), —(C₁₋₄ alkyl)-NR^(c2)C(O)NR^(c2)R^(d2),NR^(c2)C(O)OR^(a2), —(C₁₋₄ alkyl)-NR^(c2)C(O)OR^(a2),C(═NR^(i))NR^(c2)R^(d2), NR^(c2)C(═NR^(i))NR^(c2)R^(d2), P(R^(f2))₂,P(OR^(e2))₂, P(O)R^(e2)R^(f2), P(O)OR^(e2)OR^(f2), S(O)R^(b2), —(C₁₋₄alkyl)-S(O)R^(b2), S(O)NR^(c2)R^(d2), —(C₁₋₄ alkyl)-S(O)NR^(c2)R^(d2),S(O)₂R^(b2), —(C₁₋₄ alkyl)-S(O)₂R^(b2), NR^(c2)S(O)₂R^(b2), —(C₁₋₄alkyl)-NR^(c2)S(O)₂R^(b2), S(O)₂NR^(c2)R^(d2), and —(C₁₋₄alkyl)-S(O)₂NR^(c2)R^(d2);

R^(Q) is H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl,cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl, wherein saidC₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, cycloalkyl, heteroaryl,heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, orheterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5substituents independently selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆ cyanoalkyl,halosulfanyl, Cy, —(C₁₋₄ alkyl)-Cy, CN, NO₂, OR^(a2), SR^(a2),C(O)R^(b2), C(O)NR^(c2)R^(d2), C(O)OR^(a2), OC(O)R^(b2),OC(O)NR^(c2)R^(d2), NR^(c2)R^(d2), NR^(c2)C(O)R^(b2),NR^(c2)C(O)NR^(c2)R^(d2), NR^(c2)C(O)OR^(a2), C(═NR^(i))NR^(c2)R^(d2),NR^(c2)C(═NR^(i))NR^(c2)R^(d2), P(R^(f2))₂, P(OR^(e2))₂,P(O)R^(e2)R^(f2), P(O)OR^(e2)OR^(e2)OR^(f2), S(O)R^(b2),S(O)NR^(c2)R^(d2); S(O)₂R^(b2), NR^(c2)S(O)₂R^(b2), andS(O)₂NR^(c2)R^(d2);

or R⁴ and R^(Q) together with the N atom to which they are attached forma 4-20 membered heterocycloalkyl group or 5-20 membered heteroarylgroup, each optionally substituted by 1, 2, 3, 4, or 5 substituentsindependently selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆ cyanoalkyl,halosulfanyl, Cy, —(C₁₋₄ alkyl)-Cy, CN, NO₂, OR^(a2), —(C₁₋₄alkyl)-OR^(a2), SR^(a2), —(C₁₋₄ alkyl)-SR^(a2), C(O)R^(b2), —(C₁₋₄alkyl)-C(O)R^(b2), C(O)NR^(c2)R^(d2, —(C) ₁₋₄ alkyl)-C(O)NR^(c2)R^(d2),C(O)OR^(a2), —(C₁₋₄ alkyl)-C(O)OR^(a2), OC(O)R^(b2), —(C₁₋₄alkyl)-OC(O)R^(b2), OC(O)NR^(c2)R^(d2), —(C₁₋₄alkyl)-OC(O)NR^(c2)R^(d2), NR^(c2)R^(d2), —(C₁₋₄ alkyl)-NR^(c2)R^(d2),NR^(c2)C(O)R^(b2), —(C₁₋₄ alkyl)-NR^(c2)C(O)R^(b2),NR^(c2)C(O)NR^(c2)R^(d2), —(C₁₋₄ alkyl)-NR^(c2)C(O)NR^(c2)R^(d2),NR^(c2)C(O)OR^(a2), —(C₁₋₄ alkyl)-NR^(c2)C(O)OR^(a2),C(═NR^(i))NR^(c2)R^(d2), NR^(c2)C(═NR^(i))NR^(c2)R^(d2), P(R^(f2))₂,P(OR^(e2))₂, P(O)R^(e2)R^(f2), P(O)OR^(e2)OR^(f2), S(O)R^(b2), —(C₁₋₄alkyl)-S(O)R^(b2), S(O)NR^(c2)R^(d2), —(C₁₋₄ alkyl)-S(O)NR^(e2)R^(d2),S(O)₂R^(b2), —(C₁₋₄ alkyl)-S(O)₂R^(b2), NR^(c2)S(O)₂R^(b2), —(C₁₋₄alkyl)-NR^(c2)S(O)₂R^(b2), S(O)₂NR^(c2)R^(d2), and —(C₁₋₄alkyl)-S(O)₂NR^(c2)R^(d2);

Cy, Cy¹, and Cy² are independently selected from aryl, heteroaryl,cycloalkyl, and heterocycloalkyl, each optionally substituted by 1, 2,3, 4 or 5 substituents independently selected from halo, C₁₋₄ alkyl,C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, halosulfanyl, CN, NO₂,OR^(a3), SR^(a3), C(O)R^(b3), C(O)NR^(c3)R^(d3), C(O)OR^(a3),OC(O)R^(b3), OC(O)NR^(c3)R^(d3), NR^(c3)R^(d3), NR^(c3)C(O)R^(b3),NR^(c3)C(O)OR^(a3), C(═NR^(i))—NR^(c3)R^(d3);NR^(c3)C(═NR^(i))NR^(c3)R^(d3), P(R^(f3))₂, P(OR^(e3))₂,P(O)R^(e3)R^(f3), P(O)OR^(e3)OR^(f3), S(O)R^(b3), S(O)NR^(c3)R^(d3),S(O)₂R^(b3), and S(O)₂NR^(c3)R^(d3);

R¹ is H or C₁₋₄ alkyl;

R² is H, halo, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl,CN, NO₂, OH, C₁₋₄ alkoxy, amino, C₁₋₄ alkylamino, or C₂₋₈ dialkylamino;

R³ is H, C₁₋₄ alkyl, C₂₋₄ alkenyl, or C₂₋₄ alkynyl;

R⁴ is H, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C(O)—R^(4a),SO₂—R^(4a), aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl,cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl, wherein saidC₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, aryl, cycloalkyl, heteroaryl,heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, orheterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5substituents independently selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆ cyanoalkyl, aryl,heteroaryl, cycloalkyl, heterocycloalkyl, halosulfanyl, CN, NO₂,OR^(a4), SR^(a4), C(O)R^(b4), C(O)NR^(c4)R^(d4), C(O)OR^(a4), OR^(b4),C(O)OR^(a4), OC(O)R^(b4), OC(O)NR^(c4)R^(d4), NR^(c4)R^(d4),NR^(c4)C(O)R^(b4), NR^(c4)C(O)NR^(c4)R^(d4), NR^(c4)C(O)OR^(a4),C(═NR^(i))NR^(c4)R_(d4), NR^(c4)C(═NR^(i))NR^(c4)R^(d4), P(R^(f4))₂,P(OR^(e4))₂, P(O)R^(e4)R^(f4), P(O)OR^(e4)OR^(f4), S(O)R^(b4),S(O)NR^(c4)R^(d4), S(O)₂R^(b4), NR^(e4)S(O)₂R^(b4), andS(O)₂NR^(c4)R^(d4);

R^(4a) is H, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, aryl, cycloalkyl,heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl,heteroarylalkyl, or heterocycloalkylalkyl;

R⁵ and R⁶ are independently selected from H, C₁₋₈ g alkyl, aryl,heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl,cycloalkylalkyl, and heterocycloalkylalkyl, each optionally substitutedby one or more substituents independently selected from halo, CN, NO₂,OH, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, amino, C₁₋₄ alkylamino, C₂₋₈dialkylamino, C₁₋₆ alkyl, C₁₋₆ alkenyl, and C₂₋₆ alkynyl;

R^(6a) and R^(6b) are independently selected from H, C₁₋₈ alkyl, aryl,heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl,cycloalkylalkyl, and heterocycloalkylalkyl, each optionally substitutedby one or more substituents independently selected from halo, CN, NO₂,OH, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, amino, C₁₋₄ alkylamino, C₂₋₈dialkylamino, C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl;

R^(a), R^(a1), R^(a3), R^(a4), and R^(a5) are independently selectedfrom H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl,cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl,cycloalkylalkyl, and heterocycloalkylalkyl, wherein said C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, cycloalkyl,heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl,cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted withOH, amino, halo, C₁₋₆ alkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, cycloalkyl or heterocycloalkyl;

R^(b), R^(b1), R^(b3), R^(b4), and R^(b5) are independently selectedfrom H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl,cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl,cycloalkylalkyl, and heterocycloalkylalkyl, wherein said C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, cycloalkyl,heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl,cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted withOH, amino, halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, aryl, arylalkyl,heteroaryl, heteroarylalkyl, cycloalkyl, or heterocycloalkyl;

R^(a2) is H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,Cy², or Cy²-(C₁₋₆ alkyl)-, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆alkenyl, or C₂₋₆ alkynyl, is optionally substituted with 1, 2, 3, 4, or5 substituents independently selected from halo, C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆cyanoalkyl, halosulfanyl, Cy², CN, NO₂, OR^(a5), SR^(a5), C(O)R^(b5),C(O)NR^(c5)R^(d5), C(O)OR^(a5), OC(O)R^(b5), OC(O)NR^(c5)R^(d5),NR^(c5)R^(d5), NR^(c5)C(O)R^(b5), NR^(c5)C(O)NR^(c5)R^(d5),NR^(c5)C(O)OR^(a5), C(═NR^(i))NR^(c5)R^(d5),NR^(c5)C(═NR^(i))NR^(c5)R^(d5), P(R^(f5))₂, P(O)R^(e5)R^(f5),P(O)OR^(e5)OR^(f5), S(O)R^(b5), S(O)NR^(c5)R^(d5), R^(b2), S(O)₂R^(b5),NR^(c5)S(O)₂R^(b5), and S(O)₂NR^(e5)R^(d5);

R^(b2) is H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,aryl, Cy², or Cy²-(C₁₋₆ alkyl)-, wherein said C₁₋₆ alkyl, C₁₋₆haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, or aryl is optionally substitutedwith 1, 2, 3, 4, or 5 substituents independently selected from halo,C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, hydroxyalkyl,C₁₋₆ cyanoalkyl, halosulfanyl, Cy², CN, NO₂, OR^(a5), SR^(a5),C(O)R^(b5), C(O)NR^(c5)R^(d5), C(O)OR^(a5), OC(O)R^(b5),OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5), NR^(c5)C(O)R^(b5),NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5), C(═NR^(i))NR^(c5)R^(d5),NR^(c5)C(═NR^(i))NR^(c5)R^(d5), P(R^(f5))₂, P(OR^(e5))₂,P(O)R^(e5)R^(f5), P(O)OR^(e5)OR^(f5), S(O)R^(b5), S(O)NR^(c5)R^(d5),S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5), and S(O)₂NR^(c5)R^(d5);

R^(c) and R^(d) are independently selected from H, C₁₋₁₀ alkyl, C₁₋₆haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, heteroaryl, cycloalkyl,heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, andheterocycloalkylalkyl, wherein said C₁₋₁₀ alkyl, C₁₋₆ haloalkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl,arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl isoptionally substituted with OH, amino, halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl,aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl orheterocycloalkyl;

or R^(c) and R^(d) together with the N atom to which they are attachedform a 4-, 5-, 6- or 7-membered heterocycloalkyl group;

R^(c1) and R^(d1) are independently selected from H, C₁₋₁₀ alkyl, C₁₋₆haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, heteroaryl, cycloalkyl,heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, andheterocycloalkylalkyl, wherein said C₁₋₁₀ alkyl, C₁₋₆ haloalkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl,arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl isoptionally substituted with OH, amino, halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl,aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl orheterocycloalkyl;

or R^(c1) and R^(d1) together with the N atom to which they are attachedform a 4-, 5-, 6- or 7-membered heterocycloalkyl group;

R^(c2) and R^(d2) are dependently selected from H, C₁₋₁₀ alkyl, C₁₋₆haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, Cy² and Cy²-(C₁₋₆ alkyl)-,wherein said C₁₋₁₀ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, and C₂₋₆alkynyl, is optionally substituted with 1, 2, or 3, substitutentsindependently selected from halo, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄alkynyl, C₁₋₄ haloalkyl, halosulfanyl, CN, NO₂, OR^(a3), SR^(a3),C(O)R^(b3), C(O)NR^(c3)R^(d3), C(O)OR^(a3), OC(O)R^(b3),OC(O)NR^(c3)R^(d3), NR^(c3)R^(d3), NR^(d3)C(O)R^(b3)C(O)OR^(a3),C(═NR^(i))NR^(a3)R^(d3), NR^(c3)C(═NR^(i))NR^(c3)R^(d3), P(R^(f3))₂,P(OR^(e3))₂, P(O)R^(e3)R^(f3), P(O)OR^(e3)OR^(f3), S(O)R^(b3),S(O)NR^(c3)R^(d3), S(O)₂R^(b3), and S(O)₂NR^(a3)R^(d3);

or R^(c2) and R^(d2) together with the N atom to which they are attachedform a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionallysubstituted with 1, 2, or 3, substitutents independently selected fromCy², Cy²-(C₁₋₆ alkyl)-, halo, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl,C₁₋₄ haloalkyl, halosulfanyl, CN, NO₂, OR^(a3), SR^(a3), C(O)R^(b3),C(O)NR^(c3)R^(d3), SR^(a3), C(O)R^(b3), C(O)NR^(c3)R^(d3), C(O)OR^(a3),OC(O)R^(b3), OC(O)NR^(c3)R^(d3), NR^(c3)R^(d3), NR^(c3)C(O)R^(b3),NR^(c3)C(O)OR^(a3), C(═NR^(i))NR^(c3)R^(d3),NR^(c3)C(═NR^(i))NR^(c3)R^(d3), P(R^(f3))₂, P(OR^(e3))₂,P(O)R^(e3)R^(f3), P(O)OR^(e3), OR^(f3), S(O)R^(b3), S(O)NR^(c3)R^(d3),S(O)₂R^(b3), and S(O)₂NR^(c3)R^(d3);

R^(c3) and R^(d3) are independently selected from H, C₁₋₁₀ alkyl, C₁₋₆haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, heteroaryl, cycloalkyl,heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, andheterocycloalkylalkyl, wherein said C₁₋₁₀ alkyl, C₁₋₆ haloalkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl,arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl isoptionally substituted with OH, amino, halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl,aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, orheterocycloalkyl;

or R^(c3) and R^(d3) together with the N atom to which they are attachedform a 4-, 5-, 6- or 7-membered heterocycloalkyl group;

R^(c4) and R^(d4) are independently selected from H, C₁₋₁₀ alkyl, C₁₋₆haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, heteroaryl, cycloalkyl,heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, andheterocycloalkylalkyl, wherein said C₁₋₁₀ alkyl, C₁₋₆ haloalkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl,arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl isoptionally substituted with OH, amino, halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl,aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, orheterocycloalkyl;

or R^(c4) and R^(d4) together with the N atom to which they are attachedform a 4-, 5-, 6- or 7-membered heterocycloalkyl group;

R^(c5) and R^(d5) are independently selected from H, C₁₋₁₀ alkyl, C₁₋₆haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, heteroaryl, cycloalkyl,heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, andheterocycloalkylalkyl, wherein said C₁₋₁₀ alkyl, C₁₋₆ haloalkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl,arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocyclo-alkylalkylis optionally substituted with OH, amino, halo, C₁₋₆ alkyl, C₁₋₆haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, orheterocycloalkyl;

or R^(c5) and R^(d5) together with the N atom to which they are attachedform a 4-, 5-, 6- or 7-membered heterocycloalkyl group;

R^(e), R^(e1), R^(e2), R^(e3), R^(e4), and R^(e5) are independentlyselected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, (C₁₋₆alkoxy)-C₁₋₆ alkyl, C₂₋₆ alkynyl, aryl, cycloalkyl, heteroaryl,heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, andheterocycloalkylalkyl;

R^(f), R^(f1), R^(f2), R^(f3), R^(f4), and R^(f5) are independentlyselected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,aryl, cycloalkyl, heteroaryl, and heterocycloalkyl;

R^(i) is H, CN, C(O)NH₂, or NO₂;

R′ is H, halo, C₁₋₁₀ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, Cy, Cy-(C₁₋₆alkyl)-, CN, NO₂, OR^(a3), SR^(a3), C(O)R^(b3), C(O)NR^(c3)R^(d3),C(O)OR^(a3), OC(O)R^(b3), OC(O)NR^(c3)R^(d3), NR^(c3)R^(d3),NR^(c3)C(O)R^(b3), NR^(c3)C(O)OR^(a3), S(O)R^(b3), S(O)NR^(c3)R^(d3),S(O)₂R^(b3), or S(O)₂NR^(c3)R^(d3); wherein said C₁₋₁₀ alkyl, C₂₋₆alkenyl, or C₂₋₆ alkynyl is optionally substituted with 1, 2, 3, 4, or 5substituents independently selected from CN, NO₂, Cy, Cy-(C₁₋₆ alkyl)-,OR^(a3), SR^(a3), C(O)R^(b3), C(O)NR^(c3)R^(d3), C(O)OR^(a3),OC(O)R^(b3), OC(O)NR^(c3)R^(d3), NR^(c3)R^(d3), NR^(c3)C(O)R^(b3),NR^(c3)C(O)OR^(a3), C(═NR^(i))NR^(c3)R^(d3),NR^(c3)C(═NR^(i))NR^(c3)R^(d3), P(R^(f3))₂, P(OR^(e3))₂,P(O)R^(e3)R^(f3), P(O)OR^(e3)OR^(f3), S(O)R^(b3), S(O)NR^(c3)R^(d3),S(O)₂R^(b3), and S(O)₂NR^(c3)R^(d3);

-   -   R″ is H, C₁₋₁₀ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, Cy, Cy-(C₁₋₆        alkyl)-, C(O)R^(b3), C(O)NR^(c3)R^(d3), C(O)OR^(a3), S(O)R^(b3),        S(O)NR^(c3)R^(d3), S(O)₂R^(b3), or S(O)₂NR^(c3)R^(d3); wherein        said C₁₋₁₀ alkyl, C₂₋₆ alkenyl, or C₂₋₆ alkynyl is optionally        substituted with 1, 2, 3, 4, or 5 substituents independently        selected from CN, NO₂, Cy, —(C₁₋₆ alkyl)-Cy, OR^(a3), SR^(a3),        C(O)R^(b3), C(O)NR^(a3)R^(d3), C(O)OR^(a3), OC(O)R^(b3),        OC(O)NR^(c3)R^(d3), NR^(c3)R^(d3), NR^(c3)C(O)R^(b3),        NR^(c3)C(O)OR^(a3), C(═NR^(i))NR^(c3)R^(d3),        C(═NR^(i))NR^(c3)R^(d3), P(R^(f3))₂, P(OR^(e3))₂,        P(O)R^(e3)R^(f3), P(O)OR^(e3)OR^(f3), S(O)R^(b3), S(O)R^(b3),        S(O)NR^(c3)R^(d3), S(O)₂R^(b3), and S(O)₂NR^(c3)R^(d3); and

p is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

In some embodiments, V is O.

In some embodiments, U is N.

In some embodiments, W is N.

In some embodiments, U and W are both N.

In some embodiments, U and W are both N and V is O.

In some embodiments, at least one of U, V and W is N.

In some embodiments, at least one of U, V and W is N and another of U,V, and W is O or S.

In some embodiments, A is aryl, cycloalkyl, heteroaryl, orheterocycloalkyl, each optionally substituted by 1, 2, 3, 4, or 5substituents independently selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆ cyanoalkyl, Cy¹,CN, NO₂, OR^(a), SR^(a), C(O)R^(b), C(O)NR^(c)R^(d), C(O)OR^(a),OC(O)R^(b), OC(O)NR^(c)R^(d), NR^(c)R^(d), NR^(c)C(O)R^(b),NR^(c)C(O)NR^(c)R^(d), NR^(c)C(O)OR^(a), C(═NR^(i)) NR^(c)R^(d),NR^(c)C(═NR^(i))NR^(c)R^(d), P(R^(f))₂, P(OR^(e))₂, P(O)R^(e)R^(f),P(O)OR^(e)OR^(f), S(O)R^(b), S(O)R^(b), S(O)NR^(c)R^(d), S(O)₂R^(b),NR^(c)S(O)₂R^(b), and S(O)₂NR^(c)R^(d), wherein said C₁₋₆ alkyl, C₂₋₆alkenyl, and C₂₋₆ alkynyl is optionally substituted with 1, 2, or 3substitutents independently selected from Cy¹, CN, NO₂, OR^(a), SR^(a),C(O)R^(b), C(O)NR^(c)R^(d), C(O)OR^(a), OC(O)R^(b), OC(O)NR^(c)R^(d),NR^(c)R^(d), NR^(c)C(O)R^(b), NR^(c)C(O)NR^(c)R^(d), NR^(c)C(O)OR^(a),C(═NR^(i))NR^(c)R^(d), NR^(c)C(═NR^(i))NR^(c)R^(d), P(R^(f))₂,P(OR^(e))₂, P(O)R^(e)R^(f), P(O)OR^(e)OR^(f), S(O)R^(b),S(O)NR^(c)R^(d), S(O)₂R^(b), NR^(c)S(O)₂R^(b), and S(O)₂NR^(c)R^(d).

In some embodiments, A is aryl, cycloalkyl, heteroaryl, orheterocycloalkyl, each optionally substituted by 1, 2, 3, 4, or 5substituents independently selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆ cyanoalkyl, Cy¹,CN, NO₂, OR^(a), SR^(a), C(O)R^(b), C(O)NR^(c)R^(d), C(O)OR^(a),OC(O)R^(b), OC(O)NR^(c)R^(d), NRCR^(d), NR^(c)C(O)R^(b),NR^(c)C(O)NR^(c)R^(d), NR^(c)C(O)OR^(a), S(O)R^(b), S(O)NR^(C)R^(d),S(O)₂R^(b), NR^(c)S(O)₂R^(b), and S(O)₂NR^(C)R^(d).

In some embodiments, A is aryl or heteroaryl, each optionallysubstituted by 1, 2, 3, 4, or 5 substituents independently selected fromhalo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆hydroxyalkyl, C₁₋₆ cyanoalkyl, Cy¹, CN, NO₂, OR^(a), SR^(a), C(O)R⁶,C(O)NR^(c)R^(d), C(O)OR^(a), OC(O)R^(b), OC(O)NR^(e)R^(d), NR^(e)R^(d),NR^(e)C(O)R^(b), NR^(e)C(O)NR^(e)R^(d), NR^(e)C(O)OR^(a),C(═NR^(i))NR^(c)R^(d), NR^(c)C(═NR^(i))NR^(c)R^(d), P(R^(f))₂,P(OR^(e))₂, P(O)R^(e)R^(f), P(O)OR^(e)OR^(f), S(O)R^(b),S(O)NR^(e)R^(d), S(O)₂R^(b), NR^(c)S(O)₂R^(b), and S(O)₂NR^(c)R^(d),wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl is optionallysubstituted with 1, 2, or 3 substitutents independently selected fromCy¹, CN, NO₂, OR^(a), SR^(a), C(O)R^(b), C(O)NR^(c)R^(d), C(O)OR^(a),OC(O)R^(b), OC(O)NR^(e)R^(d), NR^(e)R^(d), NR^(e)C(O)R^(b),NR^(e)C(O)NR^(e)R^(d), NR^(e)C(O)OR^(a), C(═NR^(i))NR^(c)R^(d),NR^(c)C(—NR^(i))NR^(c)R^(d), P(R^(f))₂, P(OR^(e))₂, P(O)R^(e)R^(f),P(O)OR^(e)R^(f), S(O)R^(b), S(O)NR^(c)R^(d), S(O)₂R^(b),NR^(c)S(O)₂R^(b), and S(O)₂NR^(e)R^(d).

In some embodiments, A is aryl or heteroaryl, each optionallysubstituted by 1, 2, 3, 4, or 5 substituents independently selected fromhalo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆hydroxyalkyl, C₁₋₆ cyanoalkyl, aryl, cycloalkyl, heteroaryl,heterocycloalkyl, CN, NO₂, OR^(a), SR^(a), C(O)R^(b), C(O)NR^(c)R^(d),C(O)OR^(a), OC(O)R^(b), OC(O)NR^(c)R^(d), NR^(c)R^(d), NR^(c)C(O)R^(b),NR^(c)C(O)NR^(e)R^(d), NR^(c)C(O)OR^(a), S(O)R^(b), S(O)NR^(c)R^(d),S(O)₂R^(b), NR^(c)S(O)₂R^(b), and S(O)₂NR^(c)R^(d).

In some embodiments, A is phenyl optionally substituted by 1, 2, 3, 4,or 5 substituents independently selected from halo, C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆cyanoalkyl, Cy¹, CN, NO₂, OR^(a), SR^(a), C(O)R^(b), C(O)NR^(c)R^(d),C(O)OR^(a), OC(O)R^(b), OC(O)NR^(c)R^(d), NR^(c)R^(d), NR^(c)C(O)R^(b),NR^(c)C(O)NR^(c)R^(d), NR^(c)C(O)OR^(a), C(═NR^(i))NR^(c)R^(d),NR^(c)C(═NR^(i))NR^(c)R^(d), P(R^(f))₂, P(OR^(e))₂, P(O)R^(e)R^(f),P(O)OR^(e)OR^(f), S(O)R^(b), S(O)NR^(c)R^(d), S(O)₂R^(b),NR^(c)S(O)₂R^(b), and S(O)₂NR^(c)R^(d), wherein said C₁₋₆ alkyl, C₂₋₆alkenyl, and C₂₋₆ alkynyl is optionally substituted with 1, 2, or 3substitutents independently selected from Cy¹, CN, NO₂, OR^(a), SR^(a),C(O)R^(b), C(O)NR^(c)R^(d), C(O)OR^(a), OC(O)R^(b), OC(O)NR^(c)R^(d),NR^(c)R^(d), NR^(c)C(O)R^(b), NR^(c)C(O)NR^(c)R^(d), NR^(c)C(O)OR^(a),C(═NR^(i))NR^(c)R^(d), NR^(c)C(═NR^(i))NR^(c)R^(d), P(R^(f))₂,P(OR^(e))₂, P(O)R^(e)R^(f), P(O)OR^(e)OR^(f), S(O)R^(b),S(O)NR^(c)R^(d), S(O)₂R^(b), NR^(c)S(O)₂R^(b), and S(O)₂NR^(c)R^(d).

In some embodiments, A is phenyl optionally substituted by 1, 2, 3, 4,or 5 substituents independently selected from halo, C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆cyanoalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO₂,OR^(a), SR^(a), C(O)R^(b), C(O)NR^(c)R^(d), C(O)OR^(a), OC(O)R^(b),OC(O)NR^(c)R^(d), NR^(c)R^(d), NR^(c)C(O)R^(b), NR^(c)C(O)NR^(c)R^(d),NR^(c)C(O)OR^(a), S(O)R^(b), S(O)NR^(c)R^(d), S(O)₂R^(b),NR^(c)S(O)₂R^(b), and S(O)₂NR^(c)R^(d).

In some embodiments, A is phenyl optionally substituted by 1, 2, 3, 4,or 5 substituents independently selected from halo, C₁₋₆ alkyl, C₁₋₆haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆ cyanoalkyl, CN, NO₂, OR^(a), SR^(a),C(O)R^(b), C(O)NR^(c)R^(d), C(O)OR^(a), OC(O)R^(b), OC(O)NR^(c)R^(d),NR^(c)R^(d), NR^(c)C(O)R^(b), NR^(e)C(O)NR^(c)R^(d), NR^(c)C(O)OR^(a),S(O)R^(b), S(O)NR^(c)R^(d), S(O)₂R^(b), NR^(c)S(O)₂R^(b), andS(O)₂NR^(c)R^(d).

In some embodiments, A is phenyl optionally substituted by 1, 2, 3, 4,or 5 substituents independently selected from halo, C₁₋₆ alkyl, and C₁₋₆haloalkyl.

In some embodiments, Q is OR^(Q), OC(O)R^(Q), OC(O)NR⁴R^(Q), NR⁴R^(Q),NR⁴C(O)R^(Q), NR⁴C(O)NR⁴R^(Q), NR⁴C(O)OR^(Q), NR⁴S(O)R^(Q),NR⁴S(O)₂R^(Q), SR^(Q), S(O)R^(Q), S(O)NR⁴R^(Q), S(O)₂R^(Q),S(O)₂NR⁴R^(Q), C(O)R^(Q), C(O)OR^(Q), C(O)NR⁴R^(Q), halo, cyano, azido,or nitro;

In some embodiments, Q is H, CN, OR^(Q), OC(O)NR⁴R^(Q), C(O)OR^(Q),NR⁴R^(Q), NR⁴C(O)R^(Q), NR⁴C(O)NR⁴R^(Q), NR⁴C(O)OR^(Q), NR⁴S(O)₂R^(Q),SR^(Q), S(O)₂R^(Q), or OC(O)NR⁴R^(Q).

In some embodiments, Q is H, CN, OR^(Q), OC(O)NR⁴R^(Q), C(O)OR^(Q),NR⁴R^(Q), NR⁴C(O)R^(Q), NR⁴C(O)NR⁴R^(Q), NR⁴C(O)OR^(Q), NR⁴S(O)₂R^(Q),or OC(O)NR⁴R^(Q).

In some embodiments, Q is OR^(Q), OC(O)NR⁴R^(Q), or NR⁴R^(Q).

In some embodiments, Q is OR^(Q).

In some embodiments, Q is SR^(Q).

In some embodiments, Q is S(O)₂R^(Q).

In some embodiments, Q is NR⁴R^(Q).

In some embodiments, Q is NR⁴R^(Q), and R⁴ and R^(Q) together with the Natom to which they are attached form a 4-20 membered heterocycloalkylgroup or 5-20 membered heteroaryl group, each optionally substituted by1, 2, 3, 4, or 5 substituents independently selected from halo, C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl,C₁₋₆ cyanoalkyl, Cy, —(C₁₋₄ alkyl)-Cy, CN, NO₂, OR^(a2), —(C₁₋₄alkyl)-OR^(a2), SR^(a2), —(C₁₋₄ alkyl)-SR^(a2), C(O)R^(b2), —(C₁₋₄alkyl)-C(O)R^(b2), C(O)NR^(c2)R^(d2), —(C₁₋₄ alkyl)-C(O)NR^(c2)R^(d2),C(O)OR^(a2), —(C₁₋₄ alkyl)-C(O)OR^(a2), OC(O)R^(b2), —(C₁₋₄alkyl)-OC(O)R^(b2), OC(O)NR^(c2)R^(d2), —(C₁₋₄alkyl)-OC(O)NR^(c2)R^(d2), NR^(c2)R^(d2), —(C₁₋₄ alkyl)-NR^(c2)R^(d2),NR^(c2)C(O)OR^(b2), —(C₁₋₄ alkyl)-NR^(c2)C(O)R^(b2),NR^(c2)C(O)NR^(c2)R^(d2), —(C₁₋₄ alkyl)-NR^(c2)C(O)NR^(c2)R^(d2),NR^(c2)C(O)OR^(a2), —(C₁₋₄ alkyl)-NR^(c2)C(O)OR^(a2),C(═NR^(i))NR^(c2)R^(d2), NR^(c2)C(═NR¹)NR^(c2)R^(d2), P(R^(f2))₂,P(OR^(e2))₂, P(O)R^(e2)R^(f2), P(O)OR^(e2)OR^(f2), S(O)R^(b2), —(C₁₋₄alkyl)-S(O)R^(b2), S(O)NR^(c2)R^(d2), —(C₁₋₄ alkyl)-S(O)NR^(c2)R^(d2),S(O)₂R^(b2), —(C₁₋₄ alkyl)-S(O)₂R^(b2), NR^(c2)S(O)₂R^(b2), —(C₁₋₄alkyl)-NR^(c2)S(O)₂R^(b2), S(O)₂NR^(c2)R^(d2) and —(C₁₋₄alkyl)-S(O)₂NR^(c2)R^(d2).

In some embodiments, Q is NR⁴R^(Q) and R⁴ and R^(Q) together with the Natom to which they are attached form a 5-20 membered heteroaryl group,optionally substituted by 1, 2, 3, 4, or 5 substituents independentlyselected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆haloalkyl, C₁₋₆ hydroxy-alkyl, C₁₋₆ cyanoalkyl, Cy, —(C₁₋₄ alkyl)-Cy,CN, NO₂, OR^(a2), —(C₁₋₄ alkyl)-OR^(a2), SR^(a2), —(C₁₋₄ alkyl)-SR^(a2),C(O)R^(b2), —(C₁₋₄ alkyl)-C(O)R^(b2), C(O)NR^(c2)R^(d2), —(C₁₋₄alkyl)-C(O)NR^(c2)R^(d2), C(O)OR^(a2), —(C₁₋₄ alkyl)-C(O)OR^(a2),OC(O)R^(b2), —(C₁₋₄ alkyl)-OC(O)R^(b2), OC(O)NR^(c2)R^(d2), —(C₁₋₄alkyl)-OC(O)NR^(c2)R^(d2), NR^(c2)R^(d2), —(C₁₋₄ alkyl)-NR^(c2)R^(d2),NR^(c2)C(O)OR^(a2), —(C₁₋₄ alkyl)-NR^(c2)C(O)OR^(a2),C(═NR^(i))NR^(c2)R^(d2), NR^(c2)C(O)NR^(c2)R^(d2), NR^(c2)C(O)OR^(a2),—(C₁₋₄ alkyl)-NR^(c2)C(O)OR^(a2), C(═NR^(i))_(NR) ^(c2)R^(d2),NR^(c2)C(═NR^(i))NR^(c2)R^(d2), P(R^(f2))₂, P(OR^(e2))₂,P(O)R^(e2)R^(f2), P(O)OR^(e2)OR^(f2), S(O)R^(b2), —(C₁₋₄alkyl)-S(O)R^(b2), S(O)NR^(c2)R^(d2), —(C₁₋₄ alkyl)-S(O)NR^(c2)R^(d2),S(O)₂R^(b2), —(C₁₋₄ alkyl)-S(O)₂R^(b2), NR^(c2)S(O)₂R^(b2), —(C₁₋₄alkyl)-NR^(c2)S(O)₂R^(b2), S(O)₂NR^(c2)R^(d2), and —(C₁₋₄alkyl)-S(O)₂NR^(c2)R^(d2).

In some embodiments, Q is NR⁴R^(Q) and R⁴ and R^(Q) together with the Natom to which they are attached form a tetrazole group which isoptionally substituted with halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, orNR^(c2)R^(d2).

In some embodiments, Q is NR⁴R^(Q) and R⁴ and R^(Q) together with the Natom to which they are attached form a 5- or 6-membered heterocycloalkylgroup optionally substituted by 1, 2, 3, 4, or 5 substituentsindependently selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆ cyanoalkyl, Cy, —(C₁₋₄alkyl)-Cy, CN, NO₂, OR^(a2), —(C₁₋₄ alkyl)-OR^(a2), SR^(a2), —(C₁₋₄alkyl)-SR^(a2), C(O)R^(b2), —(C₁₋₄ alkyl)-C(O)R^(b2), C(O)NR^(c2)R^(d2),—(C₁₋₄ alkyl)-C(O)NR^(c2)R^(d2), C(O)OR^(a2), —(C₁₋₄ alkyl)-C(O)OR^(a2),OC(O)R^(b2), —(C₁₋₄ alkyl)-OC(O)R^(b2), OC(O)R^(b2), OC(O)NR^(c2)R^(d2),—(C₁₋₄ alkyl)-OC(O)NR^(c2)R^(d2), NR^(c2)R^(d2), —(C₁₋₄alkyl)-NR^(c2)R^(d2), NR^(c2)C(O)R^(b2), —(C₁₋₄alkyl)-NR^(c2)C(O)R^(b2), NR^(c2)C(O)NR^(c2)R^(d2), —(C₁₋₄alkyl)-NR^(c2)C(O)NR^(c2)R^(d2), NR^(c2)C(O)OR^(a2), —(C₁₋₄alkyl)-NR^(c2)C(O)OR^(a2), C(═NR^(i))NR^(c2)R^(d2),NR^(c2)C(═NR^(i))NR^(c2)R^(d2), P(R^(f2))₂, P(OR^(e2))₂,P(O)R^(e2)R^(f2), P(O)OR^(e2)OR^(f2), S(O)R^(b2), —(C₁₋₄alkyl)-S(O)R^(b2), S(O)NR^(a)R^(d2), —(C₁₋₄ alkyl)-S(O)NR^(a)R^(d2),S(O)₂R^(b2), —(C₁₋₄ alkyl)-S(O)₂R^(b2), NR″S(O)₂R^(b2), —(C₁₋₄alkyl)-NR^(e2)S(O)₂R^(b2), S(O)₂NR^(c2)R^(d2), and —(C₁₋₄alkyl)-S(O)₂NR^(c2)R^(d2).

In some embodiments, Q is NR⁴R^(Q) and R⁴ and R^(Q) together with the Natom to which they are attached form piperidinyl, morpholino,piperazinyl, 2,3-dihydro-1H-isoindolyl, or1,2,3,4-tetrahydro-isoquinoline, each optionally substituted by 1, 2, 3,4, or 5 substituents independently selected from halo, C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆cyanoalkyl, Cy, —(C₁₋₄ alkyl)-Cy, CN, NO₂, OR^(a2), —(C₁₋₄alkyl)-OR^(a2), SR^(a2), —(C₁₋₄ alkyl)-SR^(a2), C(O)R^(b2), —(C₁₋₄alkyl)-C(O)R^(b2), C(O)NR^(c2)R^(d2), —(C₁₋₄ alkyl)-C(O)NR^(c2)R^(d2),C(O)OR^(a2), —(C₁₋₄ alkyl)-C(O)OR^(a2), OC(O)R^(b2), —(C₁₋₄alkyl)-OC(O)R^(b2), OC(O)NR^(c2)R^(d2), —(C₁₋₄alkyl)-OC(O)NR^(c2)R^(d2), NR^(c2)R^(d2), —(C₁₋₄ alkyl)-NR^(c2)R^(d2),NR^(c2)C(O)R^(b2), —(C₁₋₄ alkyl)-NR^(c2)C(O)R^(b2),NR^(c2)C(O)NR^(c2)R^(d2), —(C₁₋₄ alkyl)-NR^(c2)C(O)NR^(c2)R^(d2),NR^(c2)C(O)OR^(a2), —(C₁₋₄ alkyl)-NR^(c2)C(O)OR^(a2),C(═NR^(i))NR^(c2)R^(d2), NR^(c2)C(═NR^(i))NR^(c2)R^(d2), P(R^(f2))₂,P(OR^(e2))₂, P(O)R^(e2)R^(f2), P(O)OR^(e2)OR^(f2), S(O)R^(b2), —(C₁₋₄alkyl)-S(O)R^(b2), S(O)NR^(c2)R^(d2), —(C₁₋₄ alkyl)-S(O)NR^(c2)R^(d2),S(O)₂R^(b2), —(C₁₋₄ alkyl)-S(O)₂R^(b2), NR^(c2)S(O)₂R^(b2), —(C₁₋₄alkyl)-NR^(c2)S(O)₂R^(b2), S(O)₂NR^(c2)R^(d2), and —(C₁₋₄alkyl)-S(O)₂NR^(c2)R^(d2).

In some embodiments, Q is NR⁴R^(Q) and R⁴ and R^(Q) together with the Natom to which they are attached form a 4-20 membered heterocycloalkylgroup optionally substituted by 1, 2, 3, 4, or 5 substituentsindependently selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆ cyanoalkyl, Cy, —(C₁₋₄alkyl)-Cy, CN, NO₂, OR^(a2), SR^(a2), C(O)R^(b2), C(O)NR^(c2)R^(d2),C(O)OR^(a2), OC(O)R^(b2), OC(O)NR^(c2)R^(d2), NR^(c2)R^(d2),NR^(c2)C(O)R^(b2), NR^(c2)C(O)NR^(c2)R^(d2), NR^(c2)C(O)NR^(c2)R^(d2),NR^(c2)C(O)OR^(a2), S(O)R^(b2), S(O)NR^(c2)R^(d2), S(O)₂R^(b2),NR^(c2)S(O)₂R^(b2), and S(O)₂NR^(c2)R^(d2).

In some embodiments, Q is NR⁴R^(Q) and R⁴ and R^(Q) together with the Natom to which they are attached form a 5- or 6-membered heterocycloalkylgroup optionally substituted by 1, 2, 3, 4, or 5 substituentsindependently selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆ cyanoalkyl, Cy, —(C₁₋₄alkyl)-Cy, CN, NO₂, OR^(a2), SR^(a2), C(O)R^(b2), C(O)NR^(c2)R^(d2),C(O)OR^(a2), OC(O)R^(b2), OC(O)NR^(c2)R^(d2), NR^(c2)R^(d2),NR^(c2)C(O)R^(b2), NR^(c2)C(O)NR^(c2)R^(d2), NR^(c2)C(O)OR^(a2),S(O)R^(b2), S(O)NR^(c2)R^(d2), S(O)₂R^(b2), NR^(c2)S(O)₂R^(b2), andS(O)₂NR^(c2)R^(d2).

In some embodiments, Q is NR⁴R^(Q) and R⁴ and R^(Q) together with the Natom to which they are attached form piperidinyl, morpholino,piperazinyl, 2,3-dihydro-1H-isoindolyl, or1,2,3,4-tetrahydro-isoquinoline, each optionally substituted by 1, 2, 3,4, or 5 substituents independently selected from halo, C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆cyanoalkyl, Cy, —(C₁₋₄ alkyl)-Cy, CN, NO₂, OR^(a2), SR^(a2), C(O)R^(b2),C(O)NR^(a)R^(d2), C(O)OR^(a2), OC(O)R^(b2), OC(O)NR^(c2)R^(d2),NR^(c2)R^(d2), NR^(c2)C(O)R^(b2), NR^(c2)C(O)NR^(c2)R^(d2),NR^(c2)C(O)OR^(a2), S(O)R^(b2), S(O)NR^(c2)R^(d2), S(O)₂R^(b2),NR^(c2)S(O)₂R^(b2), and S(O)₂NR^(c2)R^(d2).

In some embodiments, or Q is H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,aryl, heteroaryl, cycloalkyl, heterocycloalkyl, each optionallysubstituted by 1, 2, 3, 4, or 5 substituents independently selected fromhalo, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆hydroxyalkyl, C₁₋₆ cyanoalkyl, Cy, —(C₁₋₄ alkyl)-Cy, CN, NO₂, OR^(a2),—(C₁₋₄ alkyl)-OR^(a2), SR^(a2), —(C₁₋₄ alkyl)-SR^(a2), C(O)R^(b2),—(C₁₋₄ alkyl)-C(O)R^(b2), C(O)NR^(c2)R^(d2), —(C₁₋₄alkyl)-C(O)NR^(c2)R^(d2), C(O)OR^(a2), —(C₁₋₄ alkyl)-C(O)OR^(a2),OC(O)R^(b2), —(C₁₋₄ alkyl)-OC(O)R^(b2), OC(O)NR^(c2)R^(d2), —(C₁₋₄alkyl)-C(O)NR^(c2)R^(d2), NR^(c2)R^(d2), —(C₁₋₄ alkyl)-NR^(c2)R^(d2),NR^(c2)C(O)R^(b2), —(C₁₋₄ alkyl)-NR^(c2)C(O)R^(b2),NR^(c2)C(O)NR^(c2)R^(d2), —(C₁₋₄ alkyl)-NR^(c2)C(O)NR^(c2)R^(d2),NR^(c2)C(O)OR^(a2), —(C₁₋₄ alkyl)-NR^(c2)C(O)OR^(a2),C(═NR^(i))NR^(c2)R^(d2), NR^(c2)C(═NR^(i))NR^(c2)R^(d2), P(R^(f2))₂,P(OR^(e2))₂, P(O)R^(e2)R^(f2), P(O)OR^(e2)OR^(f2), S(O)R^(b2), —(C₁₋₄alkyl)-S(O)R^(b2), S(O)NR^(c2)R^(d2), —(C₁₋₄ alkyl)-S(O)NR^(c2)R^(d2),S(O)₂R^(b2), —(C₁₋₄ alkyl)-S(O)₂R^(b2), NR^(c2)S(O)₂R^(b2), —(C₁₋₄alkyl)-NR^(c2)S(O)₂R^(b2), S(O)₂NR^(c2)R^(d2), and —(C₁₋₄alkyl)-S(O)₂NR^(c2)R^(d2).

In some embodiments, R^(Q) is H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C₁₋₆ haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl,arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl,wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, cycloalkyl,heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl,heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by1, 2, 3, 4, or 5 substituents independently selected from halo, C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl,C₁₋₆ cyanoalkyl, Cy, —(C₁₋₄ alkyl)-Cy, CN, NO₂, OR^(a2), SR^(a2),C(O)R^(b2), C(O)NR^(c2)R^(d2), C(O)OR^(a2), OC(O)R^(b2),OC(O)NR^(c2)R^(d2), NR^(c2)R^(d2), NR^(c2)C(O)R^(b2),NR^(c2)C(O)NR^(c2)R^(d2), NR^(c2)C(O)OR^(a2), C(═NR^(i))NR^(c2)R^(d2),NR^(c2)C(═NR^(i))NR^(c2)R^(d2), P(R^(f2))₂, P(OR^(e2))₂,P(O)R^(e2)R^(f2), P(O)OR^(e2)OR^(f2), S(O)R^(b2), S(O)NR^(c2)R^(d2),S(O)₂R^(b2), and S(O)₂NR^(c2)R^(d2).

In some embodiments, R^(Q) is H, C₁₋₆ alkyl, aryl, cycloalkyl,heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl,heteroarylalkyl, or heterocycloalkylalkyl, wherein said C₁₋₆ alkyl,aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl,cycloalkylalkyl, heteroarylalkyl, or heterocyclo-alkylalkyl isoptionally substituted by 1, 2, 3, 4, or 5 substituents independentlyselected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆ cyanoalkyl, Cy, —(C₁₋₄ alkyl)-Cy, CN,NO₂, OR^(a2), SR^(a2), C(O)R^(b2), C(O)NR^(a)R^(d2), C(O)OR^(a2),OC(O)R^(b2), OC(O)NR^(c2)R^(d2), NR^(c2)R^(d2), NR^(c2)C(O)R^(b2),NR^(c2)C(O)NR^(c2)R^(d2), NR^(c2)C(O)OR^(a2), C(═NR^(i))NR^(c2)R^(d2),NR^(c2)C(═NR^(i))NR^(c2)R^(d2), P(R^(f2))₂, P(OR^(e2))₂,P(O)R^(e2)R^(f2), P(O)OR^(e2)OR^(f2), S(O)R^(b2), S(O)NR^(c2)R^(d2),S(O)₂R^(b2), NR^(c2)S(O)₂R^(b2), and s(O)₂NR^(c2)R^(d2).

In some embodiments, R^(Q) is H, C₁₋₆ alkyl, aryl, cycloalkyl,heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl,heteroarylalkyl, or heterocycloalkylalkyl, wherein said C₁₋₆ alkyl,aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl,cycloalkylalkyl, heteroarylalkyl, or heterocyclo-alkylalkyl isoptionally substituted by 1, 2, 3, 4, or 5 substituents independentlyselected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆ cyanoalkyl, Cy, —(C₁₋₄ alkyl)-Cy, CN,NO₂, OR^(a2), SR^(a2), C(O)R^(b2), C(O)—NR^(c2)R^(d2), C(O)OR^(a2),OC(O)R^(b2), OC(O)NR^(c2)R^(d2), NR^(c2)R^(d2), NR^(c2)C(O)R^(b2),NR^(c2)C(O)NR^(c2)R^(d2), NR^(c2)C(O)OR^(a2), S(O)R^(b2), S(O)R^(b2),S(O)NR^(c2)R^(d2), S(O)₂R^(b2), NR^(c2)S(O)₂R^(b2), andS(O)₂NR^(c2)R^(d2).

In some embodiments, R^(Q) is C₁₋₆ alkyl optionally substituted by 1, 2,3, 4, or 5 substituents independently selected from halo, C₁₋₆ alkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxy-alkyl, C₁₋₆cyanoalkyl, Cy, —(C₁₋₄ alkyl)-Cy, CN, NO₂, OR^(a2), SR^(a2), C(O)R^(b2),C(O)NR^(a2)R^(d2), C(O)OR^(a2), OC(O)R^(b2), OC(O)NR^(c2)R^(d2),NR^(c2)R^(d2), NR^(c2)C(O)R^(b2), NR^(c2)C(O)NR^(c2)R^(d2),NR^(c2)C(O)OR^(a2), C(═NR^(i))NR^(c2)R^(d2),NR^(c2)C(═NR^(i))NR^(c2)R^(d2), P(R^(f2))₂, P(OR^(e2))₂,P(O)R^(e2)R^(f2), P(O)OR^(e2)OR^(f2), S(O)R^(b2), S(O)NR^(c2)R^(d2),S(O)²R^(b2), NR^(c2)S(O)₂R^(b2), and S(O)₂NR^(c2)R^(d2).

In some embodiments, R^(Q) is C₁₋₆ alkyl optionally substituted by 1, 2,3, 4, or 5 substituents independently selected from halo, C₁₋₆ alkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxy-alkyl, C₁₋₆cyanoalkyl, Cy, —(C₁₋₄ alkyl)-Cy, CN, NO₂, OR^(a2), SR^(a2), C(O)R^(b2),C(O)NR^(c2)R^(d2), C(O)OR^(a2), OC(O)R^(b2), OC(O)NR^(c2)R^(d2),NR^(c2)R^(d2), NR^(c2)C(O)R^(b2), NR^(c2)C(O)OR^(a2), S(O)R^(b2),S(O)NR^(c2)R^(d2), S(O)₂R^(b2), NR^(c2)S(O)₂R^(b2), andS(O)₂NR^(c2)R^(d2).

In some embodiments, R^(Q) is aryl, heteroaryl, arylalkyl, orheteroarylalkyl, each optionally substituted by 1, 2, 3, 4, or 5substituents independently selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆ cyanoalkyl, Cy,—(C₁₋₄ alkyl)-Cy, CN, NO₂, OR^(a2), SR^(a2), C(O)R^(b2),C(O)NR^(c2)R^(d2), C(O)OR^(a2), OC(O)R^(b2), OC(O)NR^(c2)R^(d2),NR^(c2)R^(d2), NR^(c2)C(O)R^(b2), NR^(c2)C(O)NR^(c2)R^(d2),NR^(c2)C(O)OR^(a2), C(═NR^(i))NR^(c2)R^(d2),NR^(c2)C(═NR^(i))NR^(c2)R^(d2), P(R^(f2))₂, P(OR^(e2))₂,P(O)R^(e2)R^(f2), P(O)OR^(e2)OR^(f2), S(O)R^(b2), S(O)NR^(c2)R^(d2),S(O)₂R^(b2), NR^(c2)S(O)₂R^(b2), and S(O)₂NR^(e2)R^(d2).

In some embodiments, R⁴ and R^(Q) together with the N atom to which theyare attached form a 4-20 membered heterocycloalkyl group or 5-20membered heteroaryl group, each optionally substituted by 1, 2, 3, 4, or5 substituents independently selected from halo, C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆cyanoalkyl, Cy, —(C₁₋₄ alkyl)-Cy, CN, NO₂, OR^(a2), —(C₁₋₄alkyl)-OR^(a2), SR^(a2), —(C₁₋₄ alkyl)-SR^(a2), C(O)R^(b2), —(C₁₋₄alkyl)-C(O)R^(b2), C(O)NR^(c2)R^(d2), —(C₁₋₄ alkyl)-C(O)NR^(c2)R^(d2),C(O)OR^(a2), —(C₁₋₄ alkyl)-C(O)OR^(a2), OC(O)R^(b2), —(C₁₋₄alkyl)-OC(O)R^(b2), OC(O)NR^(c2)R^(d2), —(C₁₋₄alkyl)-OC(O)NR^(c2)R^(d2), NR^(c2)R^(d2), —(C₁₋₄ alkyl)-NR^(c2)R^(d2),NR^(c2)C(O)R^(b2), —(C₁₋₄ alkyl)-NR^(c2)C(O)R^(b2),NR^(c2)C(O)NR^(c2)R^(d2), —(C₁₋₄ alkyl)-NR^(c2)C(O)NR^(c2)R^(d2),NR^(c2)C(O)OR^(a2), —(C₁₋₄ alkyl)-NR^(c2)C(O)OR^(a2),C(═NR^(i))NR^(c2)R^(d2), NR^(c2)C(═NR^(i))NR^(c2)R^(d2), P(R^(f2))₂,P(OR^(e2))₂, P(O)R^(e2)R^(f2), P(O)OR^(e2)OR^(f2), S(O)R^(b2), —(C₁₋₄alkyl)-S(O)R^(b2), S(O)NR^(c2)R^(d2), —(C₁₋₄ alkyl)-S(O)NR^(c2)R^(d2),S(O)₂R^(b2), —(C₁₋₄ alkyl)-S(O)₂R^(b2), NR^(c2)S(O)₂R^(b2), —(C₁₋₄alkyl)-NR^(c2)S(O)₂R^(b2), S(O)₂NR^(c2)R^(d2) and —(C₁₋₄alkyl)-S(O)₂NR^(c2)R^(d2)

In some embodiments, R⁴ and R^(Q) together with the N atom to which theyare attached form a 4-20 membered heterocycloalkyl group optionallysubstituted by 1, 2, 3, 4, or 5 substituents independently selected fromhalo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆hydroxy-alkyl, C₁₋₆ cyanoalkyl, Cy, —(C₁₋₄ alkyl)-Cy, CN, NO₂, OR^(a2),SR^(a2), C(O)R^(b2), C(O)NR^(c2)R^(d2), C(O)OR^(a2), OC(O)R^(b2),OC(O)NR^(c2)R^(d2), NR^(c2)R^(d2), NR^(c2)C(O)R^(b2),NR^(c2)C(O)NR^(c2)R^(d2), NR^(c2)C(O)OR^(a2), S(O)R^(b2),S(O)NR^(c2)R^(d2), S(O)₂R^(b2), NR^(c2)S(O)₂R^(b2), andS(O)₂NR^(c2)R^(d2).

In some embodiments, R⁴ is H, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl,C(O)—R^(4a), SO₂—R^(4a), aryl, cycloalkyl, heteroaryl, heterocycloalkyl,arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl,wherein said C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, aryl, cycloalkyl,heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl,heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by1, 2, 3, 4, or 5 substituents independently selected from halo, C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl,C₁₋₆ cyanoalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, CN,NO₂, OR^(a4), SR^(a4), C(O)R^(b4), C(O)NR^(c4)R^(d4), C(O)OR^(a4),OC(O)R^(b4), OC(O)NR^(c4)R^(d4), NR^(c4)R^(d4), NR^(c4)C(O)R^(b4),NR^(c4)C(O)NR^(c4)R^(d4), NR^(c4)C(O)OR^(a4), C(═NR^(i))NR^(c4)R^(d4),NR^(c4)C(═NR_(i))NR^(c4)R^(d4), P(R^(f4))₂, P(OR^(e4))₂,P(O)R^(e4)R^(f4), P(O)OR^(e4)OR^(f4), S(O)R^(b4), S(O)NR^(c4)R^(d4),S(O)₂R^(b4), NR^(c4)S(O)₂R^(b4), and S(O)₂NR^(c4)R^(d4).

In some embodiments, R⁴ is H, C₁₋₄ alkyl, C(O)—R^(4a), SO₂—R^(4a), aryl,cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl,heteroarylalkyl, or heterocycloalkylalkyl, wherein said C₁₋₄ alkyl,aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl,cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionallysubstituted by 1, 2, 3, 4, or 5 substituents independently selected fromhalo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆hydroxyalkyl, C₁₋₆ cyanoalkyl, aryl, heteroaryl, cycloalkyl,heterocycloalkyl, CN, NO₂, OR^(a4), SR^(a4), C(O)R^(b4),C(O)NR^(c4)R^(d4), C(O)OR^(a4), OC(O)R^(b4), OC(O)NR^(c4)R^(d4),NR^(c4)R^(d4), NR^(c4)C(O)R^(b4), NR^(c4)C(O)NR^(c4)R^(d4),NR^(c4)C(O)OR^(a4), C(═NR^(i))NR^(c4)R^(d4),NR^(c4)C(═NR^(i))NR^(c4)R^(d4), P(R^(f4))₂, P(OR^(e4))₂,P(O)R^(e4)R^(f4), P(O)OR^(e4)OR^(f4), S(O)R^(b4), S(O)NR^(c4)R^(d4),S(O)₂R^(b4), NR^(c4)S(O)₂R^(b4), and S(O)₂NR^(c4)R^(d4).

In some embodiments, R⁴ is H.

In some embodiments, R^(A) and R^(B) are independently selected from H,F, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, aryl,cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl,heteroarylalkyl, heterocycloalkylalkyl, CN, NO₂, OR^(a1), SR^(a1),C(O)R^(b1), C(O)NR^(c1)R^(d1), C(O)OR^(a1), OC(O)R^(b1),OC(O)NR^(c1)R^(d1), NR^(c1)R^(d1), NR^(c1)C(O)R^(b1),NR^(c1)C(O)NR^(c1)R^(d1), NR^(c1)C(O)OR^(a1), C(═NR^(i))NR^(c1)R^(d1),NR^(c1)C(═NR^(i))NR^(c1)R^(d1), P(R^(f1))₂, P(OR^(e1))₂,P(O)R^(e1)R^(f1), P(O)OR^(e1)OR^(f1), S(O)R^(b1), S(O)NR^(c1)R^(d1),S(O)₂R^(b1), NR^(c1)S(O)₂R^(b1), and S(O)₂NR^(c1)R^(d1); wherein saidC₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, cycloalkyl, heteroaryl,heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, orheterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5substituents independently selected from halo, C₁₋₄ alkyl, C₂₋₄ alkenyl,C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₁₋₄ hydroxyalkyl, C₁₋₄ cyanoalkyl, CN,NO₂, OR^(a1), SR^(a1), C(O)R^(b1), C(O)NR^(c1)R^(d1), C(O)OR^(a1),OC(O)R^(b1), OC(O)NR^(c1)R^(d1), NR^(c1)R^(d1), NR^(c1)C(O)R^(b1),NR^(c1)C(O)NR^(c1)R^(d1), NR^(c1)C(O)OR^(a1), C(═NR^(i))NR^(c1)R^(d1),NR^(c1)C(═NR^(i))NR^(c1)R^(d1), P(R^(f1))₂, P(OR^(e1))₂,P(O)R^(e1)R^(f1), P(O)OR^(e1)OR^(f1), S(O)R^(b1), S(O)NR^(c1)R^(dl),S(O)₂R^(b1), NR^(c1)S(O)₂R^(b1), and S(O)₂NR^(c1)R^(d1).

In some embodiments, R^(A) and R^(B) are independently selected from H,C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, aryl,cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl,heteroarylalkyl, and heterocycloalkylalkyl, wherein said C₁₋₆ alkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, cycloalkyl, heteroaryl,heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, orheterocyclo-alkylalkyl is optionally substituted by 1, 2, 3, 4, or 5substituents independently selected from halo, C₁₋₄ alkyl, C₂₋₄ alkenyl,C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₁₋₄ hydroxyalkyl, C₁₋₄ cyanoalkyl, CN,NO₂, OR^(a1), SR^(a1), C(O)R^(b1), C(O)NR^(c1)R^(d1), C(O)OR^(a1),OC(O)R^(b1), OC(O)NR^(c1)R^(d1), NR^(c1)R^(d1), NR^(c1)C(O)R^(b1),NR^(c1)C(O)NR^(c1)R^(d1), NR_(c1)C(O)OR^(a1), S(O)R^(b1),S(O)NR^(c1)R^(d1), S(O)₂R^(b1), NR^(c1)S(O)₂R^(b1), andS(O)₂NR^(c1)R^(d1).

In some embodiments, R^(A) and R^(B) are independently selected from H,F, and C₁₋₆ alkyl.

In some embodiments, R^(A) and R^(B) are, independently, H or C₁₋₆alkyl.

In some embodiments, R^(A) and R^(B) are both H.

In some embodiments, R^(A) and R^(B) together with the carbon atom towhich they are attached form a 3-, 4-, 5-, 6-, or 7-membered cycloalkylgroup or 3-, 4-, 5-, 6-, or 7-membered heterocycloalkyl group, eachoptionally substituted with 1, 2, or 3 substituents independentlyselected from halo, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄haloalkyl, C₁₋₄ hydroxyalkyl, C₁₋₄ cyanoalkyl, CN, NO₂, OR^(a1),SR^(a1), C(O)R^(b1), C(O)NR^(c1)R^(d1), C(O)OR^(a1), OC(O)R^(b1),OC(O)NR^(c1)R^(d1), NR^(c1)R^(d1), NR^(c1)C(O)R^(b1),NR^(c1)C(O)NR^(c1)R^(d1), NR^(c1)C(O)OR^(a1), C(═NR^(i))NR^(c1)R^(d1),NR^(c1)C(═NR^(i))NR^(c1)R^(d1), P(R^(f1))₂, P(OR^(e1))₂,P(O)R^(e1)R^(f1), P(O)OR^(e1)OR^(f1), S(O)R^(b1), S(O)NR^(c1)R^(d1),S(O)₂R^(b1), NR^(c1)S(O)₂R^(b1), and S(O)₂NR^(c1)R^(d1).

In some embodiments, R^(i) is H, CN, or NO₂.

In some embodiments, R^(a2) is H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, Cy², or Cy²-(C₁₋₆ alkyl)-, wherein said C₁₋₆alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, or C₂₋₆ alkynyl, is optionallysubstituted with 1, 2, 3, 4, or 5 substituents independently selectedfrom halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ hydroxyalkyl,C₁₋₆ cyanoalkyl, Cy², CN, NO₂, OR^(a5), SR^(a5), C(O)R^(b5),C(O)NR^(c5)R^(d5), C(O)OR^(a5), OC(O)R^(b5), OC(O)NR^(c5)R^(d5),NR^(c5)R^(d5), NR^(c5)C(O)R^(b5), NR^(c5)C(O)NR^(c5)R^(d5),NR^(c5)C(O)OR^(a5), C(═NR^(i))NR^(c5)R^(d5),NR^(c5)C(═NR^(i))NR^(c5)R^(d5), P(R^(f5))₂, P(OR^(e5))₂,P(O)R^(e5)R^(f5), P(O)OR^(e5)OR^(f5), S(O)R^(b5), S(O)NR^(c5)R^(d5),R^(b2), S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5), and S(O)₂NR^(c5)R^(d5).

In some embodiments, R^(b2) is H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, aryl, Cy², or Cy²-(C₁₋₆ alkyl)-, wherein saidC₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, or aryl isoptionally substituted with 1, 2, 3, 4, or 5 substituents independentlyselected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆ cyanoalkyl, Cy², CN, NO₂, OR^(a5),SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5), C(O)OR^(a5), OC(O)R^(b5),OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5), NR^(c5)C(O)R^(b5),NR^(c5)C(O)NR_(c5)R^(d5), NR^(c5)C(O)OR^(a5), C(═NR^(i))NR^(c5)R^(d5),NR^(c5)C(═NR^(i))NR^(c5)R^(d5), P(R^(f5))₂, P(OR^(e5))₂,P(O)R^(e5)R^(f5), P(O)OR^(e5)OR^(f5), S(O)R^(b5), S(O)R^(b5),S(O)NR^(c5)R^(d5), S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5), andS(O)₂NR^(c5)R^(d5).

In some embodiments, R^(c) and R^(d) are independently selected from H,C₁₋₁₀ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl,heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl,cycloalkylalkyl, and heterocycloalkylalkyl, wherein said C₁₋₁₀ alkyl,C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, heteroaryl,cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl,cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted withOH, amino, halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, aryl, arylalkyl,heteroaryl, heteroarylalkyl, cycloalkyl, or heterocycloalkyl.

In some embodiments, R^(c) and R^(d) together with the N atom to whichthey are attached form a 4-, 5-, 6- or 7-membered heterocycloalkylgroup.

In some embodiments, Cy, Cy¹, and Cy² are independently selected fromaryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each optionallysubstituted by 1, 2, 3, 4 or 5 substituents independently selected fromhalo, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, CN, NO₂,OR^(a3), SR^(a3), C(O)R^(b3), C(O)NR^(c3)R^(d3), C(O)OR^(a3),C(O)OR^(a3), OC(O)R^(b3), OC(O)NR^(a3)R^(d3), NR^(c3)C(O)R^(b3),NR^(c3)C(O)OR^(a3), C(═NR^(i))NR^(c3)R^(d3),NR^(c3)C(═NR^(i))NR^(c3)R^(d3), P(R^(f3))₂, P(OR^(e3))₂,P(O)R^(e3)R^(f3), P(O)OR^(e3)OR^(f3), S(O)R^(b3), S(O)NR^(c3)R^(d3),S(O)₂R^(b3), and S(O)₂NR^(c3)R^(d3).

In some embodiments, Cy is aryl, heteroaryl, cycloalkyl, orheterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5substituents independently selected from halo, C₁₋₄ alkyl, C₂₋₄ alkenyl,C₂₋₄ alkynyl, C₁₋₄ haloalkyl, CN, NO₂, OR^(a3), SR^(a3), C(O)R^(b3),C(O)NR^(c3)R^(d3), C(O)OR^(a3), OC(O)R^(b3), OC(O)NR^(c3)R^(d3),NR^(c3)R^(d3), NR^(c3)C(O)R^(b3), NR^(c3)C(O)OR^(a3), S(O)R^(b3),S(O)NR^(c3)R^(d3), S(O)₂R^(b3), and S(O)₂NR^(c3)R^(d3).

In some embodiments, R¹ is H.

In some embodiments, R is H.

In some embodiments, R² is H.

In some embodiments, R³ is H.

In some embodiments, p is 1, 2, 3, 4 or 5.

In some embodiments, p is 1 or 2.

In some embodiments, p is 1.

In some embodiments, the compounds of the invention have Formula I:

In some embodiments, the compounds of the invention have Formula IIa:

In some embodiments, the compounds of the invention have Formula II:

In some embodiments, the compound has Formula III:

In some embodiments, the present invention provides compounds of FormulaI:

or pharmaceutically acceptable salts or prodrugs thereof, wherein:

U, V, and W are independently selected from N, O, S, CR², and NR³,wherein the five-membered ring containing U, V, and W is an aromaticheterocycle;

A is aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, each optionallysubstituted by 1, 2, 3, 4, or 5 substituents independently selected fromhalo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ halo-alkyl, C₁₋₆hydroxyalkyl, C₁₋₆ cyanoalkyl, aryl, cycloalkyl, heteroaryl,heterocycloalkyl, CN, NO₂, OR^(a), SR^(a), C(O)R^(b), C(O)NR^(c)R^(d),C(O)OR^(a), OC(O)R^(b), OC(O)NR^(c)R^(d), NR^(c)R^(d), NR^(c)(O)R^(b),NR^(c)C(O)NR^(c)R^(d), NR^(c)(O)OR^(a), S(O)R^(b), S(O)NR^(c)R^(d),S(O)₂R^(b), NR^(c)S(O)₂R^(b), and S(O)₂NR^(c)R^(d);

In some embodiments, R^(A) and R^(B) are independently selected from H,C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, aryl,cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl,heteroarylalkyl, and heterocycloalkylalkyl, wherein said C₁₋₆ alkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, cycloalkyl, heteroaryl,heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, orheterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5substituents independently selected from halo, C₁₋₄ alkyl, C₂₋₄ alkenyl,C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₁₋₄ hydroxyalkyl, cyanoalkyl, CN, NO₂,OR^(a1), SR^(a1), C(O)R^(b1), C(O)NR^(c1)R^(d1), C(O)OR^(a1),OC(O)R^(b1), OC(O)NR^(c1)R^(d1), NR^(c1)R^(d1), NR^(c1)C(O)R^(b1),NR^(c1)C(O)NR^(c1)R^(d1), NR^(c1)C(O)OR^(a1), S(O)R^(b1),S(O)NR^(c1)R^(d1)S(O)₂R^(b1), NR^(c1)S(O)₂R^(b1), andS(O)₂NR^(c1)R^(d1).

or R^(A) and R^(B) together with the carbon atom to which they areattached form a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group or 3-,4-, 5-, 6-, or 7-membered heterocycloalkyl group, each optionallysubstituted with 1, 2, or 3 substituents independently selected fromhalo, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₁₋₄hydroxyalkyl, C₁₋₄ cyanoalkyl, CN, NO₂, OR^(a1), SR^(a1), C(O)R^(b1),C(O)NR^(c1)R^(d1), C(O)OR^(a1), OC(O)R^(b1), OC(O)NR^(c1)R^(d1),NR^(c1)R^(d1), NR^(c1)C(O)R^(b1), NR^(c1)C(O)NR^(c1)R^(d1),NR^(c1)C(O)OR^(a1), S(O)R^(b1), S(O)NR^(c1)R^(d1), S(O)₂R^(b1),NR^(c1)S(O)₂R^(b1), and S(O)₂NR^(c1)R^(d1);

Q is OR^(Q), OC(O)R^(Q), OC(O)NR⁴R^(Q), NR⁴R^(Q), NR⁴C(O)R^(Q),NR⁴C(O)NR⁴R^(Q), SR^(Q), S(O)R^(Q), S(O)NR⁴R^(Q), S(O)₂R^(Q), orS(O)₂NR⁴R^(Q);

R^(Q) is H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl,cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl, wherein saidC₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, cycloalkyl, heteroaryl,heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, orheterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5substituents independently selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆) hydroxyalkyl, C₁₋₆ cyanoalkyl, Cy,—(C₁₋₄ alkyl)-Cy, CN, NO₂, OR^(a2), SR^(a2), C(O)R^(b2),C(O)NR^(c2)R^(d2), C(O)OR^(a2), OC(O)R^(b2), OC(O)NR^(c2)R^(d2),NR^(c2)R^(d2), NR^(c2)C(O)R^(b2), NR^(c2)C(O)NR^(c2)R^(d2),NR^(c2)C(O)OR^(a2), S(O)R^(b2), S(O)NR^(c2)R^(d2), S(O)₂R^(b2),NR^(c2)S(O)₂R^(b2), and S(O)₂NR^(c2)R^(d2);

or R⁴ and R^(Q) together with the N atom to which they are attached forma 4-20 membered heterocycloalkyl group optionally substituted by 1, 2,3, 4, or 5 substituents independently selected from halo, C₁₋₆ alkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆cyanoalkyl, Cy, —(C₁₋₄ alkyl)-Cy, CN, NO₂, OR^(a2), SR^(a2), C(O)R^(b2),C(O)NR^(c2)R^(d2), C(O)OR^(a2), OC(O)R^(b2), OC(O)NR^(c2)R^(d2),NR^(c2)R^(d2), NR^(c2)C(O)R^(b2), NR^(c2)C(O)NR^(c2)R^(d2),NR^(c2)C(O)OR^(a2), S(O)R^(b2), S(O)NR^(c2)R^(d2), S(O)₂R^(b2),NR^(c2)S(O)₂R^(b2), and S(O)₂NR^(c2)R^(d2);

Cy is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, each optionallysubstituted by 1, 2, 3, 4 or 5 substituents independently selected fromhalo, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ halo-alkyl, CN, NO₂,OR^(a3), SR^(a3), C(O)R^(b3), C(O)NR^(c3)R^(d3), C(O)OR^(a3),OC(O)R^(b3), OC(O)NR^(c3)R^(d3), NR^(c3)R^(d3), NR^(c3)C(O)R^(b3),NR^(c3)C(O)OR^(a3), S(O)R^(b3), S(O)NR^(c3)R^(d3), S(O)₂R^(b3), andS(O)₂NR^(c3)R^(d3);

R¹ is H or C₁₋₄ alkyl;

R² is H, halo, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl,CN, NO₂, OH, C₁₋₄ alkoxy, amino, C₁₋₄ alkylamino, or C₂₋₈ dialkylamino;

R³ is H, C₁₋₄ alkyl, C₂₋₄ alkenyl, or C₂₋₄ alkynyl;

R⁴ is H, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, or C(O)—(C₁₋₄ alkyl);

-   -   R^(a), R^(a1), R^(a2), and R^(a3) are independently selected        from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,        aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl,        heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl,        wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆        alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl,        arylalkyl, heteroarylalkyl, cycloalkylalkyl or        heterocycloalkylalkyl is optionally substituted with OH, amino,        halo, C₁₋₆ alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,        cycloalkyl or heterocycloalkyl;

R^(b), R^(b1), R^(b2), and R^(b3) are independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl,cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl,cyclo-alkylalkyl and heterocycloalkylalkyl, wherein said C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, cycloalkyl,heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl,cycloalkylalkyl or hetero-cycloalkylalkyl is optionally substituted withOH, amino, halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, aryl, aryl-alkyl,heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl;

R^(c) and R^(d) are independently selected from H, C₁₋₁₀ alkyl, C₁₋₆haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, heteroaryl, cycloalkyl,heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl andheterocycloalkylalkyl, wherein said C₁₋₁₀ alkyl, C₁₋₆ haloalkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, aryl, hetero-aryl, cycloalkyl, heterocycloalkyl,arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl isoptionally substituted with OH, amino, halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl,aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl orheterocycloalkyl;

or R^(c) and R^(d) together with the N atom to which they are attachedform a 4-, 5-, 6- or 7-membered heterocycloalkyl group;

R^(c1) and R^(d1) are independently selected from H, C₁₋₁₀ alkyl, C₁₋₆haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, heteroaryl, cycloalkyl,heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl andheterocycloalkylalkyl, wherein said C₁₋₁₀ alkyl, C₁₋₆ haloalkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, aryl, hetero-aryl, cycloalkyl, heterocycloalkyl,arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl isoptionally substituted with OH, amino, halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl,aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl orheterocycloalkyl;

or R^(c1) and R^(d1) together with the N atom to which they are attachedform a 4-, 5-, 6- or 7-membered heterocycloalkyl group;

R^(c2) and R^(d2) are independently selected from H, C₁₋₁₀ alkyl, C₁₋₆haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, heteroaryl, cycloalkyl,heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl orheterocycloalkylalkyl, wherein said C₁₋₁₀ alkyl, C₁₋₆ haloalkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, aryl, hetero-aryl, cycloalkyl, heterocycloalkyl,arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl isoptionally substituted with OH, amino, halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl,aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl orheterocycloalkyl;

or R^(c2) and R^(d2) together with the N atom to which they are attachedform a 4-, 5-, 6- or 7-membered heterocycloalkyl group; and

R^(c3) and R^(d3) are independently selected from H, C₁₋₁₀ alkyl, C₁₋₆haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, heteroaryl, cycloalkyl,heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl orheterocycloalkylalkyl, wherein said C₁₋₁₀ alkyl, C₁₋₆ haloalkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, aryl, hetero-aryl, cycloalkyl, heterocycloalkyl,arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl isoptionally substituted with OH, amino, halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl,aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl orheterocycloalkyl;

or R^(c3) and R^(d3) together with the N atom to which they are attachedform a 4-, 5-, 6- or 7-membered heterocycloalkyl group.

At various places in the present specification, substituents ofcompounds of the invention are disclosed in groups or in ranges. It isspecifically intended that the invention include each and everyindividual subcombination of the members of such groups and ranges. Forexample, the term “C₁₋₆ alkyl” is specifically intended to individuallydisclose methyl, ethyl, C₃ alkyl, C₄ alkyl, C₅ alkyl, and C₆ alkyl.

It is further intended that the compounds of the invention are stable.As used herein “stable” refers to a compound that is sufficiently robustto survive isolation to a useful degree of purity from a reactionmixture, and preferably capable of formulation into an efficacioustherapeutic agent.

It is further appreciated that certain features of the invention, whichare, for clarity, described in the context of separate embodiments, canalso be provided in combination in a single embodiment. Conversely,various features of the invention which are, for brevity, described inthe context of a single embodiment, can also be provided separately orin any suitable subcombination.

As used herein, the term “alkyl” is meant to refer to a saturatedhydrocarbon group which is straight-chained or branched. Example alkylgroups include methyl (Me), ethyl (Et), propyl (e.g., n-propyl andisopropyl), butyl (e.g., n-butyl, isobutyl, t-butyl), pentyl (e.g.,n-pentyl, isopentyl, neopentyl), and the like. An alkyl group cancontain from 1 to about 20, from 2 to about 20, from 1 to about 10, from1 to about 8, from 1 to about 6, from 1 to about 4, or from 1 to about 3carbon atoms.

As used herein, “alkenyl” refers to an alkyl group having one or moredouble carbon-carbon bonds. Example alkenyl groups include ethenyl,propenyl, and the like.

As used herein, “alkynyl” refers to an alkyl group having one or moretriple carbon-carbon bonds. Example alkynyl groups include ethynyl,propynyl, and the like.

As used herein, “haloalkyl” refers to an alkyl group having one or morehalogen substituents. Example haloalkyl groups include CF₃, C₂F₅, CHF₂,CCl₃, CHCl₂, C₂Cl₅, and the like.

As used herein, “halosulfanyl” refers to a sulfur group having one ormore halogen substituents. Example halosulfanyl groups includepentahalosulfanyl groups such as SF₅.

As used herein, “aryl” refers to monocyclic or polycyclic (e.g., having2, 3 or 4 fused rings) aromatic hydrocarbons such as, for example,phenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, indenyl, and thelike. In some embodiments, aryl groups have from 6 to about 20 carbonatoms.

As used herein, “cycloalkyl” refers to non-aromatic carbocyclesincluding cyclized alkyl, alkenyl, and alkynyl groups. Cycloalkyl groupscan include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings)ring systems, including spirocycles. In some embodiments, cycloalkylgroups can have from 3 to about 20 carbon atoms, 3 to about 14 carbonatoms, 3 to about 10 carbon atoms, or 3 to 7 carbon atoms. Cycloalkylgroups can further have 0, 1, 2, or 3 double bonds and/or 0, 1, or 2triple bonds. Cycloalkyl groups can further be substituted by one ormore oxo groups. Also included in the definition of cycloalkyl aremoieties that have one or more aromatic rings fused (i.e., having a bondin common with) to the cycloalkyl ring, for example, benzo derivativesof cyclopentane, cyclopentene, cyclohexane, and the like. A cycloalkylgroup having one or more fused aromatic rings can be attached thougheither the aromatic or non-aromatic portion. One or more ring-formingcarbon atoms of a cycloalkyl group can be oxidized, for example, havingan oxo or sulfido substituent. Example cycloalkyl groups includecyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl,norbornyl, norpinyl, norcarnyl, adamantyl, and the like.

As used herein, a “heteroaryl” group refers to an aromatic heterocyclehaving at least one heteroatom ring member such as sulfur, oxygen, ornitrogen. Heteroaryl groups include monocyclic and polycyclic (e.g.,having 2, 3 or 4 fused rings) systems. Any ring-forming N atom in aheteroaryl group can also be oxidized to form an N-oxo moiety. Examplesof heteroaryl groups include without limitation, pyridyl, N-oxopyridyl,pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, quinolyl,isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrryl, oxazolyl,benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl,triazolyl, tetrazolyl, indazolyl, 1,2,3-thiadiazolyl,1,2,4-thiadiazolyl, isothiazolyl, benzothienyl, purinyl, carbazolyl,benzimidazolyl, indolinyl, xanthene, and the like. In some embodiments,the heteroaryl group has from 1 to about 20 carbon atoms, and in furtherembodiments from about 3 to about 20 carbon atoms. In some embodiments,the heteroaryl group contains 3 to about 14, 3 to about 7, or 5 to 6ring-forming atoms. In some embodiments, the heteroaryl group has 1 toabout 4, 1 to about 3, or 1 to 2 heteroatoms.

As used herein, “heterocycloalkyl” refers to a non-aromatic heterocyclewhere one or more of the ring-forming atoms is a heteroatom such as anO, N, or S atom. Heterocycloalkyl groups can include mono- or polycyclic(e.g., having 2, 3 or 4 fused rings) ring systems as well asspirocycles. Any ring-forming C, N or S atom in a heterocycloalkyl groupcan be substituted by 1 or 2 oxo groups to form a carbonyl, N-oxo,sulfinyl, or sulfonyl moiety. Example “heterocycloalkyl” groups includemorpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl,tetrahydrothienyl, 2,3-dihydrobenzofuryl, 1,3-benzodioxole,benzo-1,4-dioxane, piperidinyl, pyrrolidinyl, isoxazolidinyl,isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl,imidazolidinyl, and the like. Also included in the definition ofheterocycloalkyl are moieties that have one or more aromatic rings fused(i.e., having a bond in common with) to the nonaromatic heterocyclicring, for example phthalimidyl, naphthalimidyl, and benzo derivatives ofheterocycles such as indolene, isoindoline, tetrahydroquinoline, andtetrahydroisoquinoline groups. A heterocycloalkyl group having one ormore fused aromatic rings can be attached though either the aromatic ornon-aromatic portion. In some embodiments, the heterocycloalkyl grouphas from 1 to about 20 carbon atoms, and in further embodiments fromabout 3 to about 20 carbon atoms. In some embodiments, theheterocycloalkyl group contains 3 to about 20, 3 to about 14, 3 to about7, or 5 to 6 ring-forming atoms. In some embodiments, theheterocycloalkyl group has 1 to about 4, 1 to about 3, or 1 to 2heteroatoms. In some embodiments, the heterocycloalkyl group contains 0to 3 double bonds. In some embodiments, the heterocycloalkyl groupcontains 0 to 2 triple bonds.

As used herein, “halo” or “halogen” includes fluoro, chloro, bromo, andiodo.

As used herein, “hydroxyalkyl” refers to an alkyl group substituted witha hydroxyl group.

As used herein, “cyanoalkyl” refers to an alkyl group substituted with acyano group.

As used herein, “alkoxy” refers to an O-alkyl group. Example alkoxygroups include methoxy, ethoxy, propoxy (e.g., n-propoxy andisopropoxy), t-butoxy, and the like.

As used herein, “arylalkyl” refers to alkyl substituted by aryl and“cycloalkylalkyl” refers to alkyl substituted by cycloalkyl. An examplearylalkyl group is benzyl.

As used herein, “heteroarylalkyl” refers to alkyl substituted byheteroaryl and “heterocycloalkylalkyl” refers to alkyl substituted byheterocycloalkyl.

As used herein, “amino” refers to NH₂.

As used herein, “alkylamino” refers to an amino group substituted by analkyl group.

As used herein, “dialkylamino” refers to an amino group substituted bytwo alkyl groups.

The compounds described herein can be asymmetric (e.g., having one ormore stereocenters). All stereoisomers, such as enantiomers anddiastereomers, are intended unless otherwise indicated. Compounds of thepresent invention that contain asymmetrically substituted carbon atomscan be isolated in optically active or racemic forms. Methods on how toprepare optically active forms from optically active starting materialsare known in the art, such as by resolution of racemic mixtures or bystereoselective synthesis. Many geometric isomers of olefins, C═N doublebonds, and the like can also be present in the compounds describedherein, and all such stable isomers are contemplated in the presentinvention. Cis and trans geometric isomers of the compounds of thepresent invention are described and may be isolated as a mixture ofisomers or as separated isomeric forms. A bond, in a structure diagramrepresented by a wavy line “

” is intended to indicate that the structure represents the cis or thetrans isomer, or a mixture of the cis and trans isomers in anyproportion.

Compounds of the invention also include tautomeric forms. Tautomericforms result from the swapping of a single bond with an adjacent doublebond together with the concomitant migration of a proton. Tautomericforms include prototropic tautomers which are isomeric protonationstates having the same empirical formula and total charge. Exampleprototropic tautomers include ketone—enol pairs, amide—imidic acidpairs, lactam—lactim pairs, amide—imidic acid pairs, enamine—iminepairs, and annular forms where a proton can occupy two or more positionsof a heterocyclic system, for example, 1H- and 3H-imidazole, 1H-, 2H-and 4H-1,2,4-triazole, 1H- and 2H-isoindole, and 1H- and 2H-pyrazole.Tautomeric forms can be in equilibrium or sterically locked into oneform by appropriate substitution.

Compounds of the invention can also include all isotopes of atomsoccurring in the intermediates or final compounds. Isotopes includethose atoms having the same atomic number but different mass numbers.For example, isotopes of hydrogen include tritium and deuterium.

In some embodiments, the compounds of the invention, and salts thereof,are substantially isolated. By “substantially isolated” is meant thatthe compound is at least partially or substantially separated from theenvironment in which is was formed or detected. Partial separation caninclude, for example, a composition enriched in the compound of theinvention. Substantial separation can include compositions containing atleast about 50%, at least about 60%, at least about 70%, at least about80%, at least about 90%, at least about 95%, at least about 97%, or atleast about 99% by weight of the compound of the invention, or saltthereof. Methods for isolating compounds and their salts are routine inthe art.

The present invention also includes pharmaceutically acceptable salts ofthe compounds described herein. As used herein, “pharmaceuticallyacceptable salts” refers to derivatives of the disclosed compoundswherein the parent compound is modified by converting an existing acidor base moiety to its salt form. Examples of pharmaceutically acceptablesalts include, but are not limited to, mineral or organic acid salts ofbasic residues such as amines; alkali or organic salts of acidicresidues such as carboxylic acids; and the like. The pharmaceuticallyacceptable salts of the present invention include the conventionalnon-toxic salts of the parent compound formed, for example, fromnon-toxic inorganic or organic acids. The pharmaceutically acceptablesalts of the present invention can be synthesized from the parentcompound which contains a basic or acidic moiety by conventionalchemical methods. Generally, such salts can be prepared by reacting thefree acid or base forms of these compounds with a stoichiometric amountof the appropriate base or acid in water or in an organic solvent, or ina mixture of the two; generally, nonaqueous media like ether, ethylacetate, ethanol, isopropanol, or ACN are preferred. Lists of suitablesalts are found in Remington's Pharmaceutical Sciences, 17′″ e a MackPublishing Company, Easton, Pa., 1985, p. 1418 and Journal ofPharmaceutical Science, 66, 2 (1977), each of which is incorporatedherein by reference in its entirety.

The phrase “pharmaceutically acceptable” is employed herein to refer tothose compounds, materials, compositions, and/or dosage forms which are,within the scope of sound medical judgment, suitable for use in contactwith the tissues of human beings and animals without excessive toxicity,irritation, allergic response, or other problem or complication,commensurate with a reasonable benefit/risk ratio.

The present invention also includes prodrugs of the compounds describedherein. As used herein, “prodrugs” refer to any covalently bondedcarriers which release the active parent drug when administered to amammalian subject. Prodrugs can be prepared by modifying functionalgroups present in the compounds in such a way that the modifications arecleaved, either in routine manipulation or in vivo, to the parentcompounds. Prodrugs include compounds wherein hydroxyl, amino,sulfhydryl, or carboxyl groups are bonded to any group that, whenadministered to a mammalian subject, cleaves to form a free hydroxyl,amino, sulfhydryl, or carboxyl group respectively. Examples of prodrugsinclude, but are not limited to, acetate, formate and benzoatederivatives of alcohol and amine functional groups in the compounds ofthe invention. Preparation and use of prodrugs is discussed in T.Higuchi and V. Stella, “Pro-drugs as Novel Delivery Systems,” Vol. 14 ofthe A.C.S. Symposium Series, and in Bioreversible Carriers in DrugDesign, ed. Edward B. Roche, American Pharmaceutical Association andPergamon Press, 1987, both of which are hereby incorporated by referencein their entirety.

Synthesis

The novel compounds of the present invention can be prepared in avariety of ways known to one skilled in the art of organic synthesis.The compounds of the present invention can be synthesized using themethods as hereinafter described below, together with synthetic methodsknown in the art of synthetic organic chemistry or variations thereon asappreciated by those skilled in the art.

The compounds of this invention can be prepared from readily availablestarting materials using the following general methods and procedures.It will be appreciated that where typical or preferred processconditions (i.e., reaction temperatures, times, mole ratios ofreactants, solvents, pressures, etc.) are given; other processconditions can also be used unless otherwise stated. Optimum reactionconditions may vary with the particular reactants or solvent used, butsuch conditions can be determined by one skilled in the art by routineoptimization procedures.

The processes described herein can be monitored according to anysuitable method known in the art. For example, product formation can bemonitored by spectroscopic means, such as nuclear magnetic resonancespectroscopy (e.g., ¹H or ¹³C) infrared spectroscopy, spectrophotometry(e.g., UV-visible), or mass spectrometry, or by chromatography such ashigh performance liquid chromatography (HPLC) or thin layerchromatography.

Preparation of compounds can involve the protection and deprotection ofvarious chemical groups. The need for protection and deprotection, andthe selection of appropriate protecting groups can be readily determinedby one skilled in the art. The chemistry of protecting groups can befound, for example, in Greene, et al., Protective Groups in OrganicSynthesis, 2d. Ed., Wiley & Sons, 1991, which is incorporated herein byreference in its entirety.

The reactions of the processes described herein can be carried out insuitable solvents which can be readily selected by one of skill in theart of organic synthesis. Suitable solvents can be substantiallynonreactive with the starting materials (reactants), the intermediates,or products at the temperatures at which the reactions are carried out,i.e., temperatures which can range from the solvent's freezingtemperature to the solvent's boiling temperature. A given reaction canbe carried out in one solvent or a mixture of more than one solvent.Depending on the particular reaction step, suitable solvents for aparticular reaction step can be selected.

Resolution of racemic mixtures of compounds can be carried out by any ofnumerous methods known in the art. An example method includes fractionalrecrystallization using a “chiral resolving acid” which is an opticallyactive, salt-forming organic acid. Suitable resolving agents forfractional recrystallization methods are, for example, optically activeacids, such as the D and L forms of tartaric acid, diacetyltartaricacid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid orthe various optically active camphorsulfonic acids. Resolution ofracemic mixtures can also be carried out by elution on a column packedwith an optically active resolving agent (e.g.,dinitrobenzoyl-phenylglycine). Suitable elution solvent composition canbe determined by one skilled in the art.

Compounds of the invention can be synthesized according to routinemethods by those skilled in the art and as shown in the below Schemes.

According to Scheme 1, intermediates 1-5 (such as6H-furo[3,4-c][1,2,5]oxadiazol-4-one) can be prepared starting withcleavage of bicyclic compounds I-1 with a primary amine to yieldhydroxymethyl derivatives 1-2. The hydroxyl group can be protected inany suitable manner such as by alklysilylchloride, ester, ether or othersuitable protecting group (see, e.g., Greene, et al., Protective Groupsin Organic Synthesis, supra) to yield protected compounds 1-3. Theprotected compounds 1-3 can be converted to the correspondingN-hydroxyamidines 1-4 by thionation with an appropriate reagent such asCS₂ or Lawesson's reagent followed by S-alkylation (e.g., S-methylation)with an appropriate reagent such as methyl iodide or methyltriflatefollowed by treatment with NH₂OH. The N-hydroxyamidine group can beprotected using, for example, phosgene, triphosgene,carbonyldiimidazole, etc., and the protected hydroxymethyl group canthen be deprotected (such as by treatment with acid foralkylsilylethers) for further modification if desired.

According to Scheme 2, compounds of the invention can be preparedstarting with the intermediate 2-1 (which can be prepared according toScheme 1) which can be oxidized at the hydroxymethyl group according tostandard procedures for conversion of an alcohol to an aldehyde to yieldintermediates 2-2. The aldehydes (2-2) can be further reacted withappropriate nucleophiles to yield hydroxyl (2-5) or amino (2-4)intermediates with optional substitution (R^(A)) on the methylene. Theseintermediates can be further modified by reaction of the hydroxyl groupswith suitable electrophiles (e.g., alkylation, acylate, arylation)optionally in the presence of catalytic amounts of base or acid followedby deprotection to yield compounds of the invention 2-7 and 2-11.Additionally, intermediate 2-5 can be oxidized to afford ketone 2-3which can be further reacted with appropriate nucleophiles to yieldhydroxyl (2-9) or amino (2-8) intermediates with optional substitution(R^(A) and R^(B)) on the methylene. Similarly, amines 2-4 and 2-8 can bedirectly deprotected to yield further compounds of the invention 2-6 and2-10.

Various compounds of the invention can be prepared according to themethod shown in Scheme 3 where protected N-hydroxyamidines 3-1 aremodified by Mitsonubu reaction with various aryl or heteroaryl alcohols(e.g., phenol or substituted phenol) followed by treatment with a basesuch as hydroxide to give aryloxy and heteroaryloxy derivatives 3-2.Additionally, protected N-hydroxyamidines 3-1 can be reacted withsuitable reagents R⁴R^(Q)NC(O)X (where X is halo) or isocyanatesR^(Q)—N═C═O followed by treatment with base such as hydroxide to givecompounds of the invention 3-3. In the case of reaction with theisocyanates, R⁴ of 3-3 would typically be H.

Amino methyl compounds of the invention can be prepared according to themethods of Scheme 4 where the hydroxymethyl group of a protectedN-hydroxyamidine intermediate 4-1 is treated with mesylchloride or othersuitable reagent to produce a good leaving group such as mesylate asexemplified in intermediate 4-2. The intermediate 4-2 is then reactedwith amine NHR⁴R^(Q) followed by treatment with base (such as hydroxide)to yield amino methyl compounds 4-3. The amino methyl compounds can befurther derivatized to make various amides, ureas, sulfonamides,carbamates and the like by reaction of the amino moiety withR^(Q)C(O)—X, R^(Q)S(O)₂—X, R^(Q)OC(O)—X and the like (X is a leavinggroup).

Additional amino methyl compounds of the invention can be preparedaccording to the methods of Scheme 5 where the intermediate 4-2 isreacted with sodium azide followed by reduction (such as hydrogen overpalladium or triphenylphosphine) to yield amino methyl compounds 4-6.The amino methyl compounds 4-6 can be further derivatized to makevarious compounds 4-7, such as amides, ureas, sulfonamides, carbamatesand the like, by reaction of the amino moiety with R^(Q)C(O)—X,R^(Q)S(O)₂—X, R^(Q)OC(O)—X and the like (X is a leaving group).

Alkoxy compounds 6-2 can be prepared, for example, according the routeshown in Scheme 6. Here, hydroxyalkyl or related compounds 6-1 arereacted with various electrophiles such as alkyl halides (“alkyl-X,”where X is halo) followed by reaction with base such as hydroxide toform alkylated and similar compounds of formula 6-2. The alkyl halidescan be optionally substituted with other various functional groups.

An alternative method for the synthesis of N-hydroxyamidines (e.g.,Example 33) is shown in Scheme 7 where an amide 7-1 is chlorinated withsuitable chlorination reagent (such as PCl₅, POCl₃, SO₂Cl₂, or alike)followed by addition of NH₂OH to the crude reaction mixture to affordthe desired products 7-2.

Methods of Use

Compounds of the invention can modulate activity of the enzymeindoleamine-2,3-dioxygenase (IDO). The term “modulate” is meant to referto an ability to increase or decrease activity of an enzyme or receptor.Accordingly, compounds of the invention can be used in methods ofmodulating IDO by contacting the enzyme with any one or more of thecompounds or compositions described herein. In some embodiments,compounds of the present invention can act as inhibitors of IDO. Infurther embodiments, the compounds of the invention can be used tomodulate activity of IDO in cell or in an individual in need ofmodulation of the enzyme by administering a modulating (e.g.,inhibiting) amount of a compound of the invention.

The present invention further provides methods of inhibiting thedegradation of tryptophan in a system containing cells expressing IDOsuch as a tissue, living organism, or cell culture. In some embodiments,the present invention provides methods of altering (e.g., increasing)extracellular tryptophan levels in a mammal by administering aneffective amount of a compound of composition provided herein. Methodsof measuring tryptophan levels and tryptophan degradation are routine inthe art.

The present invention further provides methods of inhibitingimmunosuppression such as IDO-mediated immunosuppression in a patient byadministering to the patient an effective amount of a compound orcomposition recited herein. IDO-mediated immunosuppression has beenassociated with, for example, cancers, tumor growth, metastasis, viralinfection, viral replication, etc.

The present invention further provides methods of treating diseasesassociated with activity or expression, including abnormal activityand/or overexpression, of IDO in an individual (e.g., patient) byadministering to the individual in need of such treatment atherapeutically effective amount or dose of a compound of the presentinvention or a pharmaceutical composition thereof. Example diseases caninclude any disease, disorder or condition that is directly orindirectly linked to expression or activity of the IDO enzyme, such asover expression or abnormal activity. An IDO-associated disease can alsoinclude any disease, disorder or condition that can be prevented,ameliorated, or cured by modulating enzyme activity. Examples ofIDO-associated diseases include cancer, viral infection such as HIVinfection, depression, neurodegenerative disorders such as Alzheimer'sdisease and Huntington's disease, trauma, age-related cataracts, organtransplantation (e.g., organ transplant rejection), and autoimmunediseases including asthma, rheumatoid arthritis, multiple sclerosis,inflammatory bowel disease, psoriasis and systemic lupuserythematosusor. Example cancers treatable by the methods herein includecancer of the colon, pancreas, breast, prostate, lung, brain, ovary,cervix, testes, renal, head and neck, lymphoma, leukemia, melanoma, andthe like.

As used herein, the term “cell” is meant to refer to a cell that is invitro, ex vivo or in vivo. In some embodiments, an ex vivo cell can bepart of a tissue sample excised from an organism such as a mammal. Insome embodiments, an in vitro cell can be a cell in a cell culture. Insome embodiments, an in vivo cell is a cell living in an organism suchas a mammal.

As used herein, the term “contacting” refers to the bringing together ofindicated moieties in an in vitro system or an in vivo system. Forexample, “contacting” the IDO enzyme with a compound of the inventionincludes the administration of a compound of the present invention to anindividual or patient, such as a human, having IDO, as well as, forexample, introducing a compound of the invention into a samplecontaining a cellular or purified preparation containing the IDO enzyme.

As used herein, the term “individual” or “patient,” usedinterchangeably, refers to any animal, including mammals, preferablymice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep,horses, or primates, and most preferably humans.

As used herein, the phrase “therapeutically effective amount” refers tothe amount of active compound or pharmaceutical agent that elicits thebiological or medicinal response that is being sought in a tissue,system, animal, individual or human by a researcher, veterinarian,medical doctor or other clinician, which includes one or more of thefollowing:

(1) preventing the disease; for example, preventing a disease, conditionor disorder in an individual who may be predisposed to the disease,condition or disorder but does not yet experience or display thepathology or symptomotology of the disease;

(2) inhibiting the disease; for example, inhibiting a disease, conditionor disorder in an individual who is experiencing or displaying thepathology or symptomotology of the disease, condition or disorder; and

(3) ameliorating the disease; for example, ameliorating a disease,condition or disorder in an individual who is experiencing or displayingthe pathology or symptomatology of the disease, condition or disorder(i.e., reversing the pathology and/or symptomatology) such as decreasingthe severity of disease.

Combination Therapy

One or more additional pharmaceutical agents or treatment methods suchas, for example, anti-viral agents, chemotherapeutics or otheranti-cancer agents, immune enhancers, immunosuppressants, radiation,anti-tumor and anti-viral vaccines, cytokine therapy (e.g., IL2, GM-CSF,etc.), and/or tyrosine kinase inhibitors can be used in combination withthe compounds of the present invention for treatment of IDO-associateddiseases, disorders or conditions. The agents can be combined with thepresent compounds in a single dosage form, or the agents can beadministered simultaneously or sequentially as separate dosage forms.

Suitable antiviral agents contemplated for use in combination with thecompounds of the present invention can comprise nucleoside andnucleotide reverse transcriptase inhibitors (NRTIs), non-nucleosidereverse transcriptase inhibitors (NNRTIs), protease inhibitors and otherantiviral drugs.

Example suitable NRTIs include zidovudine (AZT); didanosine (ddI);zalcitabine (ddC); stavudine (d4T); lamivudine (3TC); abacavir(1592U89); adefovir dipivoxil[bis(POM)-PMEA]; lobucavir (BMS-180194);BCH-10652; emitricitabine [(−)-FTC]; beta-L-FD4 (also called beta-L-D4Cand named beta-L-2′, 3′-dicleoxy-5-fluoro-cytidene); DA PD, ((−)-beta-D-2,6,-diamino-purine dioxolane); and lodenosine (FddA). Typicalsuitable NNRTIs include nevirapine (BI-RG-587); delaviradine (BHAP,U-90152); efavirenz (DMP-266); PNU-142721; AG-1549; MKC-442(1-(ethoxy-methyl)-5-(1-methylethyl)-6-(phenylmethyl)-(2,4(1H,3H)-pyrimidinedione);and (+)-calanolide A (NSC-675451) and B. Typical suitable proteaseinhibitors include saquinavir (Ro 31-8959); ritonavir (ABT-538);indinavir (MK-639); nelfnavir (AG-1343); amprenavir (141W94); lasinavir(BMS-234475); DMP-450; BMS-2322623; ABT-378; and AG-1549. Otherantiviral agents include hydroxyurea, ribavirin, IL-2, IL-12,pentafuside and Yissum Project No. 11607.

Suitable chemotherapeutic or other anti-cancer agents include, forexample, alkylating agents (including, without limitation, nitrogenmustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas andtriazenes) such as uracil mustard, chlormethine, cyclophosphamide(Cytoxan™) ifosfamide, melphalan, chlorambucil, pipobroman,triethylene-melamine, triethylenethio-phosphoramine, busulfan,carmustine, lomustine, streptozocin, dacarbazine, and temozolomide.

In the treatment of melanoma, suitable agents for use in combinationwith the compounds of the present invention include: dacarbazine (DTIC),optionally, along with other chemotherapy drugs such as carmustine(BCNU) and cisplatin; the “Dartmouth regimen,” which consists of DTIC,BCNU, cisplatin and tamoxifen; a combination of cisplatin, vinblastine,and DTIC; or temozolomide. Compounds according to the invention may alsobe combined with immunotherapy drugs, including cytokines such asinterferon alpha, interleukin 2, and tumor necrosis factor (TNF) in thetreatment of melanoma.

Compounds of the invention may also be used in combination with vaccinetherapy in the treatment of melanoma. Antimelanoma vaccines are, in someways, similar to the anti-virus vaccines which are used to preventdiseases caused by viruses such as polio, measles, and mumps. Weakenedmelanoma cells or parts of melanoma cells called antigens may beinjected into a patient to stimulate the body's immune system to destroymelanoma cells.

Melanomas that are confined to the arms or legs may also be treated witha combination of agents including one or more compounds of theinvention, using a hypothermic isolated limb perfusion technique. Thistreatment protocol temporarily separates the circulation of the involvedlimb from the rest of the body and injects high doses of chemotherapyinto the artery feeding the limb, thus providing high doses to the areaof the tumor without exposing internal organs to these doses that mightotherwise cause severe side effects. Usually the fluid is warmed to 102°to 104° F. Melphalan is the drug most often used in this chemotherapyprocedure. This can be given with another agent called tumor necrosisfactor (TNF) (see section on cytokines).

Suitable chemotherapeutic or other anti-cancer agents include, forexample, antimetabolites (including, without limitation, folic acidantagonists, pyrimidine analogs, purine analogs and adenosine deaminaseinhibitors) such as methotrexate, 5-fluorouracil, floxuridine,cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate,pentostatine, and gemcitabine.

Suitable chemotherapeutic or other anti-cancer agents further include,for example, certain natural products and their derivatives (forexample, vinca alkaloids, antitumor antibiotics, enzymes, lymphokinesand epipodophyllotoxins) such as vinblastine, vincristine, vindesine,bleomycin, dactino-mycin, daunorubicin, doxorubicin, epirubicin,idarubicin, ara-C, paclitaxel (TAXOL™), mithramycin, deoxycoformycin,mitomycin-C, L-asparaginase, interferons (especially IFN-a), etoposide,and teniposide.

Other cytotoxic agents include navelbene, CPT-11, anastrazole,tetrazole, capecitabine, reloxafine, cyclophosphamide, ifosamide, anddroloxafine.

Also suitable are cytotoxic agents such as epidophyllotoxin; anantineoplastic enzyme; a topoisomerase inhibitor; procarbazine;mitoxantrone; platinum coordination complexes such as cis-platin andcarboplatin; biological response modifiers; growth inhibitors;antihormonal therapeutic agents; leucovorin; tegafur; and haematopoieticgrowth factors.

Other anti-cancer agent(s) include antibody therapeutics such astrastuzumab (Herceptin), antibodies to costimulatory molecules such asCTLA-4, 4-1BB and PD-1, or antibodies to cytokines (IL-10, TGF-(β,etc.).

Other anti-cancer agents also include those that block immune cellmigration such as antagonists to chemokine receptors, including CCR2 andCCR4.

Other anti-cancer agents also include those that augment the immunesystem such as adjuvants or adoptive T cell transfer.

Anti-cancer vaccines include dendritic cells, synthetic peptides, DNAvaccines and recombinant viruses.

Methods for the safe and effective administration of most of thesechemotherapeutic agents are known to those skilled in the art. Inaddition, their administration is described in the standard literature.For example, the administration of many of the chemotherapeutic agentsis described in the “Physicians' Desk Reference” (PDR, e.g., 1996edition, Medical Economics Company, Montvale, N.J.), the disclosure ofwhich is incorporated herein by reference as if set forth in itsentirety.

Pharmaceutical Formulations and Dosage Forms

When employed as pharmaceuticals, the compounds of the invention can beadministered in the form of pharmaceutical compositions which is acombination of a compound of the invention and a pharmaceuticallyacceptable carrier. These compositions can be prepared in a manner wellknown in the pharmaceutical art, and can be administered by a variety ofroutes, depending upon whether local or systemic treatment is desiredand upon the area to be treated. Administration may be topical(including ophthalmic and to mucous membranes including intranasal,vaginal and rectal delivery), pulmonary (e.g., by inhalation orinsufflation of powders or aerosols, including by nebulizer;intratracheal, intranasal, epidermal and transdermal), ocular, oral orparenteral. Methods for ocular delivery can include topicaladministration (eye drops), subconjunctival, periocular or intravitrealinjection or introduction by balloon catheter or ophthalmic insertssurgically placed in the conjunctival sac. Parenteral administrationincludes intravenous, intraarterial, subcutaneous, intraperitoneal orintramuscular injection or infusion; or intracranial, e.g., intrathecalor intraventricular, administration. Parenteral administration can be inthe form of a single bolus dose, or may be, for example, by a continuousperfusion pump. Pharmaceutical compositions and formulations for topicaladministration may include transdermal patches, ointments, lotions,creams, gels, drops, suppositories, sprays, liquids and powders.Conventional pharmaceutical carriers, aqueous, powder or oily bases,thickeners and the like may be necessary or desirable.

This invention also includes pharmaceutical compositions which contain,as the active ingredient, one or more of the compounds of the inventionabove in combination with one or more pharmaceutically acceptablecarriers. In making the compositions of the invention, the activeingredient is typically mixed with an excipient, diluted by an excipientor enclosed within such a carrier in the form of, for example, acapsule, sachet, paper, or other container. When the excipient serves asa diluent, it can be a solid, semi-solid, or liquid material, which actsas a vehicle, carrier or medium for the active ingredient. Thus, thecompositions can be in the form of tablets, pills, powders, lozenges,sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups,aerosols (as a solid or in a liquid medium), ointments containing, forexample, up to 10% by weight of the active compound, soft and hardgelatin capsules, suppositories, sterile injectable solutions, andsterile packaged powders.

In preparing a formulation, the active compound can be milled to providethe appropriate particle size prior to combining with the otheringredients. If the active compound is substantially insoluble, it canbe milled to a particle size of less than 200 mesh. If the activecompound is substantially water soluble, the particle size can beadjusted by milling to provide a substantially uniform distribution inthe formulation, e.g. about 40 mesh.

Some examples of suitable excipients include lactose, dextrose, sucrose,sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates,tragacanth, gelatin, calcium silicate, microcrystalline cellulose,polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. Theformulations can additionally include: lubricating agents such as talc,magnesium stearate, and mineral oil; wetting agents; emulsifying andsuspending agents; preserving agents such as methyl- andpropylhydroxy-benzoates; sweetening agents; and flavoring agents. Thecompositions of the invention can be formulated so as to provide quick,sustained or delayed release of the active ingredient afteradministration to the patient by employing procedures known in the art.

The compositions can be formulated in a unit dosage form, each dosagecontaining from about 5 to about 100 mg, more usually about 10 to about30 mg, of the active ingredient. The term “unit dosage forms” refers tophysically discrete units suitable as unitary dosages for human subjectsand other mammals, each unit containing a predetermined quantity ofactive material calculated to produce the desired therapeutic effect, inassociation with a suitable pharmaceutical excipient.

The active compound can be effective over a wide dosage range and isgenerally administered in a pharmaceutically effective amount. It willbe understood, however, that the amount of the compound actuallyadministered will usually be determined by a physician, according to therelevant circumstances, including the condition to be treated, thechosen route of administration, the actual compound administered, theage, weight, and response of the individual patient, the severity of thepatient's symptoms, and the like.

For preparing solid compositions such as tablets, the principal activeingredient is mixed with a pharmaceutical excipient to form a solidpreformulation composition containing a homogeneous mixture of acompound of the present invention. When referring to thesepreformulation compositions as homogeneous, the active ingredient istypically dispersed evenly throughout the composition so that thecomposition can be readily subdivided into equally effective unit dosageforms such as tablets, pills and capsules. This solid preformulation isthen subdivided into unit dosage forms of the type described abovecontaining from, for example, 0.1 to about 500 mg of the activeingredient of the present invention.

The tablets or pills of the present invention can be coated or otherwisecompounded to provide a dosage form affording the advantage of prolongedaction. For example, the tablet or pill can comprise an inner dosage andan outer dosage component, the latter being in the form of an envelopeover the former. The two components can be separated by an enteric layerwhich serves to resist disintegration in the stomach and permit theinner component to pass intact into the duodenum or to be delayed inrelease. A variety of materials can be used for such enteric layers orcoatings, such materials including a number of polymeric acids andmixtures of polymeric acids with such materials as shellac, cetylalcohol, and cellulose acetate.

The liquid forms in which the compounds and compositions of the presentinvention can be incorporated for administration orally or by injectioninclude aqueous solutions, suitably flavored syrups, aqueous or oilsuspensions, and flavored emulsions with edible oils such as cottonseedoil, sesame oil, coconut oil, or peanut oil, as well as elixirs andsimilar pharmaceutical vehicles.

Compositions for inhalation or insufflation include solutions andsuspensions in pharmaceutically acceptable, aqueous or organic solvents,or mixtures thereof, and powders. The liquid or solid compositions maycontain suitable pharmaceutically acceptable excipients as describedsupra. In some embodiments, the compositions are administered by theoral or nasal respiratory route for local or systemic effect.Compositions in can be nebulized by use of inert gases. Nebulizedsolutions may be breathed directly from the nebulizing device or thenebulizing device can be attached to a face masks tent, or intermittentpositive pressure breathing machine. Solution, suspension, or powdercompositions can be administered orally or nasally from devices whichdeliver the formulation in an appropriate manner.

The amount of compound or composition administered to a patient willvary depending upon what is being administered, the purpose of theadministration, such as prophylaxis or therapy, the state of thepatient, the manner of administration, and the like. In therapeuticapplications, compositions can be administered to a patient alreadysuffering from a disease in an amount sufficient to cure or at leastpartially arrest the symptoms of the disease and its complications.Effective doses will depend on the disease condition being treated aswell as by the judgment of the attending clinician depending uponfactors such as the severity of the disease, the age, weight and generalcondition of the patient, and the like.

The compositions administered to a patient can be in the form ofpharmaceutical compositions described above. These compositions can besterilized by conventional sterilization techniques, or may be sterilefiltered. Aqueous solutions can be packaged for use as is, orlyophilized, the lyophilized preparation being combined with a sterileaqueous carrier prior to administration. The pH of the compoundpreparations typically will be between 3 and 11, more preferably from 5to 9 and most preferably from 7 to 8. It will be understood that use ofcertain of the foregoing excipients, carriers, or stabilizers willresult in the formation of pharmaceutical salts.

The therapeutic dosage of the compounds of the present invention canvary according to, for example, the particular use for which thetreatment is made, the manner of administration of the compound, thehealth and condition of the patient, and the judgment of the prescribingphysician. The proportion or concentration of a compound of theinvention in a pharmaceutical composition can vary depending upon anumber of factors including dosage, chemical characteristics (e.g.,hydrophobicity), and the route of administration. For example, thecompounds of the invention can be provided in an aqueous physiologicalbuffer solution containing about 0.1 to about 10% w/v of the compoundfor parenteral administration. Some typical dose ranges are from about 1μg/kg to about 1 g/kg of body weight per day. In some embodiments, thedose range is from about 0.01 mg/kg to about 100 mg/kg of body weightper day. The dosage is likely to depend on such variables as the typeand extent of progression of the disease or disorder, the overall healthstatus of the particular patient, the relative biological efficacy ofthe compound selected, formulation of the excipient, and its route ofadministration. Effective doses can be extrapolated from dose-responsecurves derived from in vitro or animal model test systems.

The compounds of the invention can also be formulated in combinationwith one or more additional active ingredients which can include anypharmaceutical agent such as anti-viral agents, vaccines, antibodies,immune enhancers, immune suppressants, anti-inflammatory agents and thelike.

Labeled Compounds and Assay Methods

Another aspect of the present invention relates to fluorescent dye, spinlabel, heavy metal or radio-labeled compounds of the invention thatwould be useful not only in imaging but also in assays, both in vitroand in vivo, for localizing and quantitating the IDO enzyme in tissuesamples, including human, and for identifying IDO enzyme ligands byinhibition binding of a labeled compound. Accordingly, the presentinvention includes IDO enzyme assays that contain such labeledcompounds.

The present invention further includes isotopically-labeled compounds ofFormula I. An “isotopically” or “radio-labeled” compound is a compoundof the invention where one or more atoms are replaced or substituted byan atom having an atomic mass or mass number different from the atomicmass or mass number typically found in nature (i.e., naturallyoccurring). Suitable radionuclides that may be incorporated in compoundsof the present invention include but are not limited to ²H (also writtenas D for deuterium), ³H (also written as T for tritium), ¹¹C, ¹³C, ¹⁴C,¹³N, 15N, ¹⁵O, ¹⁷O, ¹⁸O, ¹⁸F, ³⁵S, ³⁶Cl, ⁸²Br, ⁷⁵Br, ⁷⁶Br, ⁷⁷Br, ¹²³I,¹²⁴I, ¹²⁵I and ¹³¹I. The radionuclide that is incorporated in theinstant radio-labeled compounds will depend on the specific applicationof that radio-labeled compound. For example, for in vitro IDO enzymelabeling and competition assays, compounds that incorporate ³H, ¹⁴C,⁸²Br, ¹²⁵I, ¹³¹I, ³⁵S or will generally be most useful. Forradio-imaging applications ¹¹C, ¹⁸F, ¹²⁵I, ¹²³I, ¹²⁴I, ¹³¹I, ⁷⁵Br, ⁷⁶Bror ⁷⁷Br will generally be most useful.

It is understood that a “radio-labeled” or “labeled compound” is acompound that has incorporated at least one radionuclide. In someembodiments the radionuclide is selected from the group consisting of³H, ¹⁴C, ¹²⁵I, ³⁵S and ⁸²Br.

Synthetic methods for incorporating radio-isotopes into organiccompounds are applicable to compounds of the invention and are wellknown in the art.

A radio-labeled compound of the invention can be used in a screeningassay to identify/evaluate compounds. In general terms, a newlysynthesized or identified compound (i.e., test compound) can beevaluated for its ability to reduce binding of the radio-labeledcompound of the invention to the IDO enzyme. Accordingly, the ability ofa test compound to compete with the radio-labeled compound for bindingto the IDO enzyme directly correlates to its binding affinity.

Kits

The present invention also includes pharmaceutical kits useful, forexample, in the treatment or prevention of IDO-associated diseases ordisorders, obesity, diabetes and other diseases referred to herein whichinclude one or more containers containing a pharmaceutical compositioncomprising a therapeutically effective amount of a compound of theinvention. Such kits can further include, if desired, one or more ofvarious conventional pharmaceutical kit components, such as, forexample, containers with one or more pharmaceutically acceptablecarriers, additional containers, etc., as will be readily apparent tothose skilled in the art. Instructions, either as inserts or as labels,indicating quantities of the components to be administered, guidelinesfor administration, and/or guidelines for mixing the components, canalso be included in the kit.

The invention will be described in greater detail by way of specificexamples. The following examples are offered for illustrative purposes,and are not intended to limit the invention in any manner. Those ofskill in the art will readily recognize a variety of noncriticalparameters which can be changed or modified to yield essentially thesame results. The compounds of the Examples were found to be inhibitorsof IDO according to one or more of the assays provided herein. In someinstances where the compounds of the examples were isolated bypreparative HPLC in the presence of trifluoroacetic acid (TFA) or otheracid, the compound may have been obtained as the corresponding salt.

EXAMPLES Example 1N-(3-Chloro-4-fluoro-phenyl)-N′-hydroxy-4-hydroxymethyl-furazan-3-carboxamidine

Step A: 4H,6H-Furo[3,4-c][1,2,5]oxadiazol-4-one

4H,6H-Furo[3,4-c][1,2,5]oxadiazol-4-one was synthesized according toliterature procedures (Pollet, et al., Synthesis Communications, 1979,977-979.) To a stirred solution of (3Z,4Z)-furan-2,3,4(5H)-trione3,4-dioxime (3.0 g, 0.021 mol) in 1,4-dioxane (21 mL) under nitrogen,thionyl chloride (2.1 mL, 0.029 mol) was added dropwise. The resultingyellow solution was stirred overnight and then concentrated in vacuo.The resultant crystalline material was recrystallized once from aminimum amount of ethanol (EtOH) to give the desired compound as anoff-white powder. The filtrate was concentrated down and recrystallizedagain. Combined solids yielded the desired product (2.0 g, 76%). ¹H NMR(400 MHz, DMSO-d₆) δ: 5.67 (s, 2H). MF=C₄H₂N₂O₃; LCMS calculated forC₄H₃N₂O₃(M+H)⁺: m/z=127.014.

Step B.N-(3-Chloro-4-fluorophenyl)-4-(hydroxymethyl)-1,2,5-oxadiazole-3-carboxamide

4H,6H-Furo[3,4-c][1,2,5]oxadiazol-4-one (2.00 g, 0.0159 mol) wasdissolved in EtOH (80 mL) and N,N-dimethylacetamide (10 mL) and then3-chloro-4-fluoroaniline (2.5 g, 0.017 mol) was added as a solid. Thereaction was heated at 80° C. overnight. The crude reaction mixture wasconcentrated in vacuo. The oil was extracted twice with EtOAc and washedwith water. The organic was dried over Na₂SO₄ and concentrated. Thecrude residue was purified by flash column chromatography eluting withEtOAc:Hexane (1:1) to yield the desired product (3.2 g, 74%). ¹H NMR(400 MHz, DMSO-d₆) δ: 11.30 (s, 1H), 8.30 (dd, J=7.0, 2.7 Hz, 1H), 7.69(ddd, J=9.1, 4.4, 2.6 Hz, 1H) 7.45 (dd, J=9.1, 9.1 Hz, 1H), 4.86 (d=5.8Hz, 2H), 5.78 (t, 5.8 Hz, 1H); MF=C₁₀H₇ClFN₃O₃; LCMS calculated forC₁₀H₈ClFN₃O₃(M+H)⁺: m/z=272.024.

Step C:N-(3-Chloro-4-fluorophenyl)-4-[(triisopropylsilyl)oxy]methyl-1,2,5-oxadiazole-3-carboxamide

To a stirred solution ofN-(3-chloro-4-fluorophenyl)-4-(hydroxymethyl)-1,2,5-oxadiazole-3-carboxamide(3.2 g, 0.012 mol) in dichloromethane (DCM) (23 mL) at 0° C. was added2,6-lutidine (3.4 mL, 0.029 mol) followed by triisopropylsilyl triflate(4.1 mL). The solution was stirred at 0° C. for 30 min and then thereaction was warmed to rt overnight. The reaction was concentrated andchromatographed on a silica column eluting with 15% ethyl acetate/hexaneto yield a colorless oil (4.59 g, 91%). ¹H NMR (400 MHz, DMSO-d₆) δ:11.03 (s, 1H), 8.01 (dd, J=6.7, 2.6 Hz, 1H), 7.67 (ddd, J=9.1, 4.3, 2.6Hz, 1H), 7.44 (dd, J=9.1, 9.1 Hz, 1H), 5.2 (s, 2H), 1.09 (m, 3H), 0.99(d, J=7.1 Hz, 18H); MF=C₁₉H₂₇ClFN₃O₃Si; LCMS calculated forC₁₉H₂₈ClFN₃O₃Si(M+H)⁺: m/z=428.157.

Step D:N-(3-Chloro-4-fluorophenyl)-4-[(triisopropylsilyl)oxy]methyl-1,2,5-oxadiazole-3-carbothioamide

Into a round bottom flask was placed a solution ofN-(3-chloro-4-fluorophenyl)-4-[(triisopropylsilyl)oxy]methyl-1,2,5-oxadiazole-3-carboxamide(4.1 g, 9.5 mmol) in anhydrous toluene (79 mL) under N₂.2,4-Bis(4-methoxyphenyl)-2,4-dithioxo-1,3,2,4-dithiadiphosphetane (7.7g, 19 mmol) was added while stirring at ambient temperature. Afteraddition, the resulting suspension was stirred and heated at 100° C. for20 hrs. A considerable amount of solid precipitate was filtered offwhile the reaction was still hot, which was residual Lawesson's reagent.The liquid was then concentrated to give a yellow oil which wasdissolved in chloroform and loaded onto a 330 g silica column elutingwith 25% ethyl acetate/hexane to yield the desired product (3.31 g,78%). ¹H NMR (400 MHz, DMSO-d₆) δ: 12.87 (s, 1H), 7.8 (ddd, J=8.9, 4.3,2.7 Hz, 1H), 8.21 (dd, J=6.8, 2.7 Hz, 1H) 7.55 (dd, J=9.0, 9.0 Hz, 1H),5.14 (s, 2H), 1.07 (m, 3H), 0.97 (d, J=7.0, 18H); (M+H)⁺: m/z=444.134.

Step E: MethylN-(3-chloro-4-fluorophenyl)-4-[(triisopropylsilyl)oxy]methyl-1,2,5-oxadiazole-3-carbimidothioate

To a solution ofN-(3-chloro-4-fluorophenyl)-4-[(triisopropylsilyl)oxy]methyl-1,2,5-oxadiazole-3-carbothioamide(3.3 g, 7.4 mmol) in anhydrous DCM (148 mL) under N₂ was addedN,N-diisopropylethylamine (DIPEA) (1.4 mL). Methyltrifluoromethanesulfonate (900 μL, 8.2 mmol) was then added dropwise andstirred for 2 hrs. The reaction was stripped to dryness and purified ona 330 g silica ISCO cartridge, eluting with 25% EtOAc/hexane to yieldthe desired product as a yellow oil that solidified upon standing. (2.97g, 87%). ¹H NMR (400 MHz, DMSO-d₆) δ: 11.32 (s, 1H), 8.01 (dd, J=7.1,2.7 Hz, 1H), 7.45 (dd, J=9.5, 9.5 Hz, 1H), 7.67 (m, 1H), 4.4 (s=3H),5.13 (s, 2H), 1.1 (m, 3H); 0.99 (m, 18H); MF=C₂₀H₂₉ClFN₃O₂SSi; LCMScalculated for C₂₀H₃₀ClFN₃O₂SSi(M+H)⁺: m/z=458.150.

Step F:N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-[(triisopropylsilyl)oxy]methyl-1,2,5-oxadiazole-3-carboximidamide

MethylN-(3-chloro-4-fluorophenyl)-4-[(triisopropylsilyl)oxy]methyl-1,2,5-oxadiazole-3-carbimidothioate(3.0 g, 6.5 mmol) was dissolved in EtOH followed by addition of 4 mLhydroxylamine (99.9% in water solution). The reaction was stirred at 75°C. for 6 hrs and monitored by HPLC. The reaction was concentrated invacuo to a yellow oil which was dissolved in chloroform andchromatographed on 120 g of silica gel eluting with (1:4), EtOAc/hexane.The product was concentrated to give the desired product as a whitesolid (2.57 g, 89%); MF=C₁₉H₂₈ClFN₄O₃Si; LCMS calculated forC₁₉H₂₉ClFN₄O₃Si(M+H)⁺: m/z=443.168.

Step G:4-(3-Chloro-4-fluorophenyl)-3-(4-[(triisopropylsilyl)oxy]methyl-1,2,5-oxadiazol-3-yl)-1,2,4-oxadiazol-5(4H)-one

N-(3-chloro-4-fluorophenyl)-N-hydroxy-4-[(triisopropylsilyl)oxy]methyl-1,2,5-oxadiazole-3-carboximidamide(2.2 g, 5.0 mmol) was dissolved in anhydrous tetrahydrofuran (THF) (31mL) followed by addition of N,N-carbonyldiimidazole (980 mg, 6 mmol).The reaction was heated to 70° C. and monitored by LCMS. Another 0.5 eqof N,N-carbonyldiimidazole was added and the reaction was stirredovernight at 70° C. The reaction was cooled and concentrated in vacuo.The crude oil was dissolved in chloroform and loaded onto a 120 g ISCOcartridge, eluted with 25% EtOAc/Hexane. The combined fractions werestripped to dryness to give the desired product as a white solid (1.74g, 73%). ¹H NMR (400 MHz, DMSO-d₆) δ: 7.95 (m, 1H), 7.65 (m, 1H), 7.64(m, 1H), 5.12 (s, 2H), 1.14 (m, 3H), 1.04 (d, J=7.0 Hz, 18H);MF=C₂₀H₂₆ClFN₄O₄Si; LCMS calculated for C₂₀H₂₇ClFN₄O₄Si(M+H)⁺:m/z=469.147.

Step H:4-(3-Chloro-4-fluorophenyl)-3-[4-(hydroxymethyl)-1,2,5-oxadiazol-3-yl]-1,2,4-oxadiazol-5(4H)-one

4-(3-Chloro-4-fluorophenyl)-3-(4-[(triisopropylsilyl)oxy]methyl-1,2,5-oxadiazol-3-yl)-1,2,4-oxadiazol-5(4H)-one(1.7 g, 3.7 mmol) was dissolved in anhydrous MeOH(MeOH) (110 mL)followed by addition of 2 M of hydrogen chloride in MeOH (9.2 mL).Reaction was stirred at 70° C. for 4 hrs. After concentration in vacuothe sample was loaded onto 120 g ISCO cartridge eluting withEtOAc/hexane. Fractions were combined and evaporated to yield desiredproduct as an off-white powder. (1.12 g, 97%). ¹H NMR (400 MHz, DMSO-d₆)δ: 7.96 (dd, J=6.8, 2.3 Hz, 1H), 7.66 (m, 1H), 7.64 (m, 1H), 5.95 (s,1H), 4.85 (s, 2H); MF=C_(H)H₆ClFN₄O₄; LCMS calculated forC₁₁H₇ClFN₄O₄(M+H)⁺: m/z=313.014.

Step I:N-(3-Chloro-4-fluoro-phenyl)-N′-hydroxy-4-hydroxymethyl-furazan-3-carboxamidine

4-(3-Chloro-4-fluorophenyl)-3-[4-(hydroxymethyl)-1,2,5-oxadiazol-3-yl]-1,2,4-oxadiazol-5(4H)-one(20 mg, 0.064 mmol) was dissolved in anhydrous EtOH (0.6 mL) followed byaddition of 2 M of sodium hydroxide in water (60 μL). Reaction wasstirred at 50° C. for 4 hrs. Consumption of starting material wasmonitored by TLC. The sample was quenched with acetic acid, diluted withMeOH and purified by preparative LCMS. The reaction was diluted withwater and extracted with ethyl acetate three times, dried with sodiumsulfate, filtered, and concentrated in vacuo. The crude residue waspurified by flash silica column chromatography to yield the desiredproduct (16 mg, 87%). ¹1-1 NMR (400 MHz, DMSO-d₆) δ: 11.49 (s, 1H), 9.02(s, 1H), 7.18 (dd, J=9.1, 9.1 Hz, 1H), 6.97 (dd, J=6.6, 2.7 Hz, 1H),6.69 (m, 1H), 5.68 (t, J=6.2 Hz, 1H) 4.72 (d, J=5.8 Hz, 2H);MF=C₁₀H₈ClFN₄O₃; LCMS calculated for C₁₀H₉ClFN₄O₃(M+H)⁺: m/z=287.035.

Example 2N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-(phenoxymethyl)-1,2,5-oxadiazole-3-carboximidamide

Step A:4-(3-Chloro-4-fluorophenyl)-3-[4-(phenoxymethyl)-1,2,5-oxadiazol-3-yl]-1,2,4-oxadiazol-5(4H)-one

4-(3-Chloro-4-fluorophenyl)-3-[4-(hydroxymethyl)-1,2,5-oxadiazol-3-yl]-1,2,4-oxadiazol-5(4H)-one(15 mg, 0.0480 mmol), phenol (14 mg, 0.14 mmol) and triphenylphosphine(16 mg, 0.062 mmol) were dissolved in anhydrous THF (500 μL) then cooledto 0° C., followed by a dropwise addition of diethyl azodicarboxylate(9.8 μL, 0.062 mmol) in a solution of THF. Reaction was allowed to warmto rt then stirred 4 hrs. After concentration in vacuo, the sample waspurified by reverse phase HPLC to yield a white powder (9 mg, 48%).MF=C₁₇H₁₀ClFN₄O₄; LCMS calculated for C₁₇H₁₁ClFN₄O₄(M+H)⁺: m/z=389.045

Step C:N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-(phenoxymethyl)-1,2,5-oxadiazole-3-carboximidamide

Into a vial was added4-(3-chloro-4-fluorophenyl)-3-[4-(phenoxymethyl)-1,2,5-oxadiazol-3-yl]-1,2,4-oxadiazol-5(4H)-one(9 mg, 23 mmol), EtOH (0.5 mL), and 2.0 M of sodium hydroxide in water(35 μL). Reaction was stirred for 2 hrs at rt. The reaction mixture wasneutralized with acetic acid and then purified by preparative HPLC toyield the desired compound (7.6 mg, 90%). ¹H NMR (400 MHz, DMSO-d₆) δ:11.58 (s, 1H), 9.05 (s, 1H), 7.32 (t, J=7.8 Hz, 2H) 7.19 (dd, J=9.1, 9.1Hz, 1H), 7.0 (m, 1H), 6.97 (m, 2H) 6.96 (m, 1H), 6.72 (ddd, J=8.8, 4.0,2.8 Hz, 1H), 5.43 (s, 2H); MF=C₁₆H₁₂ClFN₄O₃; LCMS calculated forC₁₆H₁₃ClFN₄O₃(M+H)⁺: m/z=363.066.

Example 34-[(E/Z)-[(3-Chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-ylmethylphenylcarbamate

4-(3-Chloro-4-fluorophenyl)-3-[4-(hydroxymethyl)-1,2,5-oxadiazol-3-yl]-1,2,4-oxadiazol-5(4H)-one(20 mg, 0.064 mmol), was dissolved in anhydrous DCM (400 μL).4-Dimethylamino-pyridine (DMAP) (4 mg, 0.03 mmol) was added followed byaddition of phenyl isocyanate (7.6 μL, 0.07 mmol). Reaction was stirredat rt for 24 hrs and then concentrated in vacuo. The crude was purifiedby HPLC to yield a white powder. The intermediate was redissolved inEtOH (0.7 mL) and 2 M of sodium hydroxide in water (60 μL) was added.Reaction was stirred for 2 hr at rt. Reaction was quenched with aceticacid and diluted with MeOH and then purified by preparative LCMS toyield the desired compound as a white powder (16 mg, 62%). ¹H NMR (400MHz, DMSO-d₆) δ: 11.68 (s, 1H), 10.00 (s, 1H), 9.04 (s, 1H), 7.47 (d,J=8.1 Hz, 2H), 7.00 (m, 1H), 7.28 (dd, J=7.5, 8.0 Hz, 2H), 7.19 (dd,J=9.1, 9.1 Hz, 1H), 7.0 (m, 1H), 6.79 (m, 1H) 5.49 (s, 2H).;MF=C₁₆H₁₂ClFN₄O₃; LCMS calculated for C₁₆H₁₃ClFN₄O₃(M+H)⁺: m/z=363.066.

Example 44-[(Benzylamino)methyl]-N-(3-chloro-4-fluorophenyl)-N-hydroxy-1,2,5-oxadiazole-3-carboximidamide

Step A:4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylmethylmethanesulfonate

4-(3-Chloro-4-fluorophenyl)-3-[4-(hydroxymethyl)-1,2,5-oxadiazol-3-yl]-1,2,4-oxadiazol-5(4H)-one(250 mg, 0.7996 mmol) was dissolved in anhydrous DCM (8 mL) followed byaddition of triethylamine (TEA) (134 μL, 0.96 mmol). Reaction was cooledto 0° C. and methanesulfonyl chloride (68 μL, 0.88 mmol) was addeddropwise. The reaction was diluted with water and extracted with ethylacetate three times, dried with sodium sulfate, filtered, andconcentrated in vacuo. The crude residue was purified by flash columnchromatography eluting with 25%-70% EtOAc to yield the desired product(259 mg, 83%). MF=C₁₂H₈ClFN₄O₆S; LCMS calculated for C₁₂H₉ClFN₄O₆S(M+H)⁺: m/z=390.992.

4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylmethylmethanesulfonate (0.020 g, 0.051 mmol) was dissolved in anhydrousacetonitrile (ACN) (500 μL) followed by addition of DIPEA (44 pt, 0.26mmol) and benzylamine (8.4 μL, 0.077 mmol). The reaction was stirred andheated at 60° C. for 1 hr. The reaction was stripped to dryness,redissolved in EtOH (500 μL) and 2 M sodium hydroxide in water (0.1 mL)was added. The reaction was stirred and heated at 60° C. for 2 hrs,quenched with acetic acid, diluted with MeOH and purified by preparativeLCMS to yield desired product as a pure white powder (15 mg, 78%).MF=C₁₇H₁₅ClFN₅O₂; LCMS calculated for C₁₇H₁₆ClFN₅O₂(M+H)⁺: m/z=376.098.

Additional example compounds of the invention are provided below. Table1 below (and Tables 2 and 3, infra) provide example compounds of theinvention that show activity as IDO modulators according to one or moreof the assays provided herein. The compounds were prepared according tosynthetic procedure of the Example compound specified in the columnmarked “Prep. Ex.” and were purified by the method in the column marked“Pur. Meth.” In the “Pur. Meth.” column, “A” refers to purification byLCMS (HPLC, pH=2, trifluoroacetic acid (TFA)); “B” refers topurification by LCMS (HPLC, pH=10, NH₄OH); “C” refers to silica gelchromatography (typically hexanes/ethyl acetate); “D” refers to routinecrystallization or precipitation methods; and “E” refers to thepurification method as provided in the synthetic procedure for preparingthat compound. Certain compounds of the Tables were isolated in the freebase form or as a salt (typically as a result of the purificationprocedure) as indicated in the column marked “Salt”. The saltstoichiometry indicated in the below tables and preparation descriptionsis typically based on theory and one skilled in the art would understandthat the actual product might contain more or less acid. Actualstoichiometry can be determined by routine methods such as elementalanalysis. ACN refers to acetonitrile. DCM refers to dichloromethane. DMFrefers to dimethylformamide. TFA refers to trifluoroacetic acid. TEArefers to tetraethylamine. DMAP refers to dimethylaminopyridine. DIPEArefers to N,N-diethylisopropylamine.

TABLE 1 Ex. MS Prep. Pur. No. Structure (M + 1) Ex. Meth Salt Name  5

397.1 Ex. 2 A Free Base N-(3-chloro-4- fluorophenyl)-4- [(2-chloro-phenoxy)methyl]- N′-hydroxy-1,2,5- oxadiazole-3- carboximidamide  6

397.1 Ex. 2 A Free Base N-(3-chloro-4- fluorophenyl)-4- [(3-chloro-phenoxy)methyl]- N′-hydroxy-1,2,5- oxadiazole-3- carboximidamide  7

397.1 Ex. 2 A Free Base N-(3-chloro-4- fluorophenyl)-4- [(4-chloro-phenoxy)methyl]- N′-hydroxy-1,2,5- oxadiazole-3- carboximidamide 8

393.1 Ex. 2 B Free Base N-(3-chloro-4- fluorophenyl)-N′- hydroxy-4-[(2-methoxyphenoxy)- methyl]-1,2,5- oxadiazole-3- carboximidamide  9

393.1 Ex. 2 B Free Base N-(3-chloro-4- fluorophenyl)-N′- hydroxy-4-[(3-methoxyphenoxy)- methyl]-1,2,5- oxadiazole-3- carboximidamide 10

393.1 Ex. 2 B Free Base N-(3-chloro-4- fluorophenyl)-N′- hydroxy-4-[(4-methoxyphenoxy)- methyl]-1,2,5- oxadiazole-3- carboximidamide 11

388.1 Ex. 2 B Free Base N-(3-chloro-4- fluorophenyl)-4- [(3-cyano-phenoxy)methyl]- N′-hydroxy-1,2,5- oxadiazole-3- carboximidamide 12

427.1 Ex. 2 B Free Base N-(3-chloro-4- fluorophenyl)-4- [(4-chloro-2-methoxyphenoxy)- methyl]-N′- hydroxy-1,2,5- oxadiazole-3-carboximidamide 13

423.1 Ex. 2 B Free Base N-(3-chloro-4- fluorophenyl)-4- [(3,4-dimethoxy-phenoxy)methyl]- N′-hydroxy-1,2,5- oxadiazole-3- carboximidamide 14

420.1 Ex. 3 A Free Base {4-[(E/Z)-[(3- chloro-4-fluoro-phenyl)amino](hydroxy- imino)methyl]- 1,2,5-oxadiazol-3- yl}methylphenylcarbamate 15

372.1 Ex. 3 A Free Base {4-[(E/Z)-[(3- chloro-4-fluoro-phenyl)amino](hydroxy- imino)methyl]- 1,2,5-oxadiazol-3- yl}methylisopropylcarbamate 16

354.2 Ex. 4 B Free Base N-(3-chloro-4- fluorophenyl)-N′- hydroxy-4-(piperidin-1- ylmethyl)-1,2,5- oxadiazole-3- carboximidamide 17

314.1 Ex. 4 B Free Base N-(3-chloro-4- fluorophenyl)-4-[(dimethylamino)- methyl]- N′-hydroxy- 1,2,5-oxadiazole-3-carboximidamide 18

431.1 Ex. 4 B Free Base N-(3-chloro-4- fluorophenyl)-N′- hydroxy-4-[(4-phenylpiperazin-1- yl)methyl]-1,2,5- oxadiazole-3- carboximidamide 19

353.1 Ex. 4 B Free Base N-(3-chloro-4- fluorophenyl)-N′- hydroxy-4-[(isoxazol-3- ylamino)methyl]- 1,2,5-oxadiazole-3- carboximidamide 20

459.2 Ex. 4 B Free Base 4-{[(1- benzylpiperidin-4- yl)amino]methyl}-N-(3-chloro-4- fluorophenyl)-N′- hydroxy-1,2,5- oxadiazole-3-carboximidamide 21

461.1 Ex. 4 B Free Base N-(3-chloro-4- fluorophenyl)-N′-hydroxy-4-{[4-(2- methoxyphenyl)piper- azin-1-yl]- methyl}-1,2,5-oxadiazole-3- carboximidamide 22

377.1 Ex. 4 B Free Base N-(3-chloro-4- fluorophenyl)-N′- hydroxy-4-{[(pyridin-2- ylmethyl)amino]methyl}- 1,2,5-oxadiazole-3-carboximidamide 23

390.2 Ex. 4 A TFA N-(3-chloro-4- fluorophenyl)-N′- hydroxy-4-{[(2-phenylethyl)amino]- methyl}-1,2,5- oxadiazole-3- carboximidamidetrifluoroacetate 24

404.1 Ex. 4 A TFA N-(3-chloro-4- fluorophenyl)-N′- hydroxy-4-{[(3-phenylpropyl)amino]- methyl}-1,2,5- oxadiazole-3- carboximidamidetrifluoroacetate 25

390.1 Ex. 4 A TFA N-(3-chloro-4- fluorophenyl)-N′- hydroxy-4-({[(1R)-1-phenylethyl]- amino}methyl)- 1,2,5-oxadiazole-3- carboximidamidetrifluoroacetate 26

410.1 Ex. 4 A TFA 4-{[(2- chlorobenzyl)amino]- methyl}-N-(3-chloro-4-fluoro- phenyl)-N′- hydroxy-1,2,5- oxadiazole-3-carboximidamide trifluoroacetate 27

418.1 Ex. 4 A TFA N-(3-chloro-4- fluorophenyl)-N′- hydroxy-4-{[(4-phenylbutyl)amino]- methyl}-1,2,5- oxadiazole-3- carboximidamidetrifluoroacetate 28

402.1 Ex. 4 A TFA N-(3-chloro-4- fluorophenyl)-4- (3,4-dihydroiso-quinolin-2(1H)- ylmethyl)-N′- hydroxy-1,2,5- oxadiazole-3-carboximidamide trifluoroacetate 29

388.1 Ex. 4 A TFA N-(3-chloro-4- fluorophenyl)-4- (2,3-dihydro-1H-indol-1-ylmethyl)- N′-hydroxy-1,2,5- oxadiazole-3- carboximidamidetrifluoroacetate 30

356.1 Ex. 4 A TFA N-(3-chloro-4- fluorophenyl)-N′- hydroxy-4-(morpholin-4- ylmethyl)-1,2,5- oxadiazole-3- carboximidamidetrifluoroacetate

Example 313-(4-[(2-Morpholin-4-ylethyl)amino]methyl-1,2,5-oxadiazol-3-yl)-4-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5(4H)-one

Step A:4-(3-(Trisuoromethyl)phenyl-3-(4-[(2-morpholin-4-ylethyl)amino]methyl-1,2,5-oxadiazol-3-yl)-1,2,4-oxadiazol-5(4H)-one

4-5-oxo-4-[3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-oxadiazol-3-yl-1,2,5-oxadiazol-3-yl)methylmethanesulfonate (0.01 g, 0.025 mmol) was dissolved in anhydrous ACN (20μL) followed by addition of DIPEA(21 μL, 0.12 mmol) andN-(2-aminoethyl)morpholine (0.05 mmol). The reaction was stirred at 40°C. for 2 hrs. The reaction was diluted with MeOH and purified bypreparative LCMS to afford the desired product. MF=C₁₈H₁₉F₃N₆O₄; LCMScalculated for C₁₈H₂₀F₃N₆O₄(M+H)⁺: m/z=441.1.

Step B:3-(4-[(2-Morpholin-4-ylethyl)amino]methyl-1,2,5-oxadiazol-3-yl)-4-[3-(trifluoromethyl)-phenyl]-1,2,4-oxadiazol-5(4H)-one

The purified intermediate was evaporated to dryness and then redissolvedin EtOH (200 μL) and 2 M of sodium hydroxide in water (60 μL) was added.The reaction was stirred at rt for 2 hrs, quenched with acetic acid,diluted with MeOH and purified by preparative LCMS to afford the desiredproduct (3 mg) MF=C₁₇H₂₁F₃N₆O₃; LCMS calculated for C₁₇H₂₂F₃N₆O₃(M+H)⁺:m/z=415.2.

Example 32N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-[(methylsulfonyl)(2-morpholin-4-yl-ethyl)amino]methyl-1,2,5-oxadiazole-3-carboximidamide

Step A:4-(3-Chloro-4-fluorophenyl)-3-(4-[(2-morpholin-4-ylethyl)amino]methyl-1,2,5-oxadiazol-3-yl)-1,2,4-oxadiazol-5(4H)-one

This intermediate was prepared by procedures analogous to thosedescribed for Example 31.

Step B.N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-[(methylsulfonyl)(2-morpholin-4-ylethyl)amino]methyl-1,2,5-oxadiazole-3-carboximidamide

4-(3-Chloro-4-fluorophenyl)-3-(4-[(2-morpholin-4-ylethyl)amino]methyl-1,2,5-oxadiazol-3-yl)-1,2,4-oxadiazol-5(4H)-one(20 mg, 0.047 mmol) was dissolved in anhydrous ACN (200 μL) followed byaddition of DIPEA (40 μL, 0.2 mmol) and methanesulfonyl chloride (4.0μL, 0.052 mmol). The reaction was stirred at 40° C. for 2 hrs. Thereactions was then diluted with MeOH and purified by HPLC. The purifiedfractions were concentrated to dryness, redissolved in EtOH (1 mL) and 2M of sodium hydroxide in water (0.26 mL) was added. The reaction wasstirred at rt for 2 hrs, quenched with acetic acid, diluted with MeOHand purified by preparative LCMS to afford the desired product (1.4 mg).MF=C₁₇H₂₂ClFN₆O₅S; LCMS calculated for C₁₇H₂₃ClFN₆O₅S(M+H)⁺: m/z=477.1.

Example 33N-{4-[N-(3-Chloro-4-fluoro-phenyl)-N′-hydroxy-carbamimidoyl]-furazan-3-yl-methyl}-benzamide

Step A:3-[4-(azidomethyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one

4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylmethylmethanesulfonate (400 mg, 1.02 mmol) was dissolved in anhydrous DMF (10mL) followed by addition of sodium azide (133 mg, 2.04 mmol). Reactionwas stirred for 3 hrs. Consumption of starting material was monitored byTLC and HPLC. The reaction mixture was added to a mixture of (400 μL)bromine/water and stirred for 10 min. DCM was added and the layers wereseparated. The combined organics were dried with sodium sulfate,filtered, and concentrated in vacuo. The crude residue was purified byflash column chromatography to yield the desired product (225 mg, 65%).MF=C₁₁H₅ClFN₇O₃; LCMS calculated for C₁₁H₆ClFN₇O₃(M+H)⁺: m/z=338.020.

Step B:3-[4-(Aminomethyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one

3-[4-(Azidomethyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one(225 mg, 0.66 mmol) was dissolved in anhydrous THF (5.6 mL) and water(5.6 mL). The reaction was cooled to 0° C. followed by addition oftriphenylphosphine (192 mg, 0.73 mmol). The reaction was allowed to warmto rt and was stirred overnight. The reaction was stripped to dryness,azeotroped with toluene and redissolved in MeOH. The crude residue waspurified by preparative LCMS to yield the desired product (200 mg, 96%).MF=C₁₁H₇ClFN₅O₃; LCMS calculated for C₁₁H₈ClFN₅O₃(M+H)⁺: m/z=312.030.

Step C:4-[(Benzylamino)methyl]-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide

Benzoic acid (4.3 mg, 0.035 mmol) and3-[4-(aminomethyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one(10 mg, 0.032 mmol) was dissolved in ACN (0.2 mL) and DCM (0.2 mL). Tothe mixture was added DMAP (2.4 mg, 0.02 mmol) and DIPEA(17 μL, 0.096mmol). After the mixture became a clear solution,bromotris(pyrrolydino)phosphonium hexa-fluorophosphate (16 mg, 0.035mmol) was added, followed by additional DIPEA(17 μL, 0.0962 mmol). Thereaction mixture was stirred at rt for 6 hrs. LCMS indicated 70% ratioof product to starting amine. The reaction was then diluted with MeOHand crude residue was purified by preparative LCMS. The intermediate wasstripped to dryness, redissolved in EtOH (1 mL) and 1 M of sodiumhydroxide in water (0.06 mL). The reaction was stirred for 1 hr at rt.The reaction was quenched with acetic acid and then diluted with MeOHand crude residue was purified by preparative LCMS to afford the desiredproduct (1.1 mg). MF=C₁₇H₁₃ClFN₅O₃; LCMS calculated forC₁₇H₁₄ClFN₅O₃(M+H)⁺: m/z=390.077.

Example 34N-(3-Chloro-4-fluoro-phenyl)-N′-hydroxy-4-[(3-phenyl-ureido)-methyl]-furazan-3-carboxamidine

3-[4-(Aminomethyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one(10 mg, 0.003 mmol) was dissolved in ACN (0.2 mL) and DCM (0.2 mL).Phenyl isocyanate (7.6 mg, 0.064 mmol) DIPEA(0.012 mg, 0.096 mmol) andDMAP (0.4 mg, 0.03 mmol) were added and stirred at rt for 6 hrs. Thereaction was then diluted with MeOH and purified by preparative LCMS.The intermediate was stripped to dryness, redissolved in EtOH (1 mL) and1 M of sodium hydroxide in water (0.06 mL) was added. The reaction wasstirred at rt for 1 hour, quenched with acetic acid and diluted withMeOH. The crude was purified by preparative LCMS to afford the desiredproduct (2.0 mg). MF=C₁₇H₁₄ClFN₆O₃; LCMS calculated forC₁₇H₁₅ClFN₆O₃(M+H)⁺: m/z=405.1.

Example 354-(Benzenesulfonylamino-methyl)-N-(3-chloro-4-fluoro-phenyl)-N′-hydroxy-furazan-3-carboxamidine

3-[4-(Aminomethyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one(10 mg, 0.003 mmol) was dissolved in ACN (0.2 mL) and DCM (0.2 mL).Benzenesulfonyl chloride (11 mg, 0.064 mmol) DIPEA (12 mg, 0.096 mmol)and DMAP (0.4 mg, 0.003 mmol) were dissolved in DMF (1 mL). The reactionwas stirred at rt for 6 hrs. The reaction was then diluted with MeOH andpurified by preparative LCMS. The intermediate was stripped to dryness,redissolved in EtOH (1 mL) and 1 M of sodium hydroxide in water (0.06mL) was added. The reaction was stirred at rt for 1 hr, quenched withacetic acid, diluted with MeOH and the crude residue was purified bypreparative LCMS to afford the desired product (2.4 mg).MF=C₁₆H₁₃ClFN₅O₄S; LCMS calculated for C₁₆H₁₄ClFN₅O₄S(M+H)⁺: m/z=426.0.

Example 36Benzyl({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}methyl)carbamate

3-[4-(Aminomethyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one(10.0 mg, 0.032 mmol) was dissolved in ACN (0.2 mL) and DCM (0.3 mL).Benzyl chloroformate (4.6 μL, 0.03 mmol) and DIPEA (5.6 μL, 0.032 mmol)was added and stirred overnight at rt. The reaction was concentrated,redissolved in MeOH, then purified on the preparative HPLC to give thedesired intermediate. The intermediate was dissolved in EtOH (1.0 mL)and 1.0 M of sodium hydroxide in water (0.1 mL) and stirred for 1 hr.The reaction was quenched with acetic acid, MeOH (1 mL) was added andthe solution purified by preparative HPLC to afford the desired product(2.5 mg). MF=C₁₈H₁₅ClFN₅O₄; LCMS calculated for C₁₈H₁₆ClFN₅O₄ (M+H)⁺:m/z=419.9.

Example 37N-(3-Cyanophenyl)-N′-hydroxy-4-methyl-1,2,5-oxadiazole-3-carboximidamide

Step A: N-(3-Cyanophenyl)-4-methyl-1,2,5-oxadiazole-3-carboxamide

4-Methyl-1,2,5-oxadiazole-3-carboxylic acid (200 mg, 1.6 mmol) andbromotris-(pyrrolydino)phosphonium hexafluorophosphate was dissolved ina 1/1 mixture of DMF/DCM. To the mixture was added DMAP (120 mg, 0.95mmol) and 3-amino-benzonitrile (184 mg, 1.6 mol) followed byN,N-diisopropylethylamine. The reaction mixture was stirred at rtovernight. The volatiles were removed in vacuo and the residue dissolvedwith chloroform and loaded onto a 40 g Silica ISCO cartridge elutingwith 25%-50% EtOAc/Hexane to afford a white powder (25 mg).MF=C₁₁H₈N₄O₂; LCMS calculated for C₁₁H₉N₄O₂(M+H)⁺: m/z=229.1.

Step B:N-(3-Cyanophenyl)-N′-hydroxy-4-methyl-1,2,5-oxadiazole-3-carboximidamide

N-(3-Cyanophenyl)-4-methyl-1,2,5-oxadiazole-3-carboxamide (25 mg, 0.11mmol) was suspended in benzene (2 mL) under an atmosphere of nitrogen.Phosphorus pentachloride (25 mg, 0.12 mmol) was added and the solutionwas heated at reflux for 2.5 hrs. The reaction was then evaporated todryness. The crude was dissolved in EtOH (1.6 mL) and hydroxylamine (200μL, 3 mmol, 50% solution in water) was added to the reaction. The crudewas purified by preparative LCMS to afford the desired product (2.9 mg).MF=C₁₁H₉N₅O₂; LCMS calculated for C₁₁H₁₀N₅O₂ (M+H)⁺: m/z=244.1.

Example 38N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-methyl-1,2,3-thiadiazole-5-carboximidamide

Step A: 4-Methyl-[1,2,3]thiadiazole-5-carboxylic acid(3-chloro-4-fluoro-phenyl)-amide

4-Methyl-1,2,3-thiadiazole-5-carboxylic acid (39.6 mg, 0.275 mmol) wassuspended in DCM (2.0 mL). Bromotris(pyrrolydino)phosphoniumhexafluorophosphate (128 mg, 0.27 mmol) and DIPEA (96 μL, 0.55 mmol)were added and premixed for 5 minutes. 3-Chloro-4-fluoroaniline (40 mg,0.27 mmol) was added. The solution was stirred for 3 hrs, then purifiedby silica gel chromatography, (Hex/EA)-eluting at =60% EA in hexane toafford the desired product (44 mg). MF=C₁₀H₇ClFN₃OS; LCMS calculated forC₁₀H₈ClFN₃OS (M+H)⁺: m/z=272.0.

Step B:N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-methyl-1,2,3-thiadiazole-5-carboximidamide

4-Methyl-[1,2,3]thiadiazole-5-carboxylic acid(3-chloro-4-fluoro-phenyl)-amide (44 mg, 0.164 mmol) was dissolved intoluene (1 mL). Phosphorus pentachloride (41 mg, 0.20 mmol) was addedand the vial was sealed and heated in an oil bath at 120° C. for 2 hrs.The solvent was removed in vacuo and the crude material was redissolvedin EtOH (1.0 mL). 15.1 M of hydroxylamine in water (108 μL) was addedand the solution was mixed for 0.5 hr. The compound was purified bypreparative LCMS to afford the desired product (18 mg). MF=C₁₀H₈ClFN₄OS;LCMS calculated for C₁₀H₉ClFN₄OS (M+H)⁺: m/z=287.0.

Examples 39 and 404-[(5-Amino-1H-tetrazol-1-yl)methyl]-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide(39), and4-[(5-Amino-2H-tetrazol-2-yl)methyl]-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide(40)

4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylmethylmethanesulfonate (45 mg, 0.012 mmol) was dissolved in anhydrous ACN (100μL) followed by addition of DIPEA (100 μL, 0.6 mmol) and1H-tetrazol-5-amine (15 mg, 0.017 mmol). The reaction was stirred andheated at 40° C. for 4 hr. The reaction was diluted with MeOH andpurified by preparative LCMS to yield hydroxyamidine protected form ofisomers A and B. The separated isomers were each stripped to dryness andredissolved in EtOH (500 μL) and 2 M sodium hydroxide in water (0.1 mL).The reactions were stirred at rt for 2 hrs. The reactions were quenchedwith acetic acid, diluted with MeOH and each purified by preparativeLCMS to afford the desired products A and B as pure white powders (A, 18mg, 44%; MF=C₁₁H₉ClFN₉O₂; LCMS calculated for C₁₁H₉ClFN₉O₂(M+H)⁺:m/z=354.2; ¹H NMR (400 MHz, DMSO-d₆) δ: 11.70 (s, 1H), 8.98 (s, 1H),7.22 (dd, 1H), 7.04 (dd, 1H), 6.89 (bs, 2H), 6.82 (dd, 1H), 5.71 (s,2H); B, 25 mg, 61%, MF=C₁₁H₉ClFN₉O₂; LCMS calculated forC₁₁H₉ClFN₉O₂(M+H)⁺: m/z=354.2; NMR (500 MHz, DMSO-d₆) δ: 11.61 (s, 1H),8.98 (s, 1H), 7.21 (dd, 1H), 6.98 (dd, 1H), 6.65 (dd, 1H), 6.1 (bs, 2H),6.07 (s, 2H)).

Example 41N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-[(1H-tetrazol-5-ylamino)methyl]-1,2,5-oxadiazole-3-carboximidamide

Step A:N-(3-Chloro-4-fluorophenyl)-4-[(1H-tetrazol-5-ylamino)methyl]-1,2,5-oxadiazole-3-carboxamide

To a solution ofN-(3-chloro-4-fluorophenyl)-4-formyl-1,2,5-oxadiazole-3-carboxamide (4.5g, 17 mmol) in THF (75 mL) was added 5-aminotetrazole (4.26 g, 50.1mmol), sodium sulfate (1.0 g, 8.0 mmol) and acetic acid (50 μL, 0.80mmol). The resulting mixture was stirred at 40° C. for 36 h, and then anadditional 20 mL THF was added followed by sodium tetrahydroborate (947mg, 25 mmol). After stirring for 3 h, lithium tetrahydroborate (545 mg,25.0 mol) was added to the reaction solution and stirred overnight. Thereaction solution was diluted with 1 N NaOH solution. The aqueous layerwas separated and acidified with 6 N HCl to pH 1. A white solidprecipitated out of solution and was filtered to afford the desiredproduct (4.82 g, 85%). LCMS for C₁₁H₉ClFN₈O₂(M+H)⁺: m/z=339.0.

Step B:N-(3-Chloro-4-fluorophenyl)-4-[(1-[2-(trimethylsilyl)ethoxy]methyl-1H-tetrazol-5-yl)amino]-methyl-1,2,5-oxadiazole-3-carboxamide,andN-(3-Chloro-4-fluorophenyl)-4-[(2-[2-(trimethyl-silyl)ethoxy]methyl-2H-tetrazol-5-yl)amino]methyl-1,2,5-oxadiazole-3-carboxamide

To a solution ofN-(3-chloro-4-fluorophenyl)-4-[(1H-tetrazol-5-ylamino)methyl]-1,2,5-oxa-diazole-3-carboxamide(130 mg, 0.38 mmol) in DCM (4.0 mL) was added TEA (134 μL, 0.96 mmol)and [β-(trimethylsilyl)ethoxy]methyl chloride (143 μL, 0.806 mmol). Theresulting mixture was stirred for 1 h. The reaction was concentrated andthen purified by silica chromatography (20% ethyl acetate/hexanes) toafford the desired products as colorless oils (100 mg, 55%) and (70 mg,39%). LCMS for C₁₇H₂₃ClFN₈O₃Si(M+H)⁺: m/z=469.1.

Step C:N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[(1-[2-(trimethylsilyl)ethoxy]methyl-1H-tetrazol-5-yl)amino]methyl-1,2,5-oxadiazole-3-carboximidamide

N-(3-Chloro-4-fluorophenyl)-4-[(1-[2-(trimethylsilyl)ethoxy]methyl-1H-tetrazol-5-yl)amino]-methyl-1,2,5-oxadiazole-3-carboxamide(96 mg, 0.20 mmol) was suspended in benzene (1.0 mL) and pyridine (0.5mL) under an atmosphere of nitrogen. Phosphorus pentachloride (46.9 mg,0.225 mmol) was added and the solution was heated at reflux for 2 hrs.The reaction was then stripped to dryness in vacuo. The reaction wasdissolved in EtOH (2.6 mL) and hydroxylamine (300 μL, 5 mmol, 50%solution in water) was added to the reaction. After stirring for 1 h,the reaction solution was diluted with MeOH and purified by preparativeLCMS to afford the desired product as a white solid (32 mg, 32%). LCMSC₁₇H₂₄ClFN₉O₃Si(M+H)⁺: m/z=484.144.

Step D:N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[(1H-tetrazol-5-ylamino)methyl]-1,2,5-oxadiazole-3-carboximidamide

To a solution ofN-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[(1-[2-(trimethylsilyl)ethoxy]-methyl-1H-tetrazol-5-yl)-amino]-methyl-1,2,5-oxadiazole-3-carboximidamide(10.2 mg, 0.021 mmol) in DCM (0.5 mL) was added TFA (0.5 mL). Thereaction solution was stirred at rt for 2 hrs. The reaction solution wasconcentrated in vacuo, and purified with LCMS to afford the desiredproduct as a white powder (5.2 mg, 70%). LCMS for C₁₁H₁₀ClFN₉O₂(M+H)⁺:m/z=354.1.

Further example compounds of the invention are provided in Table 2.

TABLE 2 Ex. MS Prep. Pur. No. Structure (M + 1) Ex. Meth. Salt Name 42

394.1 Ex. 4 A 2 TFA N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-({[3-(1H-imidazol-1- yl)propyl]amino}meth- yl)-1,2,5-oxadiazole-3-carboximidamide bis(trifluoroacetate) 43

399.2 Ex. 4 A 2 TFA N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-{[(2-morpholin-4-yl- ethyl)amino]methyl}- 1,2,5-oxadiazole-3-carboximidamide bis(trifluoroacetate) 44

420.2 Ex. 4 A TFA {4-{({4-[(E/Z)-[(3- chloro-4-fluoro- phenyl)amino]-(hydroxyimino)methyl]- 1,2,5-oxadiazol-3- yl}methyl)amino]phenyl}-acetic acid trifluoroacetate 45

370.2 Ex. 4 A TFA N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-[(4-hydroxypiperidin- 1-yl)methyl]-1,2,5- oxadiazole-3- carboximidamidetrifluoroacetate 46

399.2 Ex. 4 A 2 TFA N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-{[4-(2-hydroxyethyl)- piperazin-1-yl]- methyl}-1,2,5- oxadiazole-3-carboximidamide bis(trifluoroacetate) 47

406.2 Ex. 4 A TFA N-(3-chloro-4-fluoro- phenyl)-N-hydroxy-4-({[(1R)-2-hydroxy-1- phenylethyl]amino}- methyl)-1,2,5- oxadiazole-3-carboximidamide trifluoroacetate 48

330.2 Ex. 4 A TFA N-(3-chloro-4-fluoro- phenyl)-N-hydroxy-4-{[(2-hydroxyethyl)- amino]methyl}-1,2,5- oxadiazole-3- carboximidamidetrifluoroacetate 49

391.2 Ex. 4 A 2 TFA N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-{[(2-pyridin-4- ylethyl)amino]methyl}- 1,2,5-oxadiazole-3-carboximidamide bis(trifluoroacetate) 50

370.2 Ex. 4 A TFA N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-{[(tetrahydrofuran-2- ylmethyl)amino]meth- yl}-1,2,5-oxadiazole-3-carboximidamide trifluoroacetate 51

383.2 Ex. 4 A TFA N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-{[(1,3-thiazol-2- ylmethyl)amino]meth- yl}-1,2,5-oxadiazole-3-carboximidamide trifluoroacetate 52

455.2 Ex. 4 A TFA 4-({[4-(amino- sulfony)benzyl]amino}-methyl)-N-(3-chloro- 4-fluorophenyl)-N′- hydroxy-1,2,5- oxadiazole-3-carboximidamide trifluoroacetate 53

358.2 Ex. 3 A Free Base {4-[(E/Z)-[(3-chloro- 4-fluorophenyl)-amino](hydroxyimino)- methyl]-1,2,5- oxadiazol-3-yl}methyldimethylcarbamate 54

442.2 Ex. 2 A Free Base 4-{[4-(amino- sulfonyl)phenoxy]meth-yl}-N-(3-chloro-4- fluorophenyl)-N′- hydroxy-1,2,5- oxadiazole-3-carboximidamide 55

441.2 Ex. 2 A Free Base N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-{[4-(methylsulfonyl)- phenoxy]methyl}- 1,2,5-oxadiazole-3-carboximidamide 56

337.2 Exs. 39 and 40 A TFA N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-(1H-imidazol-1-yl- methyl)-1,2,5- oxadiazole-3- carboximidamidetrifluoroacetate 57

338.2 Exs. 39 and 40 A Free Base N-(3-chloro-4-fluoro-phenyl)-N′-hydroxy-4- (1H-1,2,4-triazol-1-yl- methyl)-1,2,5-oxadiazole-3- carboximidamide 58

469.2 Ex. 4 A TFA 4-[({2-[4-(amino- sulfonyl)phenyl]ethyl}-amino)methyl]-N-(3- chloro-4-fluoro- phenyl)-N′-hydroxy-1,2,5-oxadiazole-3- carboximidamide trifluoroacetate 59

339.2 Exs. 39 and 40 A Free Base N-(3-chloro-4-fluoro-phenyl)-N′-hydroxy-4- (2H-tetrazol-2- ylmethyl)-1,2,5- oxadiazole-3-carboximidamide 60

339.2 Exs. 39 and 40 B Free Base N-(3-chloro-4- fluorophenyl)-N′-hydroxy-4-(1H- tetrazol-1-ylmethyl)- 1,2,5-oxadiazole-3- carboximidamide61

400.2 Ex. 3 A Free Base {4-[(E/Z)-[(3-chloro- 4-fluorophenyl)-amino](hydroxyimino)- methyl]-1,2,5- oxadiazol-3-yl}methyl-morpholine-4- carboxylate 62

420.2 Ex. 2 A Free Base 2-[4-({4-[(E/Z)-[(3- chloro-4-fluoro-phenyl)amino](hydroxy- imino)methyl- oxadiazol-3-yl}-methoxy)phenyl]aceta- mide 63

286.2 Ex. 33, Step B A TFA 4-(aminomethyl)-N- (3-chloro-4-fluoro-phenyl)-N′-hydroxy- 1,2,5-oxadiazole-3- carboximidamide trifluoroacetate64

370.1 Exs. 39 and 40 A Free Base 4-[(5-amino-1H- tetrazol-1-yl)methyl]-N-[3-(trifluoro- methyl)phenyl]-N′- hydroxy-1,2,5- oxadiazole-3-carboximidamide 65

429.2 Exs. 39 and 40 A Free Base 4-[(5-benzyl-1H- tetrazol-1-yl)methyl]-N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy- 1,2,5-oxadiazole-3-carboximidamide 66

429.2 Exs. 39 and 40 A Free Base 4-[(5-benzyl-2H- tetrazol-2-yl)methyl]-N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy- 1,2,5-oxadiazole-3-carboximidamide 67

397.2 Exs. 39 and 40 B Free base [2-({4-[(E/Z)-[(3- chloro-4-fluoro-phenyl)amino](hydroxy- imino)methyl]-1,2,5- oxadiazol-3- yl}methyl)-2H-tetrazol-5-yl]acetic acid 68

296.2 Exs. 39 and 40 B Free Base N-(3-chloro-4-fluoro- phenyl)-4-(cyano-methyl)-N′-hydroxy- 1,2,5-oxadiazole-3- carboximidamide 69

356.2 Exs. 39 and 40 B Free Base N-(3-chloro-4-fluoro-phenyl)-N′-hydroxy-4- [(2-oxo-1,3- oxazolidin-3-yl)- methyl]-1,2,5-oxadiazole-3- carboximidamide 70

357.2 Ex. 4 B Free Base N-(3-chloro-4-fluoro- phenyl)-4-({[2-(dimethylamino)ethyl]- amino}methyl)-N′- hydroxy-1,2,5- oxadiazole-3-carboximidamide 71

413.2 Ex. 4 B Free Base N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-{[(3-morpholin-4- ylpropyl)amino]meth- yl}-1,2,5-oxadiazole-3-carboximidamide 72

416.2 Exs. 39 and 40 B Free Base N-(3-chloro-4-fluoro-phenyl)-N′-hydroxy-4- [(5-pyridin-4-yl-2H- tetrazol-2-yl)methyl]-1,2,5-oxadiazole-3- carboximidamide 73

471.2 Ex. 4 B Free Base 4-({[4-(amino- sulfonyl)benzyl]amino}-methyl)-N-[3- (trifluoromethyl)phenyl]- N′-hydroxy-1,2,5- oxadiazole-3-carboximidamide 74

355.2 Exs. 39 and 40 B Free Base N-[3-(trifluoro- methyl)phenyl]-N′-hydroxy-4-(1H- tetrazol-1-ylmethyl)- 1,2,5-oxadiazole-3- carboximidamide75

355.2 Exs. 39 and 40 B Free Base N-[3-(trifluoro- methyl)phenyl]-N′-hydroxy-4-(2H- tetrazol-2-ylmethyl)- 1,2,5-oxadiazole-3- carboximidamide76

415.2 Ex. 4 B Free Base N-[3-(trifluoro- methyl)phenyl]-N′-hydroxy-4-{[(2- morpholin-4-ylethyl)- amino]methyl}-1,2,5- oxadiazole-3-carboximidamide 77

377.2 Ex. 4 B Free Base N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-{[(pyridin-3-yl- methyl)amino]methyl}- 1,2,5-oxadiazole-3-carboximidamide 78

383.2 Ex. 4 B Free Base N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-{[(2-pyrrolidin-1- ylethyl)amino]methyl}- 1,2,5-oxadiazole-3-carboximidamide 79

380.2 Ex. 4 B Free Base N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-({[2-(1H-imidazol-4- yl)ethyl]amino}methyl)- 1,2,5-oxadiazole-3-carboximidamide 80

397.2 Ex. 4 B Free Base N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-({[2-(2-oxopyrrolidin- 1-yl)ethyl]amino}- methyl)-1,2,5- oxadiazole-3-carboximidamide 81

353.2 Exs. 39 and 40 B Free Base N-(3-chloro-4-fluoro-phenyl)-N′-hydroxy-4- [(5-methyl-1H- tetrazol-1-yl)methyl]-1,2,5-oxadiazole-3- carboximidamide 82

353.2 Exs. 39 and 40 B Free Base N-(3-chloro-4-fluoro-phenyl)-N′-hydroxy-4- [(5-methyl-2H- tetrazol-2-yl)methyl]-1,2,5-oxadiazole-3- carboximidamide 83

441.2 Ex. 33 B Free Base N-({4-[(E/Z)-[(3- chloro-4-fluoro-phenyl)amino](hydroxy- imino)methyl]-1,2,5- oxadiazol-3-yl}methyl)-N-(2- morpholin-4- ylethyl)acetamide 84

385.2 Exs. 39 and 40 B Free Base N-(3-chloro-4- fluorophenyl)-N′-hydroxy-4-{[5- (methylthio)-2H- tetrazol-2-yl]methyl}-1,2,5-oxadiazole-3- carboximidamide 85

385.2 Exs. 39 and 40 B Free Base N-(3-chloro-4-fluoro-phenyl)-N′-hydroxy-4- {[5-(methylthio)-1H- tetrazol-1-yl]methyl}-1,2,5-oxadiazole-3- carboximidamide 86

415.2 Exs. 39 and 40 B Free Base N-(3-chloro-4-fluoro-phenyl)-N′-hydroxy-4- [(5-phenyl-1H- tetrazol-1-yl)methyl]-1,2,5-oxadiazole-3- carboximidamide 87

415.2 Exs. 39 and 40 B Free Base N-(3-chloro-4-fluoro-phenyl)-N′-hydroxy-4- [(5-phenyl-2H- tetrazol-2-yl)methyl]-1,2,5-oxadiazole-3- carboximidamide 88

499.2 Exs. 39 and 40 B Free Base N-(3-chloro-4-fluoro-phenyl)-N′-hydroxy-4- ({5-[3-(trifluoro- methoxy)phenyl]-2H-tetrazol-2-yl}methyl)- 1,2,5-oxadiazole-3- carboximidamide 89

416.2 Exs. 39 and 40 B Free Base N-(3-chloro-4-fluoro-phenyl)-N′-hydroxy-4- [(5-pyridin-3-yl-2H- tetrazol-2-yl)methyl]-1,2,5-oxadiazole-3- carboximidamide 90

408.2 Exs. 39 and 40 B Free Base N-(3-chloro-4-fluoro-phenyl)-N′-hydroxy-4- [(5-pyrrolidin-1-yl- 2H-tetrazol-2-yl)-methyl]-1,2,5- oxadiazole-3- carboximidamide 91

499.2 Exs. 39 and 40 B Free Base N-(3-chloro-4-fluoro-phenyl)-N′-hydroxy-4- ({5-[3-(trifluoro- methoxy)phenyl]-1H-tetrazol-1-yl}methyl)- 1,2,5-oxadiazole-3- carboximidamide 92

416.2 Exs. 39 and 40 B Free Base N-(3-chloro-4-fluoro-phenyl)-N′-hydroxy-4- [(5-pyridin-2-yl-1H- tetrazol-1-yl)methyl]-1,2,5-oxadiazole-3- carboximidamide 93

408.2 Exs. 39 and 40 B Free Base N-(3-chloro-4-fluoro-phenyl)-N′-hydroxy-4- [(5-pyrrolidin-1-yl- 1H-tetrazol-1-yl)methyl]-1,2,5- oxadiazole-3- carboximidamide 94

433.2 Exs. 39 and 40 B Free Base N-(3-chloro-4-fluoro- phenyl)-4-{[5-(4-fluorophenyl)-1H- tetrazol-1-yl]methyl]- N′-hydroxy-1,2,5- oxadiazole-3-carboximidamide 95

410.2 Exs. 39 and 40 B Free Base N-(3-chloro-4- fluorophenyl)-4-({5-[2-(dimethylamino)- ethyl]-1H-tetrazol-1- yl}methyl)-N′- hydroxy-1,2,5oxadiazole-3- carboximidamide 96

433.2 Exs. 39 and 40 B Free Base N-(3-chloro-4-fluoro- phenyl)-4-{[5-(4-fluorophenyl)-2H- tetrazol-2-yl]methyl}- N′-hydroxy-1,2,5- oxadiazole-3-carboximidamide 97

494.2 Exs. 39 and 40 B Free Base N-(3-chloro-4-fluoro-phenyl)-4-({5-[2-(4- chlorophenoxy)ethyl]- 2H-tetrazol-2-yl}-methyl)-N′-hydroxy- 1,2,5-oxadiazole-3- carboximidamide 98

484.2 Exs. 39 and 40 B Free Base N-(3-chloro-4-fluoro-phenyl)-N′-hydroxy-4- ({5-[5-(trifluoro- methyl)pyridin-2-yl]-2H-tetrazol-2-yl}- methyl)-1,2,5- oxadiazole-3- carboximidamide 99

494.2 Exs. 39 and 40 B Free Base N-(3-chloro-4-fluoro-phenyl)-4-({5-[2-(4- chlorophenoxy)ethyl]- 1H-tetrazol-1- yl}methyl)-N′-hydroxy-1,2,5- oxadiazole-3- carboximidamide 100

427.2 Ex. 4 B Free Base N-(3-chloro-4-fluoro- phenyl)-4-[({2-[(2R,6S)-2,6- dimethylmorpholin-4- yl]ethyl}amino)methyl]-N′-hydroxy-1,2,5- oxadiazole-3- carboximidamide 101

411.2 Ex. 4 B Free Base N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-({[2-(2- methylpiperidin-1- yl)ethyl]amino}methyl)- 1,2,5-oxadiazole-3-carboximidamide 102

427.2 Ex. 4 B Free Base N-(3-chloro-4-fluoro- phenyl)-4-{[(1,1-dimethyl-2- morpholin-4- ylethyl)amino]methyl}- N′-hydroxy-1,2,5-oxadiazole-3- carboximidamide 103

398.2 Ex. 4 B Free Base N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-{[(2-piperazin-1- ylethyl)amino]methyl}- 1,2,5-oxadiazole-3-carboximidamide 104

397.2 Ex. 4 B Free Base N-(3-chloro-4-fluoro- phenyl)-4-({[(1-ethylpyrrolidin-2- yl)methyl]amino}- methyl)- N′-hydroxy-1,2,5-oxadiazole-3- carboximidamide 105

371.2 Ex. 4 B Free Base N-(3-chloro-4-fluoro- phenyl)-4-({[2-(dimethylamino)propyl]- amino}methyl)-N′- hydroxy-1,2,5- oxadiazole-3-carboximidamide 106

427.2 Ex. 4 B Free Base N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-{[(2-methyl-2- morpholin-4- ylpropyl)amino]- methyl}-1,2,5-oxadiazole-3- carboximidamide 107

425.1 Ex. 4 B Free Base N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-{[(2-methyl-2- piperidin-1-ylpropyl)- amino]methyl}-1,2,5- oxadiazole-3-carboximidamide 108

383.1 Ex. 4 B Free Base N-(3-chloro-4- fluorophenyl)-N′- hydroxy-4-{[(piperidin-2- ylmethyl)amino]methyl}- 1,2,5-oxadiazole-3-carboximidamide 109

447.1 Ex. 4 B Free Base N-(3-chloro-4-fluoro- phenyl)-4-({[2-(1,1-dioxidothiomorpholin- 4-yl)ethyl]amino}- methyl)-N′-hydroxy-1,2,5-oxadiazole-3- carboximidamide 110

369.2 Ex. 4 B Free Base N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-{[(piperidin-3-yl- amino)methyl]-1,2,5- oxadiazole-3- carboximidamide111

369.2 Ex. 4 B Free Base N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-{[(pyrrolidin-3-yl- methyl)amino]methyl}- 1,2,5-oxadiazole-3-carboximidamide 112

355.1 Ex. 33 B Free Base N-({4-[(E/Z)-[(3- chloro-4-fluoro-phenyl)amino](hydroxy- imino)methyl]-1,2,5- oxadiazol-3-yl}-methyl)-2-methyl- propanide 113

369.1 Ex. 33 B Free Base N-({4-[(E/Z)-[(3- chloro-4-fluoro-phenyl)amino]- (hydroxyimino)- methyl]-1,2,5- oxadiazol-3-yl}-methyl)-2,2- dimethylpropanamide 114

403.1 Ex. 33 B Free Base N-({4-[(E/Z)-[(3- chloro-4-fluoro-phenyl)amino](hydroxy- imino)methyl]-1,2,5- oxadiazol-3- yl}methyl)-2-phenylacetamide 115

417.1 Ex. 33 B Free Base N-({4-[(E/Z)-[(3- chloro-4-fluoro-phenyl)amino](hydroxy- imino)methyl]-1,2,5- oxadiazol-3-yl}-methyl)-3-phenyl- propanamide 116

396.0 Ex. 33 B Free Base N-({4-[(E/Z)-[(3- chloro-4-fluoro-phenyl)amino](hydroxy- imino)methyl]-1,2,5- oxadiazol-3-yl}-methyl)-1,3-thiazole- 5-carboxamide 117

381.1 Ex. 33 B Free Base N-({4-[(E/Z)-[(3- chloro-4-fluoro-phenyl)amino](hydroxy- imino)methyl]-1,2,5- oxadiazol-3-yl}-methyl)cyclopentane- carboxamide 118

363.0 Ex. 35 B Free Base N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-{[(methylsulfonyl)amino]- methyl}-1,2,5- oxadiazole-3- carboximidamide119

418.1 Ex. 34 B Free Base 4-({[(benzylamino)- carbonyl]amino}-methyl)-N-(3-chloro- 4-fluorophenyl)-N′- hydroxy-1,2,5- oxadiazole-3-carboximidamide 120

432.1 Ex. 34 B Free Base N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-[({[(2-phenylethyl)- amino]carbonyl}amino)- methyl]-1,2,5- oxadiazole-3-carboximidamide 121

370.1 Ex. 34 B Free Base N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-({[(isopropylamino)- carbonyl]- amino}methyl)- 1,2,5-oxadiazole-3-carboximidamide 122

398.1 Ex. 34 B Free Base N-({4-[(E/Z)-[(3- chloro-4-fluoro-phenyl)amino](hydroxy- imino)methyl]-1,2,5- oxadiazol-3-yl}-methyl)morpholine-4- carboxamide 123

356.1 Ex. 34 B Free Base N-(3-chloro-4-fluoro- phenyl)-4-({[(dimeth-ylamino)carbonyl]amino]- methyl)-N′- hydroxy-1,2,5-oxa- diazole-3-carboximidamide 124

327.1 Ex. 33 B Free Base N-({4-[(E/Z)-[(3- chloro-4-fluoro-phenyl)amino](hydroxy- imino)methyl]-1,2,5- oxadiazol-3-yl}-methyl)acetamide 125

343.0 Ex. 36 B Free Base methyl ({4-[(E/Z)-[(3- chloro-4-fluoro-phenyl)amino](hydroxy- imino)methyl]-1,2,5- oxadiazol-3-yl]-methyl)carbamate 126

385.1 Ex. 36 B Free Base isobutyl ({4-[(E/Z)- [(3-chloro-4-fluoro-phenyl)amino](hydroxy- imino)methyl]-1,2,5- oxadiazol-3-yl}-methyl)carbamate 127

419.1 Ex. 36 B Free Base benzyl ({4-[(E/Z)-[(3- chloro-4-fluoro-phenyl)amino](hydroxy- imino)methyl]-1,2,5- oxadiazol-3-yl}-methyl)carbamate 128

377.0 Ex. 35 B Free Base N-(3-chloro-4-fluoro- phenyl)-4-{[(ethyl-sulfonyl)amino]methyl]- N′-hydroxy-1,2,5- oxadiazole-3- carboximidamide129

503.0 Ex. 35 B Free Base N-(5-{[({4-[(E/Z)-[(3- chloro-4-fluoro-phenyl)amino](hydroxy- imino)methyl- oxadiazol-3-yl}-methyl)amino]sulfonyl}- 4-methyl-1,3- thiazol-2-yl)acetamide 130

579.0 Ex. 35 B Free Base N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-{[({5-[1-methyl-5-(tri- fluoromethyl)-1H- pyrazol-3-yl]-2-thienyl}sulfonyl)- amino]methyl}-1,2,5- oxadiazole-3- carboximidamide131

429.0 Ex. 35 B Free Base N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-({[(1-methyl-1H- imidazol-4-yl)- sulfonyl]amino}- methyl)-1,2,5-oxadiazole-3- carboximidamide 132

460.0 Ex. 35 B Free Base N-(3-chloro-4-fluoro- phenyl)-4-({[(2,4-dimethyl-1,3-thiazol- 5-yl)sulfonyl]- amino}methyl)-N′- hydroxy-1,2,5-oxadiazole-3- carboximidamide 133

444.0 Ex. 35 B Free Base N-(3-chloro-4-fluoro- dimethylisoxazol-4-yl)sulfonyl]amino}- methyl)-N′-hydroxy- 1,2,5-oxadiazole-3-carboximidamide 134

457.1 Ex. 35 B Free Base N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-({[(1,3,5-trimethyl- 1H-pyrazol-4-yl)- sulfonyl]amino}methyl)-1,2,5-oxadiazole-3- carboximidamide 135

443.1 Ex. 35 B Free Base N-(3-chloro-4-fluoro- phenyl)-4-({[(1,2-di-methyl-1H-imidazol- 4-yl)sulfonyl]amino}- methyl)-N′-hydroxy-1,2,5-oxadiazole-3- carboximidamide 136

391.1 Ex. 35 B Free Base N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-{[(propylsulfonyl)- amino]methyl}-1,2,5- oxadiazole-3- carboximidamide137

389.0 Ex. 35 B Free Base N-(3-chloro-4-fluoro- phenyl)-4-{[(cyclo-propylsulfonyl)amino]- methyl}-N′-hydroxy- 1,2,5-oxadiazole-3-carboximidamide 138

382.0 Ex. 4 B Free Base N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-{[(3-methylisothiazol- 5-yl)amino]methyl}- 1,2,5-oxadiazole-3-carboximidamide

Example 139 Ethyl3-(4-(N-(3-chloro-4-fluorophenyl)-N′-hydroxyearbamimidoyl)-1,2,5-oxadiazol-3-yl)propanoate

Step 1:N-(3-Chloro-4-fluorophenyl)-4-formyl-1,2,5-oxadiazole-3-carboxamide

A solution ofN-(3-chloro-4-fluorophenyl)-4-(hydroxymethyl)-1,2,5-oxadiazole-3-carboxamide(8.50 g, 31.3 mmol) and Dess-Martin periodinane (14.6 g, 34.4 mmol) inDCM (400 mL) was stirred at 25° C. for 3 h. The reaction was dilutedwith saturated sodium bicarbonate solution and extracted with ethylacetate three times, dried with sodium sulfate, filtered, andconcentrated in vacuo. The crude residue was purified by flash columnchromatography to yield the desired product (7.50 g, 89%). LCMS forC₁₀H₆ClFN₃O₃(M+H)⁺: m/z=270.0.

Step 2: Ethyl(2E)-3-(4-[(3-chloro-4-fluorophenyl)amino]carbonyl-1,2,5-oxadiazol-3-yl)acrylate

To a solution of (carbethoxymethyl)triphenylphosphonium bromide (3.14 g,7.32 mmol) in toluene (37 mL) was added sodium tert-butoxide (723 mg,7.52 mmol) at rt under a nitrogen atmosphere. After stirring for 30 min,a solution ofN-(3-chloro-4-fluorophenyl)-4-formyl-1,2,5-oxadiazole-3-carboxamide (811mg, 3.01 mmol) in THF (10 mL) was cannulated into reaction flask. Theresulting solution was heated at 80° C. for 3 h, then cooled to rtovernight. The reaction was quenched with a 1 N HCl solution, theaqueous solution was then extracted with ethyl acetate. The combinedorganic solutions were washed with brine, dried over Na₂SO₄, filteredand concentrated under reduced pressure. The residue was purified withflash chromatography (30% ethyl acetate/hexane) to give the desiredproduct as a white solid. ¹H NMR (400 MHz, CD₃OD): δ 7.92 (m, 2H), 7.65(m, 1H), 7.26 (m, 1H), 7.01 (m, 1H), 4.27 (m, 2H), 1.33 (m, 3H); LCMSfor C₁₄H₁₂ClFN₃O₄(M+H)⁺: m/z=340.

Step 3: Ethyl3-(4-[(3-chloro-4-fluorophenyl)amino]carbonyl-1,2,5-oxadiazol-3-yl)propanoate

To a solution of ethyl(2E)-3-(4-[(3-chloro-4-fluorophenyl)amino]carbonyl-1,2,5-oxadiazol-3-yl)acrylate(0.86 g, 0.0025 mol) in ethyl acetate (10 mL, 0.1 mol) was addedpalladium (600 mg, 0.006 mol). The mixture was stirred at rt under anatmosphere of hydrogen for 2 h. The reaction solution was filteredthrough a pad of celite. The filtrate was concentrated and purified byflash chromatography (40% ethyl acetate/hexane) to give the desiredproduct as a white solid (609 mg, 70%). LCMS for C₁₄H₁₄ClFN₃O₄(M+H)⁺:m/z=342.1.

Step 4: Ethyl 3-4-[(Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-ylpropanoate

Ethyl3-(4-[(3-chloro-4-fluorophenypamino]carbonyl-1,2,5-oxadiazol-3-yl)-propanoate(27 mg, 0.079 mmol) was suspended in benzene (1 mL) under a nitrogenatmosphere, and phosphorus pentachloride (18.0 mg, 0.086 mmol) was addedand the solution was heated to reflux for 2.5 h. The solvent was removedin vacuo. The residue was dissolved in EtOH (1.0 mL) and hydroxylamine(100 μL, 2 mmol) (50% solution in water) was added to the reaction.After stirring 1 h, the solution was diluted with MeOH and purified withpreparative LCMS to give the desired product (8.5 mg, 30%). ¹H NMR (400MHz, CD₃OD): δ 7.03 (t, J=8.9 Hz, 1H), 6.95 (dd, J=6.4, 2,7 Hz, 1H),6.71 (m, 1H), 4.12 (q, J=7.2 Hz, 2H), 3.11 (t, J=7.2 Hz, 2H), 2.80 (t,J=7.2 Hz, 2H), 1.23 (t, J=7.2 Hz, 3H); LCMS for C₁₄H₁₅ClFN₄O₄(M+H)⁺:m/z=357.1.

Example 140N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-(3-morpholin-4-ylpropyl)-1,2,5-oxadiazole-3-carboximidamide

Step 1:N-(3-Chloro-4-fluorophenyl)-4-(3-hydroxypropyl)-1,2,5-oxadiazole-3-carboxamide

To a solution of ethyl3-(4-[(3-chloro-4-fluorophenyl)amino]carbonyl-1,2,5-oxadiazol-3-yl)propanoate(97.5 mg, 0.285 mmol) in THF (1.2 mL) was added lithium tetrahydroborate(14.3 mg, 0.656 mmol) at 0° C. under an atmosphere of nitrogen. Thereaction solution was allowed to warm to rt for 2 h. The reaction wasquenched with MeOH and concentrated. The residue was purified by flashchromatography (60% ethyl acetate/hexane) to give product. LCMS forC₁₂H₁₂ClFN₃O₃(M+H)⁺: m/z=300.1.

Step 2:3-(4-[3-Chloro-4-fluorophenyl)amino]carbonyl-1,2,5-oxadiazol-3-yl)propylmethanesulfonate

N-(3-Chloro-4-fluorophenyl)-4-(3-hydroxypropyl)-1,2,5-oxadiazole-3-carboxamide(60 mg, 0.20 mmol) was dissolved in anhydrous DCM (2 mL), followed byaddition of TEA (57 μL, 0.41 mmol). The reaction was stirred and cooledto 0° C., and then methanesulfonyl chloride (29 μL, 0.37 mmol) was addeddropwise. The reaction was quenched with water and diluted with DCM. Theorganic solution was separated, dried over Na₂SO₄, filtered,concentrated and purified by silica gel chromatography (25%-70%EtOAc/hexane) to give the desired product (19 mg). LCMS forC₁₃H₁₄ClFN₃O₅S(M+H)⁺: m/z=378.

Step 3:N-(3-Chloro-4-fluorophenyl)-4-(3-morpholin-4-ylpropyl)-1,2,5-oxadiazole-3-carboxamide

3-(4-[(3-Chloro-4-fluorophenyl)amino]carbonyl-1,2,5-oxadiazol-3-yl)propylmethanesulfonate(19 mg, 0.051 mmol) was dissolved in anhydrous ACN (100 μL) followed byaddition of DIPEA (44 μL, 0.26 mmol) and morpholine (6.7 μL, 76.8 μmol).The reaction was stirred and heated at 70° C. for 3 h. The reaction wasconcentrated and purified with silica gel chromatography (60-100% ethylacetate/hex) to give the desired product (10 mg, 54%). LCMS forC₁₆H₁₉ClFN₄O₃(M+H)⁺: m/z=369.1.

Step 4:N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-(3-morpholin-4-ylpropyl)-1,2,5-oxadiazole-3-carboximidamide

N-(3-Chloro-4-fluorophenyl)-4-(3-morpholin-4-ylpropyl)-1,2,5-oxadiazole-3-carboxamide(10.0 mg, 27.1 μmol) was suspended in benzene (0.4 mL) under a nitrogenatmosphere and phosphorus pentachloride (6.2 mg, 29.8 μmol) was addedand the solution was heated at reflux for 2.5 h. The reaction was thenstripped to dryness in vacuo. The reaction was dissolved in EtOH (0.3mL) and hydroxylamine (40 μL, 0.7 mmol) (50% solution in water) wasadded to the reaction. After stirring for 1 h, the reaction solution wasdiluted with MeOH and purified with preparative LCMS to give product(5.2 mg, 50%). LCMS for C₁₆H₂₀ClFN₅O₃(M+H)⁺: m/z=384.1.

Example 1415-[(5-Amino-1H-tetrazol-1-yl)methyl]-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,3-thiadiazole-4-carboximidamide

Step A: Methyl 2-diazo-4-methoxy-3-oxobutanoate

Methyl 4-methoxy-3-oxobutanoate (4.28 g, 0.029 mol) was dissolved inether (20 mL). The solution was cooled in an ice bath. To the solutionwas added p-toluenesulfonyl azide (5.78 g, 0.029 mol) followed byN-ethylethanamine (2.0 mL, 0.019 mol). The solution was stirred at 0° C.for 15 minutes, then at rt for 30 minutes. Upon evaporation, the tosylamide bi-product solidified. This was filtered off and the filtrate waspurified by flash chromatography to give the desired product (4.5 g,89%) as a light oil. ¹H NMR (400 MHz, CDCl₃): δ 4.55 (s, 2H), 3.83 (s,3H), 3.45 (s, 3H). MF C₆H₈N₂O₄. LCMS calculated for C₆H₉N₂O₄(M+H)⁺:m/z=173.0.

Step B: Methyl 5-(methoxymethyl)-1,2,3-thiadiazole-4-carboxylate

Methyl 2-diazo-4-methoxy-3-oxobutanoate (4.5 g, 0.026 mol) was cooled inan ice bath and ammonium sulfide (8.0 g, 0.12 mol) (40-48%) was addeddrop-wise over 2 minutes. White precipitate formed. The slurry wasstirred for 30 minutes, and then purified by flash chromatography togive the desired product (4.2 g, 85%) as a light oil, that crystallizedreadily upon standing. ¹H NMR (400 MHz, CD₃OD): δ≡ 5.02 (s, 2H), 3.98(s, 3H), 3.57 (s, 3H). MF=C₆H₈N₂O₃S; LCMS calculated for C₆H₉N₂O₃S(M+H)⁺: m/z=189.0.

Step C: Methyl 5-formyl-1,2,3-thiadiazole-4-carboxylate

Methyl 5-(methoxymethyl)-1,2,3-thiadiazole-4-carboxylate (4.18 g, 0.022mol) was dissolved in carbon tetrachloride (60 mL). To the solution wasadded bromine (4.18 g, 0.026 mol) and the solution was refluxed uponirradiation with long wavelength UV light (100 watts) for 3 h. Thevolatiles were evaporated in vacuo and the crude material purified byflash chromatography to give the desired product (2.70 g, 71%) as aviscous oil. ¹H NMR (400 MHz, CDCl₃): δ 10.67 (s, 1H), 4.15 (s, 3H).MF=C₅H₄N₂O₃S; LCMS calculated for C₅H₅N₂O₃S (M+H)⁺: m/z=173.0.

Step D: Methyl 5-(hydroxymethyl)-1,2,3-thiadiazole-4-carboxylate

Methyl 5-formyl-1,2,3-thiadiazole-4-carboxylate (460.0 mg, 0.0026 mol)was dissolved in ethanol (40 mL) and sodium tetrahydroborate (50 mg,0.0013 mol) was added at 0° C. The orange solution was allowed to warmto room temp and was stirred for 30 minutes. The reaction was quenchedwith acetic acid and then purified by preparative LCMS to give thedesired product (340 mg, 73%). MF=C₅H₆N₂O₃S; LCMS calculated forC₅H₇N₂O₃S (M+H)⁺: m/z=175.1.

Step E: Methyl5-[(triisopropylsilyl)oxy]methyl-1,2,3-thiadiazole-4-carboxylate

To a solution of methyl5-(hydroxymethyl)-1,2,3-thiadiazole-4-carboxylate (1.22 g, 0.007 mol) inDCM (20 mL) at 0° C. was added 2,6-lutidine (2.0 mL, 0.018 mol) followedby triisopropylsilyl triflate (2.4 mL, 0.0091 mol). The solution wasstirred at 0° C. for 5 minutes. The reaction was then concentrated andpurified by flash chromatography to give the desired product (2.0 g,87%). ¹H NMR (400 MHz, CDCl₃): 6; MF=C₁₄H₂₆N₂O₃SSi; LCMS calculated forC₁₄H₂₇N₂O₃SSi (M+H)⁺: m/z 331.1.

Step F:N-(3-chloro-4-fluorophenyl)-5-[(triisopropylsilyl)oxy]methyl-1,2,3-thiadiazole-4-carboxamide

To a cooled solution (0° C.) of methyl5-[(triisopropylsilyl)oxy]methyl-1,2,3-thiadiazole-4-carboxylate (2.2 g,0.0066 mol) and 3-chloro-4-fluoroaniline (1.5 g, 0.010 mol) in DCM (20mL, 0.4 mol) was added 2.0 M of trimethylaluminum in hexane (12 mL)under nitrogen and stirred for 15 minutes. The volatiles were removed invacuo and the crude was purified by flash chromatography to give thedesired product (2.3 g, 78%). MF=C₁₉H₂₇ClFN₃O₂SSi; LCMS calculated forC₁₉H₂₈ClFN₃O₂SSi (M+H)⁺: m/z=444.1.

Step G:N-(3-chloro-4-fluorophenyl)-5-[(triisopropylsilyl)oxy]methyl-1,2,3-thiadiazole-4-carbothioamide

A solution ofN-(3-chloro-4-fluorophenyl)-5-[(triisopropylsilyl)oxy]methyl-1,2,3-thiadiazole-4-carboxamide(2.3 g, 0.0052 mol) in anhydrous THF (10 mL) was distributed equallyinto 2 microwave vials.2,4-bis(4-methoxyphenyl)-2,4-dithioxo-1,3,2,4-dithiadiphosphetane (4.2g, 0.010 mol) (Lawesson's reagent) was added to each vial. The reactionswere each heated at 160° C. in a microwave for 15 minutes. The solutionswere combined, concentrated and purified by flash chromatography to givethe desired product (1.80 g, 76%). MF=C₁₉H₂₇ClFN₃OS₂Si; LCMS calculatedfor C₁₉H₂₈ClFN₃OS₂Si (M+H)⁺: m/z=460.1.

Step H: MethylN-(3-chloro-4-fluorophenyl)-5-[(triisopropylsilyl)oxy]methyl-1,2,3-thiadiazole-4-carbimidothioate

To a solution ofN-(3-chloro-4-fluorophenyl)-5-[(triisopropylsilyl)oxy]methyl-1,2,3-thia-diazole-4-carbothioamide(0.18 g, 0.00039 mol) in anhydrous DCM (3 mL, 0.04 mol) under N₂ wasadded DIPEA (82 μL, 0.00047 mol) followed by methyltrifluoromethanesulfonate (47 μL, 0.00043 mol). The reaction was stirredfor 5 minutes and then concentrated in vacuo. The crude material wasused in the next step. The product amount was estimated (185 mg, 100%).MF=C₂₀H₂₉ClFN₃OS₂Si; LCMS calculated for C₂₀H₃₀ClFN₃OS₂Si (M+H)⁺:m/z=474.1.

Step 1:N-(3-chloro-4-fluorophenyl)-N′-hydroxy-5-[(triisopropylsilyl)oxy]methyl-1,2,3-thiadiazole-4-carboximidamide

MethylN-(3-chloro-4-fluorophenyl)-5-[(triisopropylsilyl)oxy]methyl-1,2,3-thiadiazole-4-carbimidothioate(90 mg, 0.0002 mol) was dissolved in EtOH (2 mL) followed by addition ofhydroxylamine (116 μL, 0.00190 mol) (50% by wt, 99.9% in watersolution). The reaction was stirred at 60° C. for 4 h and overnight atroom temperature. The reaction was evaporated and purified by flashchromatography to give the desired product (85 mg, 98%). ¹H NMR (400MHz, CDCl₃): SE 7.32 (s, 1H), 7.25 (s, 1H), 6.90 (m, 2H), 6.62 (m, 2H),5.17 (s, 2H), 1.05 (m, 21H). MF=C₁₉H₂₈ClFN₄O₂SSi; LCMS calculated forC₁₉H₂₉ClFN₄O₂SSi (M+H)⁺: m/z=459.2.

Step J:4-(3-Chloro-4-fluorophenyl)-3-(5-[(triisopropylsilyl)oxy]methyl-1,2,3-thiadiazol-4-yl)-1,2,4-oxadiazol-5(4H)-one

Into a round bottom flask was addedN-(3-chloro-4-fluorophenyl)-N′-hydroxy-5-[(triisopropylsilyl)oxy]methyl-1,2,3-thiadiazole-4-carboximidamide(85.0 mg, 0.185 mmol), anhydrous THF (1.1 mL), andN,N-carbonyldiimidazole (55 mg, 0.34 mmol). The reaction was heated to70° C. for 2.5 h. The reaction was concentrated in vacuo and the crudepurified by flash chromatography to give the desired product (89 mg,99%). MF=C₂₀H₂₆ClFN₄O₃SSi; LCMS calculated for C₂₀H₂₇ClFN₄O₃S Si (M+H)⁺:m/z=485.2.

Step K:4-(3-Chloro-4-fluorophenyl)-3-[5-(hydroxymethyl)-1,2,3-thiadiazol-4-yl]-1,2,4-oxadiazol-5(4H)-one

Into a round bottom flask was added4-(3-chloro-4-fluorophenyl)-3-(5-[(triisopropylsilyl)-oxy]methyl-1,2,3-thiadiazol-4-yl)-1,2,4-oxadiazol-5(4H)-one(89 mg, 0.18 mmol), anhydrous MeOH (1.5 mL), and hydrogen chloride in1,4-dioxane (1.5 mL, 4.0 M). The reaction was heated to 70° C. for 2.5h. The reaction was concentrated in vacuo and the crude purified byflash chromatography to give the desired product (52 mg, 86%).MF=C₁₁H₆ClFN₄O₃S; LCMS calculated for C₁₁H₇ClFN₄O₃S (M+H)⁺: m/z=329.0.

Step L:4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,3-thiadiazol-5-ylmethylmethanesulfonate

4-(3-Chloro-4-fluorophenyl)-3-[5-(hydroxymethyl)-1,2,3-thiadiazol-4-yl]-1,2,4-oxadiazol-5(4H)-onewas dissolved in anhydrous DCM (2 mL) followed by addition of TEA (26μL, 0.19 mmol). The reaction was stirred at 0° C. for 15 minutes.Methanesulfonyl chloride (13 μL, 0.17 mmol) was added drop-wise andstirred for 15 minutes at 0° C. The reaction was concentrated in vacuoand the crude purified by flash chromatography to give the desiredproduct (42 mg, 65%). ¹H NMR (400 MHz, CDCl₃): δ 7.50 (m, 1H), 7.25 (m,2H), 5.83 (s, 2H), 3.20 (s, 3H). MF C₁₂H₈ClFN₄O₅S₂; LCMS calculated forC₁₂H₉ClFN₄O₅S₂(M+H)⁺: m/z=406.9.

Step M:3-5-[(5-Amino-1H-tetrazol-1-yl)methyl]-1,2,3-thiadiazol-4-yl-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-onetrifluoroacetate

4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,3-thiadiazol-5-ylmethylmethanesulfonate (42 mg, 0.10 mmol) was dissolved in anhydrous ACN (100μL) followed by addition of DIPEA (90 μL, 0.52 mmol) and1H-tetrazol-5-amine (13 mg, 0.15 mmol). The reaction was stirred andheated at 40° C. for 2 hrs. The reaction was diluted with MeOH andpurified by preparative HPLC to yield 2 isomers, the desired product ispeak 1 (15 mg, 37%). ¹H NMR (400 MHz, d₆-DMSO): δ□ 8.0 (m, 1H), 7.67 (m,2H), 6.98 (s, 2H), 5.80 (s, 2H). MF=C₁₂H₇ClFN₉O₂S; LCMS calculated forC₁₂H₈ClFN₉O₂S (M+H)⁺: m/z=396.0.

Step N:5-[(5-Amino-1H-tetrazol-1-yl)methyl]-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,3-thiadiazole-4-carboximidamidetrifluoroacetate

To a solution of3-5-[(5-amino-1H-tetrazol-1-yl)methyl]-1,2,3-thiadiazol-4-yl-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-onein EtOH (400 μL, 0.006 mol) was added a solution of sodium hydroxide inwater (76 μL, 2.0 M). After stirring for 2 h, the reaction was quenchedwith acetic acid and diluted with MeOH and purified by preparative LCMSto give the desired product as white powder, (9.9 mg, 71%). ¹H NMR (400MHz, d₆-DMSO): δ 11.29 (s, 1H), 9.18 (s, 1H), 7.09 (m, 3H), 6.86 (m,1H), 6.60 (m, 1H), 5.92 (s, 1H). MF=C₁₁H₉ClFN₉OS; LCMS calculated forC₁₁H₁₀ClFN₉OS (M+H)⁺: m/z=370.0.

Example 142N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-5-(hydroxymethyl)-1,2,3-thiadiazole-4-carboximidamide

N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-5-[(triisopropylsilyl)oxy]methyl-1,2,3-thiadiazole-4-carboximidamide(10.0 mg, 0.0218 mmol) was stirred in MeOH (500 μL) and hydrogenchloride in 1,4-dioxane (500 μL, 4.0 M) was added. The mixture wasstirred for 30 min at rt. Purification by preparative LCMS gave thedesired product (2.8 mg, 42%). ¹H NMR (400 MHz, d₆-DMSO): δ□ 11.00 (s,1H), 8.99 (s, 1H), 7.09 (m, 1H), 6.82 (m, 1H), 6.53 (m, 1H), 5.92 (s,1H), 4.95 (s, 1H). MF=C₁₀H₈ClFN₄O₂S; LCMS calculated for C₁₀H₉ClFN₄O₂S(M+H)⁺: m/z=303.0.

Example 1434-[(Aminosulfonyl)amino]methyl-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate

3-[4-(Aminomethyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-onetrifluoroacetate (30 mg, 0.07 mmol) and sulfamide (20 mg, 0.2 mmol) wasdissolved in pyridine (1.0 mL) and heated at 120° C. for 3 min in amicrowave. A solution of sodium hydroxide in water (0.5 mL, 1 N) wasadded and the solution was stirred for 30 minutes. Acidification withacetic acid and purification by preparative LCMS gave the desiredproduct (17 mg, 50%). MF=C₁₀H₁₀ClFN₆O₄S; LCMS calculated forC₁₀H₁₁ClFN₆O₄S (M+H)⁺: m/z=364.9. ¹H NMR (400 MHz, CD₃OD): δ 7.02 (m,2H), 6.76 (m, 1H), 4.50 (s, 2H).

Example 144N-(3-Chloro-4-fluorophenyl)-4-([(E/Z)-(cyanoimino)(methylamino)methyl]-aminomethyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide

3-[4-(Aminomethyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-onetrifluoroacetate (50 mg, 0.1 mmol) was dissolved in THF (3.0 mL).Diphenyl cyanocarbonimidate (33.6 mg, 0.141 mmol) and TEA (49 μL, 0.35mmol) were added. The reaction was stirred at room temperature for 2 h.A solution of methylamine in THF (0.6 mL, 2.0 M) was then added and themixture stirred for 2 h at rt. 1.0 M of sodium hydroxide in water (1.7mL) was added and the mixture stirred for 1 h at rt. Acidification withacetic acid and purification by preparative LCMS at pH 10 gave thedesired product as a white powder, (27 mg, 63%). MF=C₁₃H₁₂ClFN₈O₂; LCMScalculated for C₁₃H₁₃ClFN₈O₂(M+H)⁺: m/z=367.0. ¹H NMR (400 MHz, CD₃OD):δ 7.01 (m, 2H), 6.75 (m, 1H), 4.66 (s, 2H), 2.83 (s, 3H).

Example 145N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-([(methylamino)sulfonyl]amino-methyl)-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate

Sulfamide (32 mg, 0.33 mmol) and methylamine (15 μL, 0.33 mmol) weredissolved in pyridine (1.0 mL). The solution was heated to 120° C. for 5minutes in a microwave.3-[4-(aminomethyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-onetrifluoroacetate (32 mg, 0.075 mmol) was than added and the solution washeated to 120° C. for 3 minutes. A solution of sodium hydroxide in water(1 mL, 1 N) was added and the solution stirred at room temperature for30 minutes. Acidification with acetic acid and purification bypreparative LCMS gave the desired product (2.3 mg, 7%).MF=C₁₁H₁₂ClFN₆O₄S; LCMS calculated for C₁₁H₁₃ClFN₆O₄S (M+H)⁺: m/z=378.9.

Example 1464-[(Aminocarbonyl)amino]methyl-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate

4-([(tert-Butylamino)carbonyl]aminomethyl)-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate (10 mg, 0.02 mmol) was stirred in TFA (2.0 mL) for 2hrs. The reaction was warmed gently with heat gun. Evaporation andpurification by preparative LCMS gave the desired product (8 mg, 70%).MF=C_(1I)H₁₃ClFN₆O₃; LCMS calculated for C₁₁H₁₁ClFN₆O₃(M+H)⁺: m/z=329.0.¹H NMR (400 MHz, CD₃OD): δ 7.01 (m, 2H), 6.85 (m, 1H), 4.59 (s, 2H).

Example 1474-([(Tert-butylamino)carbonyl]aminomethyl)-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate

3-[4-(Aminomethyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-onetrifluoroacetate (15 mg, 0.035 mmol) and TEA (15 pt, 0.10 mmol) weredissolved in DCM (0.5 mL) and then 2-isocyanato-2-methylpropane (24 μL,0.21 mmol) was added. The reaction was stirred for 16 h at roomtemperature. A solution of sodium hydroxide in water (0.50 mL, 1.0; N)was added and the mixture stirred at room temperature for 2 h.Acidification with acetic acid and purification by preparative LCMS gavethe desired product (12 mg, 68%). MF=C₁₅H₁₈ClFN₆O₃; LCMS calculated forC₁₅H₁₉ClFN₆O₃ (M+H)⁺: m/z=385.0.

Example 148N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-([(3-morpholin-4-ylpropyl)sulfonyl]-aminomethyl)-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate

Step A:3-Chloro-N-({4-[4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-yl}methyl)propane-1-sulfonamide

To a solution of3-[4-(aminomethyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one(100 mg, 0.32 mol) in DCM (2 mL) under an atmosphere of nitrogen wasadded DIPEA (168 μL, 0.96 mmol), and 3-chloropropane-1-sulfonyl chloride(117 μL, 0.66 mmol). The reaction was stirred at 25° C. for 5 min. Thereaction was quenched with MeOH and purified by preparative HPLC toyield the desired product (38 mg, 20%). ¹H NMR (400 MHz, CDCl₃): δ□ 7.5(m, 1H), 7.3 (m, 2H), 4.8 (d, 2H), 3.7 (t, 2H), 3.25 (t, 2H), 2.3 (m,2H). MF=C₁₄H₁₂Cl₂FN₅O₅S; LCMS calculated for C₁₄H₁₃Cl₂FN₅O₅S (M+H)⁺:m/z=452.2

Step B:N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-([(3-morpholin-4-ylpropyl)sulfonyl]aminomethyl)-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate

A solution of3-chloro-N-(4-[4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylmethyl)propane-1-sulfonamide(8.20 mg, 0.018 mmol) and morpholine (500 μL, 5.7 mmol) was stirred at25° C. overnight. The reaction mixture was purified on preparative LCMSusing pH 2 buffer. The solvents were evaporated in vacuo and the productwas treated with a solution of sodium hydroxide in water (500 μL, 1 N)and ethanol (500 μL) at 25° C. for 20 min. The reaction was neutralizedwith acetic acid and purified on preparative LCMS using pH 2 buffer togive the desired product (2 mg, 23.1%). MF=C₁₇H₂₂ClFN₆O₅S; LCMScalculated for C₁₇H₂₃ClFN₆O₅S (M+H)⁺: m/z=477.1

Example 149N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-[(piperidin-4-ylsulfonyl)amino]-methyl-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate

Step A:N-(4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylmethyl)piperidine-4-sulfonamidetrifluoroacetate

A solution of3-[4-(aminomethyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4h)-one(100 mg, 0.32 mmol), DIPEA (170 pt, 0.96 mmol), benzyl4-(chloro-sulfonyl)piperidine-1-carboxylate (310 mg, 0.96 mmol) in DCM(2 mL) was stirred at 25° C. for 15 min. The crude was quenched withMeOH and purified by preparative LCMS using pH 2 buffer. The pure Cbzprotected product was treated with a solution of hydrogen bromide inacetic acid (2.0 mL, 4 N) for 20 minutes. The reaction was quenched withMeOH and purified on LCMS using pH 2 buffer to yield the desired product(38 mg, 20%). MF=C₁₆H₁₆ClFN₆O₅S; LCMS calculated for C₁₆H₁₇ClFN₆O₅S(M+H)⁺: m/z=459.0.

Step B:N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-[(piperidin-4-ylsulfonyl)amino]methyl-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate

To a solution ofN-(4-[4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylmethyl)piperidine-4-sulfonamide(7 mg, 0.015 mmol) in EtOH (500 μL), a solution of sodium hydroxide inwater (500 μL, 1 N) was added and was stirred at 25° C. for 20 min. Thereaction was neutralized with acetic acid and diluted with MeOH andpurified on preparative LCMS using pH 2 buffer to yield the desiredproduct (2.8 mg, 42%). MF=C₁₅H₁₉ClFN₆O₄S; LCMS calculated forC₁₅H₁₉ClFN₆O₄S (M+H)⁺: m/z=433.1.

Example 1504-[([1-(Aminosulfonyl)piperidin-4-yl]sulfonylamino)methyl]-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate

A solution ofN-(4-[4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylmethyl)piperidine-4-sulfonamide(15 mg, 0.033 mmol) and sulfamide (9.4 mg, 0.098 mmol) in pyridine (1mL) was heated at 130° C. for 3 min in a microwave. A solution of sodiumhydroxide in water (0.5 mL, 1 N) was added and stirred for 20 minutes.The reaction mixture was acidified with acetic acid and purified bypreparative LCMS to yield the desired product (8.2 mg, 49%).MF=C₁₅K₉ClFN₇O₆S₂; LCMS calculated for C₁₅H₂₀ClFN₇O₆S₂(M+H)⁺: m/z=512.1

Example 1514-([(1-Acetylpiperidin-4-yl)sulfonyl]aminomethyl)-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate

A solution ofN-(4-[4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylmethyl)piperidine-4-sulfonamide(23 mg, 0.050 mmol) and acetic anhydride (500 μL, 5.30 mmol) in pyridine(1 mL) was stirred at 25° C. for 30 min. A solution of sodium hydroxidein water (0.5 mL, 1 N) was added and stirred for another 30 min.Acidification with acetic acid and purification by preparative LCMS gavethe desired product (23 mg, 96%). MF=C₁₇H₂₀ClFN₆O₅S; LCMS calculated forC₁₇H₂₁ClFN₆O₅S (M+H)⁺: m/z=475.1

Example 152N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-[5-(morpholin-4-ylmethyl)-2H-tetrazol-2-yl]methyl-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate

and Example 153N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-[5-(morpholin-4-ylmethyl)-1H-tetrazol-1-yl]methyl-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate

Step A: 4-(1H-tetrazol-5-ylmethyl)morpholine

A solution of 5-(chloromethyl)-1H-tetrazole (260 mg, 2.2 mmol) inmorpholine (1.5 mL, 17.2 mmol) was stirred at 25° C. for 20 minutes. Thecrude reaction mixture was purified by preparative LCMS using pH 2buffer to yield the desired product (300 mg, 82%). MF=C₆H₁₁N₅O; LCMScalculated for C₆H₁₂N₅O (M+H)⁺: m/z=170.1.

Step B:N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[5-(morpholin-4-ylmethyl)-2H-tetrazol-2-yl]-methyl-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate andN-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-[5-morpholin-4-ylmethyl)-1H-tetrazol-1-yl]methyl-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate

4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylmethylmethanesulfonate (81 mg, 0.21 mmol) was dissolved in anhydrous ACN (500μL) followed by addition of DIPEA (0.18 mL, 1.0 mmol) and4-(1H-tetrazol-5-ylmethyl)morpholine (110 mg, 0.62 mmol). The reactionmixture was stirred and heated at 45° C. for 1 hour. The reaction wasthen diluted with MeOH and purified by preparative LCMS to yield twoisomers. The purified isomers were concentrated to dryness, redissolvedin EtOH (1.0 mL) and a solution of sodium hydroxide in water (0.5 mL, 1N) was added. The reactions were stirred for 20 minutes. Reactions werequenched with acetic acid, diluted with MeOH and purified by preparativeLCMS to yield the two isomers (2.2 mg, 2.4%) and (3.2 mg, 3.5%).

Example 152

¹H NMR (400 MHz, DMSO-d₆): δ□ 11.5 (s, 1H), 9.0 (s, 1H), 7.2 (t, 1H),7.0 (d, 1H), 6.75 (d, 1H), 6.4 (s, 2H), 3.6 (bs, 8H). MF=C₁₆H₁₇ClFN₉O₃;LCMS calculated for C₁₆H₁₈ClFN₉O₃ (M+H)⁺: m/z=438.1

Example 153

¹H NMR (400 MHz, DMSO-d₆): SE 11.5 (1H, s), 9.0 (1H, s), 7.2 (1H, t),7.0 (1H, d), 6.8 (1H, d), 6.15 (2H, s), 3.6 (8H, bs). MF=C₁₆H₁₇ClFN₉O₃;LCMS calculated for C₁₆H₁₈ClFN₉O₃ (M+H)⁺: m/z=438.1

Example 1544-[(5-Amino-1,3,4-thiadiazol-2-yl)thio]methyl-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate

4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylmethylmethanesulfonate (23 mg, 0.059 mmol) was dissolved in anhydrous ACN (1.0mL) followed by addition of DIPEA (51 μL, 0.29 mmol) and5-amino-1,3,4-thiadiazole-2-thiol (24 mg, 0.18 mmol). The reaction wasstirred and heated at 45° C. for 16 h. The reaction mixture was dilutedwith MeOH and purified by preparative LCMS. The purified product wasevaporated to dryness, redissolved in EtOH (0.5 mL) and a solution ofsodium hydroxide in water (0.5 mL, 1 N) was added. The reaction wasstirred for 20 minutes and quenched with acetic acid, diluted with MeOHand purified by preparative LCMS using pH 2 buffer to yield the desiredproduct (7.1 mg, 23%). ¹H NMR (400 MHz, DMSO-d₆): δ□ 11.7 (s, 1H), 9.1(s, 1H), 7.2 (t, 1H), 7.0 (1H, d), 6.75 (1H, m), 4.6 (s, 2H).MF=C₁₂H₉ClFN₇O₂S₂; LCMS calculated for C₁₂H₁₀ClFN₇O₂S₂(M+H)⁺: m/z=402.1

Example 1554-[(5-Amino-4H-1,2,4-triazol-3-yl)thio]methyl-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate

4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylmethylmethanesulfonate (23 mg, 0.059 mmol) was dissolved in anhydrous ACN (1.0mL) followed by addition of DIPEA (51 μL, 0.29 mmol) and5-amino-4H-1,2,4-triazole-3-thiol (21 mg, 0.18 mmol). The reactionmixture was stirred and heated at 45° C. for 16 h. The reaction wasdiluted with MeOH and purified by preparative LCMS. The purified productwas evaporated to dryness, redissolved in EtOH(1 mL) and a solution ofsodium hydroxide in water (0.5 mL, 1 N) was added and stirred for 20minutes. The reaction was quenched with acetic acid, diluted with MeOHand purified by preparative LCMS using pH 2 buffer to yield the desiredproduct (15 mg, 52%). ¹H NMR (400 MHz, d₆-DMSO): δ□ 11.7 (s, 1H), 9.1(s, 1H), 7.2 (t, 1H), 7.0 (d, 1H), 6.75 (m, 1H), 4.6 (s, 2H).MF=C₁₂H₉ClFN₈O₂S; LCMS calculated for C₁₂H₁₀ClFN₈O₂S (M+H)⁺: m/z=385.1.

Example 1564-[(5-Amino-4H-1,2,4-triazol-3-yl)sulfonyl]methyl-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate

A solution of4-[(5-amino-4h-1,2,4-triazol-3-yl)thio]methyl-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate (11 mg, 0.023 mmol), m-chloroperbenzoic acid (10 mg,0.046 mmol) and 1,4-dioxane (0.5 mL) was stirred at 25° C. for 1 hr. Thereaction was diluted with MeOH and purified on preparative LCMS using pH2 buffer to yield the desired product (5.8 mg, 48%). MF=C₁₂H₉ClFN₈O₄S;LCMS calculated for C₁₂H₁₀ClFN₈O₄S (M+H)⁺: m/z=417.1

Example 157N-(3-Chloro-4-fluorophenyl)-4-[((E/Z)-(cyanoimino)[(4-methoxybenzyl)amino]-methylamino)methyl]-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate

Into the reaction was dissolved3-[4-(aminomethyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-onetrifluoroacetate (30 mg, 0.07 mmol) in THF (0.74 mL). Diphenylcyanocarbonimidate (20 mg, 0.08 mmol) and TEA (29 μL, 0.21 mmol) wereadded and the reaction was stirred at room temperature for 2 hr. Asolution of sodium hydroxide in water (0.5 mL, 1 N) was added and themixture was stirred at room temperature for 30 minutes. Acidificationwith acetic acid and purification by preparative LCMS gave the desiredproduct (40 mg, 97%). MF=C₂₂H₁₉ClF₄N₈O₅; LCMS calculated forC₂₂H₂₀ClF₄N₈O₅ (M+H)⁺: m/z=473.1. ¹H NMR (400 MHz, CD₃OD): δ□ 7.2 (m,2H), 7.03 (m, 1H), 6.95 (m, 1H), 6.8 (m, 2H), 6.74 (m, 1H), 4.68 (s,2H), 4.38 (s, 2H), 3.75 (s, 3H).

Example 1584-[({(E/Z)-[(Aminocarbonyl)imino][(4-methoxybenzyl)amino]methyl}amino)-methyl]-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate

N-(3-Chloro-4-fluorophenyl)-4-[((E/Z)-(cyanoimino)[(4-methoxybenzyl)amino]methyl-amino)methyl]-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate (20 mg, 0.04 mmol) was dissolved in TFA (1.0 mL) andstirred for 1 hour at rt. Purification by preparative LCMS gave thedesired product (12 mg, 50%).

MF=C₂₂H₂₁ClF₄N₈O₆; LCMS calculated for C₂₂H₂₂ClF₄N₈O₆ (M+H)⁺: m/z=491.0.¹H NMR (400 MHz, CD₃OD): δ□ 7.24 (m, 2H), 7.03 (m, 1H), 7.00 (m, 1H),6.95 (m, 2H), 6.80 (m, 1H), 4.93 (s, 2H), 4.52 (s, 2H), 3.79 (s, 3H).

Example 1594-({[(E/Z)-Amino(nitroimino)methyl]amino}methyl)-N-(3-chloro-4-fluoro-phenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate

and Example 1604-({[Amino(imino)methyl]amino}methyl)-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide

3-[4-(Aminomethyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-onetrifluoroacetate (30 mg, 0.07 mmol) and nitroguanidine (50 mg, 0.5 mmol)were dissolved in pyridine (1.0 mL). The reaction mixture was heated ina microwave at 170° C. for 30 minutes. The pyridine was evaporated and asolution of sodium hydroxide in water (0.5 mL, 1 N) was added. Themixture was stirred at room temperature for 30 minutes. Acidificationwith acetic acid and purification by preparative LCMS gave the desirednitroguanyl product (3.2 mg, 9%) and the guanyl product (4.7 mg,contaminated with pyridine). The guanyl material was treated withsaturated aqueous sodium bicarbonate solution (1.0 mL) and extractedwith ethyl acetate (3×3 mL). The combined extracts were dried withsodium sulfate, filtered and concentrated to give the desired guanylfree base (2.3 mg, 10%). MF=C₁₁H₁₀ClFN₈O₄; LCMS calculated forC₁₁H₁₁ClFN₈O₄ (M+H)⁺: m/z=373.0. ¹H NMR (400 MHz, CD₃OD): δ□ 7.03 (m,2H), 6.80 (m, 1H), 4.77 (s, 2H). MF=C₁₁H₁₁ClFN₇O₂; LCMS calculated forC₁₁H₁₂ClFN₇O₂ (M+H)⁺: m/z=328.0. ¹H NMR (400 MHz, CD₃OD): δ□ 7.04 (m,1H), 7.00 (m, 1H), 6.80 (m, 1H), 4.77 (s, 2H).

Example 161N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-(4H-1,2,4-triazol-4-ylmethyl)-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate

A solution of3-[4-(aminomethyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4h)-onetrifluoroacetate (14.0 mg, 32.0 mmol),N′-[(1e)-(dimethylamino)methylene]-N,N-dimethylhydrazonoformamide (6.80mg, 48.0 mmol), and p-toluenesulfonic acid (550 mg, 3.2 mmol) in DMF (1mL) was heated at 170° C. for 15 min in the microwave. A solution ofsodium hydroxide in water (0.5 mL, 1 N) was added and the mixture wasstirred for 30 minutes at room temperature. Acidification with aceticacid and purification by preparative LCMS gave the desired product (1.3mg, 9%). MF=C₁₂H₉ClFN₇O₂; LCMS calculated for C₁₂H₁₀ClFN₇O₂ (M+H)⁺:m/z=337.9.

Example 1624-[2-(5-Amino-1H-tetrazol-1-yl)ethyl]-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide

Step A:N-(3-Chloro-4-fluorophenyl)-4-[(E)-2-methoxyvinyl]-1,2,5-oxadiazole-3-carboxamideN-(3-chloro-4-fluorophenyl)-4-[(Z)-2-methoxyvinyl]-1,2,5-oxadiazole-3-carboxamide

To a solution of (methoxymethyl)(triphenyl)phosphonium chloride (23.0 g,66.0 mmol) in toluene (183 mL) was added sodium tert-butoxide (6.60 g,0.066 mol) at rt under an atmosphere of nitrogen. After stirring for 30min, a solution ofN-(3-chloro-4-fluorophenyl)-4-formyl-1,2,5-oxadiazole-3-carboxamide (7.6g, 28 mmol) in THF (18 mL) was cannulated into reaction flask. Theresulting solution was stirred at rt for 1 h. The reaction was quenchedwith 1 N HCl and diluted with ethyl acetate and the aqueous layer wasextracted with ethyl acetate once. The combined organic solutions werewashed with brine, dried over Na₂SO₄, filtered and concentrated. Theresidue was purified with silica gel chromatography (20% ethylacetate/Hex) to give product (2.0 g 24%, E isomer, 2.6 g, 31%, Z isomer)as white solids. Z isomer: ¹H NMR (400 MHz, CDCl₃): δ□ 8.54 (s, 1 H)7.87 (dd, J=6.4, 2.7 Hz, 1H), 7.42 (m, 1H), 7.16 (t, J=8.5 Hz, 1H), 6.66(d, J=6.6 Hz, 1H), 6.03 (d, J=6.6 Hz, 1H), 3.97 (s, 3H).MF=C₁₂H₁₀ClFN₃O₃; LCMS for C₁₂H₁₀ClFN₃O₃(M+H)⁺: m/z=298.0.

Step B:N-(3-Chloro-4-fluorophenyl)-4-(2-methoxyethyl)-1,2,5-oxadiazole-3-carboxamide

N-(3-Chloro-4-fluorophenyl)-4-[(E,Z)-2-methoxyvinyl]-1,2,5-oxadiazole-3-carboxamide(4.6 g, 15 mmol) was dissolved in and ethyl acetate (77 mL) and 10%palladium on carbon (0.8 g) was added to reaction flask. The mixture wasreacted under a 55 psi hydrogen atmosphere for 4 h. The solution wasfiltered through a pad of celite. The filtrate was concentrated andpurified by silica gel chromatography (20% ethyl acetate/hex) to givethe desired product as a white solid (2.5 g, 54%). MF=C₁₂H₁₁ClFN₃O₃;LCMS calculated for C₁₂H₁₂ClFN₃O₃(M+H)⁺: m/z=300.1.

Step C:N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-(2-methoxyethyl)-1,2,5-oxadiazole-3-carboximidamide

N-(3-Chloro-4-fluorophenyl)-4-(2-methoxyethyl)-1,2,5-oxadiazole-3-carboxamide(2.5 g, 8.3 mmol) was suspended in benzene (40 mL), pyridine (2.7 mL)and phosphorus pentachloride (3.5 g, 17 mmol) was added to the solution.The mixture was heated at 60° C. for 2.5 h. The reaction was thenconcentrated to dryness in vacuo. The crude was dissolved in EtOH (50mL) and cooled to 0° C. and 50% hydroxylamine in water (10 mL) was addedto the reaction flask until the pH reached 8. The reaction solution wasconcentrated, diluted with ethyl acetate and the aqueous layer wasextracted with ethyl acetate once. The combined organic solutions wereconcentrated in vacuo and purified by silica gel chromatography (20%-50%ethyl acetate/hex) to give the desired product (2.5 g, 95%) as a yellowsolid. MF=C₁₂H₁₂ClFN₄O₃; LCMS calculated for C₁₂H₁₃ClFN₄O₃(M+H)⁺:m/z=315.1.

Step D:4-(3-Chloro-4-fluorophenyl)-3-[4-(2-methoxyethyl)-1,2,5-oxadiazol-3-yl]-1,2,4-oxadiazol-5(4H)-one

N-(3-Chloro-4-fluorophenyl)-N-hydroxy-4-(2-methoxyethyl)-1,2,5-oxadiazole-3-carboximidamide(2.5 g, 7.9 mmol) was dissolved in THF (44 mL) followed by addition ofN,N-carbonyl-diimidazole (1.5 g, 9.5 mmol). The reaction was heated to70° C. for 1.5 h. The reaction solution was concentrated and purified bysilica gel chromatography (20% ethyl acetate/hexane) to give the desiredproduct (2.7 g, 99%). MF=C₁₃H₁₀ClFN₄O₄; LCMS calculated forC₁₃H₁₁ClFN₄O₄(M+H)⁺: m/z=341.0.

Step E:4-(3-Chloro-4-fluorophenyl)-3-[4-(2-hydroxyethyl)-1,2,5-oxadiazol-3-yl]-1,2,4-oxadiazol-5(4H)-one

To a solution of4-(3-chloro-4-fluorophenyl)-3-[4-(2-methoxyethyl)-1,2,5-oxadiazol-3-yl]-1,2,4-oxadiazol-5(41-1)-one(2.55 g, 0.00748 mol) in DCM (24 mL) was added 1.0 M of boron tribromidein DCM (22.4 mL) under an atmosphere of nitrogen at −78° C. The reactionsolution was allowed to warm to rt over 2.5 h. The reaction was quenchedwith saturated NaHCO₃ at 0° C. and diluted with ethyl acetate. Theaqueous layer was extracted with ethyl acetate once, the combinedorganic solutions were dried over Na₂SO₄, filtered and concentrated invacuo. The crude product was purified by silica gel chromatography (60%ethyl acetate/hexane) to give the desired product as an off white solid(2.3 g, 96%). MF=C₁₂H₈ClFN₄O₄; LCMS calculated for C₁₂H₉ClFN₄O₄(M+H)⁺:m/z 327.0.

Step F:2-4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylethylmethanesulfonate

To a solution of4-(3-chloro-4-fluorophenyl)-3-[4-(2-hydroxyethyl)-1,2,5-oxadiazol-3-yl]-1,2,4-oxadiazol-5(4H)-one(2.50 g, 7.65 mmol) in DCM (34 mL) was added TEA (2.1 mL, 15 mmol) andmethanesulfonyl chloride (0.83 mL, 10.7 mmol) at rt. After stirring for30 min, the reaction was quenched with a 0.1 N HCl solution and dilutedwith ethyl acetate. The organic layer was dried over Na₂SO₄, filtered,concentrated. The residue was purified by silica gel column (20-70%ethyl acetate/hexane) to give the desired product as a white solid (2.74g, 88%); MF=C₁₃H₁₀ClFN₄O₆S; LCMS calculated for C₁₃H₁₁ClFN₄O₆S(M+H)⁺:m/z=405.0.

Step G:4-[2-(5-Amino-1H-tetrazol-1-yl)ethyl]-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide

2-4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylethylmethanesulfonate (16.0 mg, 0.039 mmol) was dissolved in anhydrous ACN(0.6 mL), followed by addition of DIPEA (27.5 μL, 0.158 mmol) and1H-tetrazol-5-amine (4.0 mg, 0.047 mmol). The mixture was heated at 50°C. for 4 h. The reaction solution was then diluted with MeOH andpurified by preparative HPLC to yield two isomers. The first elutingpeak (isomer 1) was dissolved in MeOH (0.5 mL) and 2.0 N of sodiumhydroxide in water (0.079 mL) was added. After stirring for 0.5 h,reaction solution was diluted with MeOH and few drops of acetic acid andpurified by preparative LCMS to give the desired product as a whitepowder (2.1 mg, 14%). MF=C₁₂H₁₁ClFN₉O₂; LCMS calculated forC₁₂H₁₂ClFN₉O₂ (M+H)⁺: m/z=368.1. ¹H NMR (400 MHz, DMSO-d₆): δ 11.60 (s,1H), 8.99 (s, 1H), 7.17 (t, J=9.0 Hz, 1H), 7.00 (dd, J=6.4, 2.7 Hz, 1H),6.79 (s, 2H), 6.72 (m 1H), 4.55 (t, J=7.0 Hz, 2H), 3.41 (t, J=7.0 Hz,2H);

Example 1634-[2-(5-Amino-2H-tetrazol-2-yl)ethyl]-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide

2-4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylethylmethanesulfonate (16.0 mg, 0.039 mmol) was dissolved in anhydrous ACN(0.6 mL), followed by addition of DIPEA (27.5 μL, 0.158 mmol) and1H-tetrazol-5-amine (4.0 mg, 0.047 mmol). The solution was heated at 50°C. for 4 h. The reaction solution was then diluted with MeOH andpurified by preparative HPLC to yield two isomers. The first elutingpeak (isomer 1) was dissolved in MeOH (0.5 mL) and 2.0 N of sodiumhydroxide in water (0.079 mL) was added. After stirring for 0.5 h,reaction solution was diluted with MeOH and few drops of acetic acid andpurified by preparative LCMS to give the desired product as a whitepowder (3.8 mg, 26%). MF=C₁₂H₁₁ClFN₉O₂; LCMS calculated forC₁₂H₁₂ClFN₉O₂(M+H)⁺: m/z=368.1.

Example 164N-(3-Chloro-4-fluorophenyl)-N-hydroxy-4-[2-(1H-imidazol-1-yl)ethyl]-1,2,5-oxadiazole-3-carboximidamide

2-4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylethylmethanesulfonate (9.0 mg, 0.022 mmol) was dissolved in anhydrous ACN(0.5 mL), followed by addition of DIPEA (15.5 μL, 0.0889 mmol), andimidazole (3.0 mg, 0.044 mmol). The reaction solution was heated at 60°C. for 12 h. The reaction solution was then treated with 2.0 M of sodiumhydroxide in water (0.20 mL). After stirring for 0.5 h, to the solutionwas added a few drops of acetic acid and diluted with MeOH and purifiedby preparative LCMS to give the desired product (3.5 mg, 45%).MF=C₁₄H₁₂ClFN₆O₂; LCMS for C₁₄H₁₃ClFN₆O₂ (M+H)⁺: m/z=351.1.

Example 165N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-(2-morpholin-4-ylethyl)-1,2,5-oxadiazole-3-carboximidamide

This compound was prepared according to the procedure of Example 164,using2-4-[4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylethylmethanesulfonate and morpholine as the starting materials.MF=C₁₅H₁₇ClFN₅O₃; LCMS for C₁₅H₁₈ClFN₅O₃ (M+H)⁺: m/z=370.1.

Example 166N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-[2-(4-methylpiperazin-1-yl)ethyl]-1,2,5-oxadiazole-3-carboximidamide

This compound was prepared according to the procedure of Example 164,using2-4-[4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylethylmethane-sulfonate and 1-methylpiperazine as the starting materials.MF=C₁₆H₂₀ClFN₆O₂; LCMS for C₁₆H₂₁ClFN₆O₂ (M+H)⁺: m/z=383.1.

Example 167N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-[2-(4H-1,2,4-triazol-4-yl)ethyl]-1,2,5-oxadiazole-3-carboximidamide

This compound was prepared according to the procedure of Example 164,using2-4-[4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylethylmethane-sulfonate and 1H-1,2,4-triazole as the starting materials.MF=C₁₃H₁₁ClFN₇O₂; LCMS for C₁₃H₁₂ClFN₇O₂ (M+H)⁺: m/z=352.1. ¹H NMR (400MHz, DMSO-d₆): δ□ 11.60 (s, 1H), 10.53 (s, 0.1; H), 9.14 (s, 0.1; H),8.99 (s, 1H), 8.58 (s, 2H), 8.52 (s, 0.2; H), 7.98 (m, 0.1; H), 7.35 (m,0.2; H), 7.10 (t, J=9.0 Hz, 1H), 6.98 (dd, J=6.5, 2.8 Hz, 1H), 6.68 (m,1H), 4.49 (t, J=7.1 Hz, 2H), 3.41 (t, J=7.1 Hz, 2H) 3.34 (t, J=6.8 Hz,0.4; H);

Example 168N-(3-Chloro-4-fluorophenyl)-N-hydroxy-4-[2-(1H-1,2,4-triazol-1-yl)ethyl]-1,2,5-oxadiazole-3-carboximidamide

This compound was prepared according to the procedure of Example 164,using2-4-[4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylethylmethane-sulfonate and 1H-1,2,4-triazole as the starting materials.MF=C₁₃H₁₁ClFN₇O₂; LCMS for C₁₃H₁₂ClFN₇O₂ (M+H)⁺: m/z=352.1.

Example 169N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-[2-(1H-tetrazol-1-yl)ethyl]-1,2,5-oxa-diazole-3-carboximidamide

This compound was prepared according to the procedure of Example 164,using2-4-[4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylethylmethane-sulfonate and 1H-tetrazole as the starting materials.MF=C₁₂H₁₀ClFN₈O₂; LCMS for C₁₂H₁₁ClF₈O₂ (M+H)⁺: m/z=353.1. ¹H NMR (400MHz, DMSO-d₆): δ 11.61 (s, 1H), 9.43 (s, 1H), 9.39 (s, 0.1; H), 9.11 (s,0.1; H), 8.99 (s, 1H), 7.34 (m, 0.2; H), 7.17 (t, J=9.0 Hz, 1H), 7.00(dd, J=6.4 Hz, 2.7 Hz, 1H), 6.72 (m, 1H), 4.93 (t, J=6.8 Hz, 2H), 3.56(t, J=6.8 Hz, 2H);

Example 170N-(3-Chloro-4-fluorophenyl)-N-hydroxy-4-[2-(2H-tetrazol-2-yl)ethyl]-1,2,5-oxadiazole-3-carboximidamide

This compound was prepared according to the procedure of Example 164,using2-4-[4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylethylmethane-sulfonate and 1H-tetrazole as the starting materials.MF=C₁₂H₁₀ClFN₈O₂; LCMS for C₁₂H₁₁ClFN₈O₂ (M+H)⁺: m/z=353.1.

Example 171N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-vinyl-1,2,5-oxadiazole-3-carboximidamide

This compound was prepared according to the procedure of Example 164,using2-4-[4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylethylmethane-sulfonate and DIPEA as the starting materials. MF=C₁₁H₈ClFN₄O₂;LCMS for C₁₁H₉ClFN₄O₂ (M+H)⁺: m/z=283.0.

Example 172N-(3-Chloro-4-fluorophenyl)-4-[2-(dimethylamino)ethyl]-N′-hydroxy-1,2,5-oxa-diazole-3-carboximidamide

This compound was prepared according to the procedure of Example 164,using2-4-[4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylethylmethane-sulfonate and dimethylamine as the starting materials.MF=C₁₃H₅ClFN₅O₂; LCMS for C₁₃H₁₆ClFN₅O₂(M+H)⁺: m/z=3281

Example 173N-(3-Chloro-4-fluorophenyl)-N-hydroxy-4-(2-thiomorpholin-4-ylethyl)-1,2,5-oxadiazole-3-carboximidamide

This compound was prepared according to the procedure of Example 164,using2-4-[4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylethylmethane-sulfonate and thiomorpholine as the starting materials.MF=C₁₅H₁₇ClFN₅O₂S; LCMS for C₁₅H₁₈ClFN₅O₂S (M+H)⁺: m/z=386.1.

Example 174N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-(2-pyrrolidin-1-ylethyl)-1,2,5-oxadiazole-3-carboximidamide

This compound was prepared according to the procedure of Example 164,using2-4-[4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylethylmethane-sulfonate and pyrrolidine as the starting materials.MF=C₁₅H₁₇ClFN₅O₂; LCMS for C₁₅H₁₈ClFN₅O₂ (M+H)⁺: m/z=354.1.

Example 175N-(3-Chloro-4-fluorophenyl)-1\-hydroxy-4-{2-[isopropyl(methyl)amino]ethyl}1,2,5-oxadiazole-3-carboximidamide

This compound was prepared according to the procedure of Example 164,using2-4-[4-(3-chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylethylmethane-sulfonate and N-methyl-2-propanamine as the starting materials.MF=C₁₅H₁₉ClFN₅O₂; LCMS for C₁₅H₂₀ClFN₅O₂(M+H)⁺: m/z=356.1.

Example 176N-(3-Chloro-4-fluorophenyl)-N-hydroxy-4-2-[(methylsulfonyl)amino]ethyl-1,2,5-oxadiazole-3-carboximidamide

Step A:3-[4-(2-azidoethyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one

2-4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylethylmethanesulfonate (370 mg, 0.91 mmol) was dissolved in DMF (5 mL)followed by addition of sodium azide (120 mg, 1.80 mmol). The reactionmixture was heated at 60° C. for 2 h. The reaction solution was thencooled to rt and diluted with water and ethyl acetate and the aqueouslayer was extracted with ethyl acetate once. The combined organicsolutions were dried over Na₂SO₄, filtered and concentrated. The residuewas purified by silica gel chromatography (30% ethyl acetate/hex) togive the desired product as a white solid (231 mg, 72%).MF=C₁₂H₇ClFN₇O₃; LCMS calculated for C₁₂H₈ClFN₇O₃(M+H)⁺: m/z=352.0.

Step B:3-[4-(2-aminoethyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one trifluoroacetate

3-[4-(2-Azidoethyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one(230 mg, 0.65 mmol) was dissolved in THF (4.0 mL) and water (4.0 mL).The reaction solution was cooled to 0° C., followed by additiontriphenylphosphine (0.34 g, 1.3 mmol). After stirring at 0° C. for 30min, solvent was removed in vacuo and the residue was dissolved in MeOH.The compound was purified by preparative LCMS to give the desiredproduct as a white solid (121 mg, 56.8%). MF=C₁₂H₉ClFN₅O₃; LCMScalculated for C₁₂H₁₀ClFN₅O₃(M+H)⁺: m/z=326.0.

Step C:N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-2-[(methylsulfonyl)amino]ethyl-1,2,5-oxadiazole-3-carboximidamide

To a solution of 3-[4-(2-aminoethyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-onetrifluoroacetate (16.0 mg, 0.037 mmol) in DCM (1.0 mL) was added TEA (15μL, 0.11 mmol) and methanesulfonyl chloride (4.2 μL, 0.055 mmol). Theresulting mixture was stirred at rt for 1 h and then the solvent wasremoved under reduced pressure. The residue was dissolve in MeOH (1 mL)and 2.0 M sodium hydroxide in water (0.10 mL) was added. After stirringfor 4 h, the reaction solution was diluted with MeOH and a few drop ofacetic acid and then purified by preparative LCMS to give the desiredproduct as a white solid (14.1 mg, 78.3%). MF=C₁₂H₁₃ClFN₅O₄S; LCMScalculated C₁₂H₁₄ClFN₅O₄S (M+H)⁺: m/z=377.0.

Example 177N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-(2-(sulfamoylamino)ethyl)-1,2,5-oxadiazole-3-carboximidamide

A solution of3-[4-(2-aminoethyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4h)-onetrifluoroacetate (23.0 mg, 53.0 mmol), sulfamide (15.0 mg, 160 mmol) andpyridine (1.0 mL) was heated at 120° C. for 3 min in a microwave. To thereaction solution was added 0.5 mL 1 N NaOH and stirred for 30 min. Thereaction solution was then acidified with acetic acid and purified bypreparative LCMS to give the desired product (12 mg, 46%).MF=C₁₁H₁₂ClFN₆O₄S; LCMS calculated for C₁₁H₁₃ClFN₆O₄S (M+H)⁺: m/z=379.0.¹H NMR (400 MHz, DMSO-d₆): d 11.52 (s, 1H), 10.45 (s, 0.1; H), 9.05 (s,0.1; H), 8.98 (s, 1H), 7.95 (m, 0.1; H), 7.32 (m, 0.2; H), 7.15 (t,J=9.0 Hz, 1H), 7.00 (dd, J=6.5 Hz, 2.7 Hz, 1H), 6.76 (t, J=5.9 Hz, 1H),6.65 (m, 1H), 6.59 (s, 2H), 3.29 (m, 2H), 3.07 (t, J=7.2 Hz, 2H);

Example 178 Ethyl3-(4-(N-(3-chloro-4-fluorophenyl)-N′-hydroxycarbamimidoyl)-1,2,5-oxadiazol-3-yl)propanoate

Step 1:N-(3-Chloro-4-fluorophenyl)-4-formyl-1,2,5-oxadiazole-3-carboxamide

A solution ofN-(3-chloro-4-fluorophenyl)-4-(hydroxymethyl)-1,2,5-oxadiazole-3-carbox-amide (8.50 g, 31.3 mmol), Dess-Martin periodinane (14.6 g, 34.4 mmol)and DCM (400 mL) was stirred at 25° C. for 3 h. The reaction was dilutedwith a saturated sodium bicarbonate solution and extracted with ethylacetate three times, dried with sodium sulfate, filtered, andconcentrated in vacuo. The crude residue was purified by flash columnchromatography to yield the desired product (7.50 g, 89%). LCMS forC₁₀H₆ClFN₃O₃(M+H)⁺: m/z=270.0.

Step 2: Ethyl(2E)-3-(4-[(3-chloro-4-fluorophenyl)amino]carbonyl-1,2,5-oxadiazol-3-yl)acrylate

To a solution of (carbethoxymethyl)triphenylphosphonium bromide (3.14 g,7.32 mmol) in toluene (37 mL) was added sodium tert-butoxide (723 mg,7.52 mmol) at rt under a nitrogen atmosphere. After stirring for 30 min,a solution ofN-(3-chloro-4-fluorophenyl)-4-formyl-1,2,5-oxadiazole-3-carboxamide (811mg, 3.01 mmol) in THF (10 mL) was cannulated into reaction flask. Theresulting solution was heated at 80° C. for 3 h, then cooled to rtovernight. The reaction was quenched with a 1 N HCl solution, theaqueous solution was extracted with ethyl acetate. The combined organicsolutions were washed with brine, dried over Na₂SO₄, filtered andconcentrate under reduced pressure. The residue was purified with flashchromatography (30% ethyl acetate/hexane) to give the desired product asa white solid (0.91 g, 89%). ¹H NMR (400 MHz, CD₃OD): δ 7.92 (m, 2H),7.65 (m, 1H), 7.26 (m, 1H), 7.01 (m, 1H), 4.27 (m, 2H), 1.33 (m, 3H);LCMS for C₁₄H₁₂ClFN₃O₄(M+H)⁺: m/z=340.

Step 3: Ethyl3-(4-[(3-chloro-4-fluorophenyl)amino]carbonyl-1,2,5-oxadiazol-3-yl)propanoate

To a solution of ethyl(2E)-3-(4-[(3-chloro-4-fluorophenyl)amino]carbonyl-1,2,5-oxadiazol-3-yl)acrylate(0.86 g, 0.0025 mol) in ethyl acetate (10 mL, 0.1 mol) was addedpalladium (600 mg, 0.006 mol). The mixture was stirred at roomtemperature under an atmosphere of hydrogen for 2 h. The reactionsolution was filtered through a pad of celite. The filtrate wasconcentrated and purified by flash chromatography (40% ethylacetate/hexane) to give the desired product as a white solid (609 mg,70%). LCMS for C₁₄H₁₄ClFN₃O₄(M+H)⁺: m/z-=342.1.

Step 4: Ethyl3-(4-(N-(3-chloro-4-fluorophenyl)-N′-hydroxycarbamimidoyl)-1,2,5-oxadiazol-3-yl)propanoate

Ethyl3-(4-[(3-chloro-4-fluorophenyl)amino]carbonyl-1,2,5-oxadiazol-3-yl)propanoate(27 mg, 0.079 mmol) was suspended in benzene (1 mL) under an atmosphereof nitrogen and phosphorus pentachloride (18.0 mg, 0.086 mmol) wasadded. The solution was heated to reflux for 2.5 h. The solvent wasremoved in vacuo. The residue was dissolved in EtOH (1.0 mL) andhydroxylamine (100 μL, 2 mmol) (50% solution in water) was added to thereaction. After stirring 1 h, the solution was diluted with MeOH andpurified by preparative LCMS to give the desired product (8.5 mg, 30%).¹H NMR (400 MHz, CD₃OD): δ 7.03 (t, J=8.9 Hz, 1H), 6.95 (dd, J=6.4, 2.7Hz, 1H), 6.71 (m, 1H), 4.12 (q, J=7.2 Hz, 2H), 3.11 (t, J=7.2 Hz, 2H),2.80 (t, J=7.2 Hz, 2H), 1.23 (t, J=7.2 Hz, 3H); LCMS forC₁₄H₁₅ClFN₄O₁(M+H)⁺: m/z=357.1.

Example 179N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-(3-morpholin-4-ylpropyl)-1,2,5-oxadiazole-3-carboximidamide

Step 1:N-(3-Chloro-4-fluorophenyl)-4-(3-hydroxypropyl)-1,2,5-oxadiazole-3-carboxamide

To a solution of ethyl3-(4-[(3-chloro-4-fluorophenypamino]carbonyl-1,2,5-oxadiazol-3-yl)propanoate(97.5 mg, 0.285 mmol) in THF (1.2 mL) was added lithium tetrahydroborate(14.3 mg, 0.656 mmol) at 0° C. under an atmosphere of nitrogen. Thereaction solution was allowed to warm to rt for 2 h. The reaction wasquenched with MeOH and concentrated. The residue was purified by flashchromatography (60% ethyl acetate/hexane) to give the desired product(70 mg, 80%). LCMS for C₁₂H₁₂ClFN₃O₃(M+H)⁺: m/z=300.1.

Step 2:3-(4-[(3-Chloro-4-fluorophenyl)amino]carbonyl-1,2,5-oxadiazol-3-yl)propylmethane-sulfonate

N-(3-Chloro-4-fluorophenyl)-4-(3-hydroxypropyl)-1,2,5-oxadiazole-3-carboxamide(60 mg, 0.20 mmol) was dissolved in anhydrous DCM (2 mL), followed byaddition of TEA (57 μL, 0.41 mmol). The reaction was stirred and cooledto 0° C., and methanesulfonyl chloride (29 μL, 0.37 mmol) was addeddrop-wise. The reaction was quenched with water and diluted with DCM.The organic layer was separated, dried over Na₂SO₄, filtered,concentrated and purified by silica gel chromatography (25%-75%EtOAc/hexane) to give the desired product (60 mg, 80%). LCMS forC₁₃H₁₄ClFN₃O₅S (M+H)⁺: m/z=378.

Step 3:N-(3-Chloro-4-fluorophenyl)-4-(3-morpholin-4-ylpropyl)-1,2,5-oxadiazole-3-carboxamide

3-(4-[(3-Chloro-4-fluorophenyl)amino]carbonyl-1,2,5-oxadiazol-3-yl)propylmethane-sulfonate (19 mg, 0.051 mmol) was dissolved in anhydrous ACN(100 μL) followed by the addition of DIPEA (44 μL, 0.26 mmol) andmorpholine (6.7 μL, 76.8 μmol). The reaction were stirred and heated at70° C. for 3 h. The reaction was concentrated and purified by silica gelchromatography (60-100% ethyl acetate/hexanes) to give the desiredproduct (10.2 mg, 54%). LCMS for C₁₆H₁₉ClFN₄O₃ (M+H)⁺ m/z=369.1.

Step 4:N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-(3-morpholin-4-ylpropyl)-1,2,5-oxadiazole-3-carboximidamide

N-(3-Chloro-4-fluorophenyl)-4-(3-morpholin-4-ylpropyl)-1,2,5-oxadiazole-3-carboxamide(10.0 mg, 27 μmol) was suspended in benzene (0.4 mL) under an atmosphereof nitrogen and phosphorus pentachloride (6.2 mg, 29.8 μmol) was added.The solution was heated at reflux for 2.5 h. The volatiles wereevaporated in vacuo. The reaction was dissolved in EtOH (0.3 mL) andhydroxylamine (40 μL, 0.7 mmol) (50% solution in water) was added to thereaction. After stirring for 1 h, the reaction solution was diluted withMeOH and purified by preparative LCMS to give the desired product (5.2mg, 50%). LCMS for C₁₆H₂₀ClFN₅O₃(M+H)⁺: m/z=384.1.

Example 1804-{3-[(Aminosulfonyl)amino]propyl}-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide

3-[4-(3-Aminopropyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-onetrifluoroacetate (7.8 mg, 0.017 mmol) and sulfamide (9.4 mg, 0.98 mol)was dissolved in pyridine (1.0 mL). The solution was heated at 120° C.for 3 minutes in a microwave. A solution of sodium hydroxide in water(0.5 mL, 1.0; N) was added and the mixture stirred at room temperaturefor 16 hrs. Acidification with acetic acid and purification bypreparative LCMS gave the desired product (5.7 mg, 84%). ¹H NMR (400MHz, CD₃OD): δ 7.02 (t, 1H), 6.95 (m, 1H), 6.7 (m, 1H), 3.1 (m, 2H), 2.9(m, 2H), 2.0 (m, 2H). MF=C₁₂H₁₄ClFN₆O₄S. LCMS calculated forC₁₂H₁₅ClFN₆O₄S (M+H)⁺: m/z=393.0.

Step 1:3-[4-(3-Azidopropyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one

3-4-[4-(3-Chloro-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-ylpropylmethanesulfonate (0.25 g, 0.60 mmol) was dissolved in anhydrous DMF (3.0mL). Sodium azide (97 mg, 1.5 mmol) was added and the reaction wasstirred at 65° C. for 1 h. The reaction mixture was quenched with waterand extracted with EtOAc. EtOAc extracts were washed with water andbrine, dried over Na₂SO₄, filtered and volatiles evaporated. Crudematerial was used in the next step without further purification (200 mg,92%). MF=C₁₃H₉ClFN₇O₃; LCMS calculated for C₁₃H₁₀ClFN₇O₃(M+H)⁺:m/z=366.0.

Step 2:3-[4-(3-Aminopropyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-onetrifluoroacetate

3-[4-(3-Azidopropyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one(200 mg, 0.5 mmol) was dissolved in anhydrous THF (3 mL) and water (3mL). The reaction was cooled to 0° C. followed by addition oftriphenylphosphine (430 mg, 1.6 mmol). The reaction was stirred at 0° C.for 30 minutes and then the volatiles evaporated in vacuo. The residuewas azeotroped with toluene, dissolved in MeOH and purified bypreparative LCMS using pH 2 buffer to give the desired product (45.3 mg,20%). MF=C₁₃H₁₀ClFN₅O₃; LCMS calculated for C₁₃H₁₁ClFN₅O₃(M+H)⁺:m/z=340.0.

Example 181N-(3-Chloro-4-fluorophenyl)-4-(3-{[(E/Z)-(cyanoimino)(methyl-amino)methyl]amino}propyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate

3-[4-(3-Aminopropyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-onetrifluoroacetate (11.0 mg, 0.0251 mmol) was dissolved in THF (0.32 mL).Diphenyl cyanocarbonimidate (8.73 mg, 0.0366 mmol) and TEA (13 μL, 0.092mmol) were added and the reaction stirred at room temperature for twohrs. A solution of methylamine in THF (46 μL, 2.0; N) was added and thereaction was stirred at room temperature for two hrs. A solution ofsodium hydroxide in water (0.5 mL, 1.0; N) was added and the mixturestirred at room temperature for 16 hrs. Acidification with acetic acidand purification by preparative LCMS gave the desired product (5.6 mg,44%). MF=C₁₅H₁₅ClFN₈O₂; LCMS calculated for C₁₅H₁₆ClFN₈O₂(M+H)⁺:m/z=395.0.

Example 182N-(3-Chloro-4-fluorophenyl)-N′-hydroxy-4-[3-(4H-1,2,4-triazol-4-yl)propyl]-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate

To a microwave tube was added3-[4-(3-aminopropyl)-1,2,5-oxadiazol-3-yl]-4-(3-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-onetrifluoroacetate (26.3 mg, 0.0580 mmol),N-[(1E)-(dimethylamino)methylene]-N,N-dimethylhydrazonoformamide (9.1mg, 0.064 mmol), p-toluene-sulfonic acid monohydrate (1 mg, 0.006 mmol)and toluene (0.5 mL). The reaction was heated in a microwave at 170° C.for 30 minutes. Solvent was removed in vacuo and the residue waspurified by preparative LCMS. A solution of sodium hydroxide in water(0.5 mL, 1.0; N) was added and the mixture stirred at room temperaturefor 16 hrs. Acidification with acetic acid and purification bypreparative LCMS gave the desired product give product (13 g, 48%).¹HNMR (400 MHz, CD₃OD): δ 9.0 (s, 2H), 7.02 (m, 1H), 6.9 (m, 1H), 6.7(m, 1H), 4.3 (m, 2H), 2.95 (m, 2H), 2.4 (m, 2H). MF=C₁₄H₁₂ClFN₇O₂; LCMScalculated for C₁₄H₁₃ClFN₇O₂(M+H)⁺: m/z=366.0.

Data for additional example compounds of the invention are provided inTable 3, below.

TABLE 3 Ex. MS Prep. Pur. No. Structure (M + 1) Ex. Meth. Salt Name 183

408.0 143 A Free Base 4-{[(aminosulfonyl)- amino]methyl}-N-(3-bromo-4-fluoro- phenyl)-N′-hydroxy- 1,2,5-oxadiazole-3- carboximidamide184

381.0 143 A Free Base 4-{[(aminosulfonyl)- amino]methyl}-N′-hydroxy-N-[3-(tri- fluoromethyl)phenyl]- 1,2,5-oxadiazole-3-carboximidamide 185

423.0 144 B Free Base N-({4-[(E/Z)-[(3- chloro-4-fluoro-phenyl)amino](hydroxy- imino)methyl]-1,2,5- oxadiazol-3-yl}-methyl)-N′-cyano- morpholine-4- carboximidamide 186

466.0 144 B Free Base N-(3-chloro-4-fluoro- phenyl)-4-[({(E/Z)-(cyanoimino)[(2- morpholin-4-ylethyl)- amino]methyl}amino)methyl]-N′-hydroxy- 1,2,5-oxadiazole-3- carboximidamide 187

484.1 144 B Free Base 4-[({(E/Z)-[(amino- carbonyl)imino][(2-morpholin-4-ylethyl)- amino]methyl}amino) methyl]-N-(3-chloro-4-fluorophenyl)-N′- hydroxy-1,2,5- oxadiazole-3- carboximidamide 188

424.0 144 B Free Base N-(3-chloro-4-fluoro- phenyl)-4-{[((E/Z)-(cyanoimino){[2- (dimethylamino)ethyl] amino}methyl)amino]methyl}-N′-hydroxy- 1,2,5-oxadiazole-3- carboximidamide 189

447.1 144 B Free Base N-(3-chloro-4-fluoro- phenyl)-4-{[((E/Z)-(cyanoimino){[2-(1H- imidazol-5-yl)ethyl]- amino}methyl)amino]methyl}-N′-hydroxy- 1,2,5-oxadiazole-3- carboximidamide 190

465.1 144 B Free Base 4-{[((E/Z)-[(amino- carbonyl)imino]{[2-(1H-imidazol-5-yl)- ethyl]amino}methyl) amino]methyl}-N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy- 1,2,5-oxadiazole-3- carboximidamide191

411.0 144 B Free Base N-(3-chloro-4-fluoro- phenyl)-4-[({(E/Z)-(cyanoimino)[(2- hydroxy-1-methyl- ethyl)amino]methyl} amino)methyl]-N′-hydroxy-1,2,5- oxadiazole-3- carboximidamide 192

395.1 144 A TFA N-(3-chloro-4-fluoro- phenyl)-4-({[(E/Z)-(cyanoimino)(isoprop- ylamino)methyl]- amino}methyl)-N′- hydroxy-1,2,5-oxadiazole-3- carboximidamide trifluoroacetate 193

425.1 144 A TFA N-(3-chloro-4-fluoro- phenyl)-4-[({(E/Z)-(cyanoimino)[(2- methoxy-1-methyl- ethyl)amino]methyl} amino)methyl]-N′-hydroxy-1,2,5- oxadiazole-3- carboximidamide trifluoroacetate 194

411.0 144 A TFA N-(3-chloro-4-fluoro- phenyl)-4-[({(E/Z)-(cyanoimino)[(2- methoxyethyl)amino] methyl}amino)methyl]-N′-hydroxy-1,2,5- oxadiazole-3- carboximidamide trifluoroacetate 195

437.0 144 A TFA N-(3-chloro-4-fluoro- phenyl)-4-({[(E/Z)-(cyanoimino)(tetrahydro- 2H-pyran-4-yl- amino)methyl]amino}methyl)-N′-hydroxy- 1,2,5-oxadiazole-3- carboximidamide trifluoroacetate196

464.1 144 A 2 TFA N-(3-chloro-4-fluoro- phenyl)-4-{[((E/Z)-(cyanoimino){[(1- ethylpyrrolidin-2-yl)- methyl]amino}methyl)amino]methyl}-N′- hydroxy-1,2,5- oxadiazole-3- carboximidamidebis(trifluoroacetate) 197

353.0 144 A TFA 4-({[(E/Z)-amino- (cyanoimino)methyl]amino}methyl)-N-(3 - chloro-4-fluoro- phenyl)-N′-hydroxy-1,2,5-oxadiazole-3- carboximidamide trifluoroacetate 198

397.1 144 A TFA N-(3-chloro-4-fluoro- phenyl)-4-[({(E/Z)-(cyanoimino)[(2- hydroxyethyl)amino] methyl}amino)- methyl]-N′-hydroxy-1,2,5-oxadiazole-3- carboximidamide trifluoroacetate 199

381.0 144 B Free Base N-(3-chloro-4-fluoro- phenyl)-4-({[(E/Z)-(cyanoimino)(di- methylamino)methyl]- amino}methyl)-N′- hydroxy-1,2,5-oxadiazole-3- carboximidamide 200

381.0 144 B Free Base N-(3-chloro-4-fluoro- phenyl)-4-({[(E/Z)-(cyanoimino)(ethyl- amino)methyl]amino} methyl)-N′-hydroxy-1,2,5-oxadiazole-3- carboximidamide 201

424.0 144 B Free Base N-(3-bromo-4-fluoro- phenyl)-4-({[(E/Z)-(cyanoimino)(ethyl- amino)methyl]amino} methyl)-N′-hydroxy-1,2,5-oxadiazole-3- carboximidamide 202

397.1 144 B Free Base 4-({[(E/Z)-(cyano- imino)(dimethyl-amino)methyl]amino} methyl)-N′-hydroxy- N-[3-(trifluoro-methyl)phenyl]-1,2,5- oxadiazole-3- carboximidamide 203

397.1 144 B Free Base 4-({[(E/Z)-(cyano- imino)(ethylamino)-methyl]amino}- methyl)-N′-hydroxy- N-[3-(trifluoro-methyl)phenyl]-1,2,5- oxadiazole-3- carboximidamide 204

424.0 144 B Free Base N-(3-bromo-4-fluoro- phenyl)-4-({[(E/Z)-(cyanoimino)(di- methylamino)methyl] amino}methyl)-N′- hydroxy-1,2,5-oxadiazole-3- carboximidamide 205

383.0 144 A TFA 4-({[(E/Z)-(cyano- imino)(methylamino) methyl]amino}-methyl)-N′-hydroxy- N-[3-(trifluoro- methyl)phenyl]-1,2,5- oxadiazole-3-carboximidamide trifluoroacetate 206

410.0 144 B Free Base N-(3-bromo-4-fluoro- phenyl)-4-({[(E/Z)-(cyanoimino)(methyl- amino)methyl]amino} methyl)-N′-hydroxy-1,2,5-oxadiazole-3- carboximidamide 207

396.0 144 B Free Base 4-({[(E/Z)-amino- (cyanoimino)methyl]-amino}methyl)-N-(3- bromo-4-fluoro- phenyl)-N′-hydroxy-1,2,5-oxadiazole-3- carboximidamide 208

369.0 144 B Free Base 4-({[(E/Z)-amino- (cyanoimino)methyl]-amino}methyl)-N′- hydroxy-N-[3-(tri- fluoromethyl)phenyl]-1,2,5-oxadiazole-3- carboximidamide 209

407.0 145 A Free Base N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-({[(isopropylamino) sulfonyl]amino}methyl)- 1,2,5-oxadiazole-3-carboximidamide 210

422.0 145 A Free Base N-(3-bromo-4-fluoro- phenyl)-N′-hydroxy-4-({[(methylamino) sulfonyl]amino}methyl)- 1,2,5-oxadiazole-3-carboximidamide 211

392.9 145 A Free Base N-(3-chloro-4-fluoro- phenyl)-4-({[(ethyl-amino)sulfonyl]amino} methyl)-N′-hydroxy- 1,2,5-oxadiazole-3-carboximidamide 212

393.0 145 B Free Base N-(3-chloro-4-fluoro- phenyl)-4-({[(di-methylamino)sulfonyl] amino}methyl)-N′- hydroxy-1,2,5- oxadiazole-3-carboximidamide 213

337.0  39 A Free Base N-[3-(difluoro- methyl)phenyl]-N′- hydroxy-4-(1H-tetrazol-1-ylmethyl)- 1,2,5-oxadiazole-3- carboximidamide 214

337.0  40 A Free Base N-[3-(difluoro- methyl)phenyl]-N′- hydroxy-4-(2H-tetrazol-2-ylmethyl)- 1,2,5-oxadiazole-3- carboximidamide 215

354.0 161 A Free Base N′-hydroxy-4-(4H- 1,2,4-triazol-4-yl-methyl)-N-[3-(tri- fluoromethyl)phenyl]- 1,2,5-oxadiazole-3-carboximidamide 216

381.0 161 A Free Base N-(3-bromo-4-fluoro- phenyl)-N′-hydroxy-4-(4H-1,2,4-triazol-4-yl- methyl)-1,2,5- oxadiazole-3- carboximidamide 217

397.0  39 A Free Base 4-[(5-amino-1H- tetrazol-1-yl)methyl]-N-(3-bromo-4-fluoro- phenyl)-N′-hydroxy- 1,2,5-oxadiazole-3-carboximidamide 218

397.0  40 A Free Base 4-[(5-amino-2H- tetrazol-2-yl)methyl]-N-(3-bromo-4-fluoro- phenyl)-N′-hydroxy- 1,2,5-oxadiazole-3-carboximidamide 219

380.0  33 A TFA N-({4-[(Z)-[(3-chloro- 4-fluorophenyl)- amino](hydroxy-imino)methyl]-1,2,5- oxadiazol-3-yl}- methyl)-1H- imidazole-2-carboxamide trifluoroacetate 220

380.0  33 A TFA N-({4-[(Z)-[(3-chloro- 4-fluorophenyl)- amino](hydroxy-imino)methyl]-1,2,5- oxadiazol-3-yl}- methyl)-1H-pyrazole- 4-carboxamidetrifluoroacetate 221

412.0  33 A Free Base N-({4-[(Z)-[(3-chloro- 4-fluorophenyl)-amino](hydroxy- imino)methyl]-1,2,5- oxadiazol-3-yl}- methyl)-4-methyl-1,2,3-thiadiazole-5- carboxamide 222

380.0  33 A TFA N-({4-[(Z)-[(3-chloro- 4-fluorophenyl)- amino](hydroxy-imino)methyl]-1,2,5- oxadiazol-3-yl}- methyl)-1H- imidazole-4-carboxamide trifluoroacetate 223

398.0  33 A Free Base N-({4-[(Z)-[3-chloro- 4-fluorophenyl)-amino](hydroxy- imino)methyl]-1,2,5- oxadiazol-3-yl}- methyl)-1,2,3-thiadiazole-4- carboxamide 224

413.0  33 A Free Base 5-amino-N-({4-[(Z)- [(3-chloro-4-fluoro-phenyl)amino]- (hydroxyimino)- methyl]-1,2,5- oxadiazol-3-yl}-methyl)-1,3,4- thiadiazole-2- carboxamide 225

395.0  33 A Free Base 5-amino-N-({4-[(Z)- [(3-chloro-4-fluoro-phenyl)amino](hydroxy- imino)methyl]-1,2,5- oxadiazol-3-yl}-methyl)-1H-pyrazole- 4-carboxamide 226

329.0 Ex. 33 (step B) A TFA 4-(aminomethyl)-N- (3-bromo-4-fluoro-phenyl)-N′-hydroxy- 1,2,5-oxadiazole-3- carboximidamide trifluoroacetate227

407.0  35 B Free Base N-(3-bromo-4-fluoro- phenyl)-N′-hydroxy-4-{[(methylsulfonyl) amino]methyl}-1,2,5- oxadiazole-3- carboximidamide228

302.0 Ex. 33 (step B) A TFA 4-(aminomethyl)-N′- hydroxy-N-[3-(tri-fluoromethyl)phenyl]- 1,2,5-oxadiazole-3- carboximidamidetrifluoroacetate 229

380.0  35 B Free Base N′-hydroxy-4- {[(methylsulfonyl)-amino]methyl}-N-[3- (trifluoromethyl)- phenyl]-1,2,5- oxadiazole-3-carboximidamide 230

432.0  35 B Free Base N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-({[(2,2,2-trifluoro- ethyl)sulfonyl]amino} methyl)-1,2,5- oxadiazole-3-carboximidamide 231

382.0  39 A Free Base N-(3-bromo-4-fluoro- phenyl)-N′-hydroxy-4-(1H-tetrazol-1-yl- methyl)-1,2,5- oxadiazole-3- carboximidamide 232

379.0  39 A Free Base [1-({4-[(Z)-[(3-chloro- 4-fluorophenyl)-amino](hydroxy- imino)methyl]-1,2,5- oxadiazol-3-yl}-methyl)-1H-tetrazol- 5- yl]acetic acid 233

460.0  35 B Free Base N-(3-chloro-4-fluoro- phenyl)-4-({[(2,4-dioxo-1,2,3,4-tetra- hydropyrimidin-5-yl)- sulfonyl]amino}-methyl)-N′-hydroxy- 1,2,5-oxadiazole-3- carboximidamide 234

488.0  35 B Free Base N-(3-chloro-4-fluoro- phenyl)-4-({[(1,3-dimethyl-2,4-dioxo- 1,2,3,4-tetrahydro- pyrimidin-5-yl)sulfonyl]amino}methyl)-N′- hydroxy-1,2,5- oxadiazole-3- carboximidamide 235

367.0  39 A Free Base N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-[3-(1H-tetrazol-1-yl)- propyl]-1,2,5- oxadiazole-3- carboximidamide 236

367.0  40 A Free Base N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-[3-(2H-tetrazol-2-yl)- propyl]-1,2,5- oxadiazole-3- carboximidamide 237

366.0  39 A Free Base N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-[3-(4H-1,2,4-triazol-4- yl)propyl]-1,2,5- oxadiazole-3- carboximidamide238

353.0  39 A Free Base 4-[(3-amino-4H-1,2,4- triazol-4-yl)methyl]-N-(3-chloro-4-fluoro- phenyl]-N′-hydroxy- 1,2,5-oxadiazole-3-carboximidamide 239

353.0  39 A Free Base 4-[(5-amino-1H-1,2,4- triazol-1-yl)methyl]-N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy- 1,2,5-oxadiazole-3-carboximidamide 240

370.0  4 A TFA N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy-4-[(1,3,4-thiadiazol-2- ylamino)methyl]- 1,2,5-oxadiazole-3-carboximidamide trifluoroacetate 241

377.0 145 B Free Base N-[3-(difluoro- methyl)phenyl]-N′-hydroxy-4-({[(methyl- amino)sulfonyl]- amino}methyl)-1,2,5-oxadiazole-3- carboximidamide 242

352.0  39 B Free Base 4-[(5-amino-1H- tetrazol-1-yl)methyl]-N-[3-(difluoro- methyl)phenyl]-N′- hydroxy-1,2,5- oxadiazole-3-carboximidamide 243

334.0  40 B Free Base 4-[(5-amino-2H- tetrazol-2-yl)methyl]-N-(4-fluoro-3-methyl- phenyl)-N′-hydroxy- 1,2,5-oxadiazole-3-carboximidamide 244

337.0  39 A Free Base N-[3-(difluoro- methyl)phenyl]-N′- hydroxy-4-(1H-tetrazol-1-ylmethyl)- 1,2,5-oxadiazole-3- carboximidamide 245

337.0  40 A Free Base N-[3-(difluoro- methyl)phenyl]-N′- hydroxy-4-(2H-tetrazol-2-ylmethyl)- 1,2,5-oxadiazole-3- carboximidamide 246

362.0  35 B Free Base N-[3-(difluoro- methyl)phenyl]-N′-hydroxy-4-{[(methyl- sulfonyl)amino]methyl}- 1,2,5-oxadiazole-3-carboximidamide 247

363.0 143 B Free Base 4-{[(aminosulfonyl) amino]methyl}-N-[3-(difluoromethyl)- phenyl]-N′-hydroxy- 1,2,5-oxadiazole-3-carboximidamide 248

416.0  35 B Free Base N-[3-(difluoro- methyl)phenyl]-N′-hydroxy-4-({[(tri- fluoromethyl)sulfonyl] amino}methyl)-1,2,5-oxadiazole-3- carboximidamide 249

440.0  35 B Free Base 4-{[bis(methyl- sulfonyl)amino]methyl}-N-[3-(difluoro- methyl)phenyl]-N′- hydroxy-1,2,5- oxadiazole-3-carboximidamide 250

334.0  39 B Free Base 4-[(5-amino-1H- tetrazol-1-yl)methyl]-N-(4-fluoro-3-methyl- phenyl)-N′-hydroxy- 1,2,5-oxadiazole-3-carboximidamide 251

385.0  3 B Free Base 4-{[(6-aminohexyl)- amino]methyl}-N-(3-chloro-4-fluoro- phenyl)-N′-hydroxy- 1,2,5-oxadiazole-3- carboximidamide252

744.0  3 B Free Base 5-[({6-[({4-[(Z)-[(3- chloro-4-fluoro-phenyl)amino](hydroxy- imino)methyl]-1,2,5- oxadiazol-3-yl}-methyl)amino]hexyl}- amino)carbonyl]-2-(7- hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid 253

344.0  35 B Free Base N-(4-fluoro-3-methyl- phenyl)-N′-hydroxy-4-{[(methylsulfonyl)- amino]methyl}-1,2,5- oxadiazole-3- carboximidamide254

412, 414 162 A Free Base 4-[2-(5-amino-1H- tetrazol-1-yl)ethyl]-N-(3-bromo-4-fluoro- phenyl)-N′-hydroxy- 1,2,5-oxadiazole-3-carboximidamide 255

422, 424 176 A Free Base N-(3-bromo-4-fluoro- phenyl)-N′-hydroxy-4-{2-[(methylsulfonyl)- amino]ethyl}-1,2,5- oxadiazole-3- carboximidamide256

423, 425 177 A Free Base 4-{2-[(aminosulfonyl) amino]ethyl}-N-(3-bromo-4-fluoro- phenyl)-N′-hydroxy- 1,2,5-oxadiazole-3- carboximidamide

Example A Human Indoleamine 2,3-Dioxygenasae (IDO) Enzyme Assay

Human indoleamine 2,3-dioxygenasae (IDO) with an N-terminal His tag wasexpressed in E. coli and purified to homogeneity. IDO catalyzes theoxidative cleavage of the pyrrole ring of the indole nucleus oftryptophan to yield N′-formylkynurenine. The assays were performed atroom temperature as described in the literature using 95 nM IDO and 2 mMD-Trp in the presence of 20 mM ascorbate, 5 μM methylene blue and 0.2mg/mL catalase in 50 mM potassium phosphate buffer (pH 6.5). The initialreaction rates were recorded by continuously following the absorbanceincrease at 321 nm due to the formation of N′-formlylkynurenine. See:Sono, M., Taniguchi, T., Watanabe, Y., and Hayaishi, O. (1980) J. Biol.Chem. 255, 1339-1345 Compounds of the invention having an IC₅₀ less thanabout 100 μM were considered active.

Example B Determination of Inhibitor Activity in HeLa Cell-BasedIndoleamine 2,3-Dioxygenase (IDO)/Kynurenine Assay

HeLa cells (#CCL-2) were obtained from the American Type Tissue CultureCollection (ATCC, Manassas, Va.) and routinely maintained in minimumessential medium (eagle) with 2 mM L-glutamine and Earle's BSS adjustedto contain 1.5 g/L sodium bicarbonate, 0.1 mM non-essential amino acids,1 mM sodium pyruvate and 10% fetal bovine serum (all from Invitrogen).Cells were kept at 37° C. in a humidified incubator supplied with 5%CO₂. The assay was performed as follows: HeLa cells were seeded in a 96well culture plate at a density of 5×10³ per well and grown overnight.On the next day, IFN-γ (50 ng/mL final concentration) and serialdilutions of compounds (in total volume of 200 μL culture medium) wereadded into cells. After 48 hours of incubation, 140 μL of thesupernatant per well was transferred to a new 96 well plate. 10 μL of6.1; N trichloroacetic acid (#T0699, Sigma) was mixed into each well andincubated at 50° C. for 30 min to hydrolyze N-formylkynurenine producedby indoleamine 2,3-dioxygenase to kynurenine. The reaction mixture wasthen centrifuged for 10 min at 2500 rpm to remove sediments. 100 μL, ofthe supernatant per well was transferred to another 96 well plate andmixed with 100 μL of 2% (w/v) p-dimethyl-aminobenzaldehyde (#15647-7,Sigma-Aldrich) in acetic acid. The yellow color derived from Kynureninewas measured at 480 nm using a SPECTRAmax 250 microplate reader(Molecular Devices). L-kynurenine (#K8625, Sigma) was used as standard.The standards (240, 120, 60, 30, 15, 7.5, 3.75, 1.87 μM) were preparedin 100 μL culture media and mixed with equal volume of 2% (w/v)p-dimethylaminobenzaldehyde. The percent inhibition at individualconcentrations was determined and the average values of duplicates wereobtained. The data was analyzed by using nonlinear regression togenerate IC₅₀ values (Prism Graphpad). See: Takikawa O, et al. (1988).Mechanism of interferon-gamma action. Characterization of indoleamine2,3-dioxygenase in cultured human cells induced by interferon-gamma andevaluation of the enzyme-mediated tryptophan degradation in itsanticellular activity. J. Biol. Chem. 263(4):2041-8. Compounds of theinvention having an IC₅₀ less than about 100 μM were considered active.

Example C Determination of Effect of IDO Inhibitors on T CellProliferation that is Suppressed by IDO-Expressing Dendritic Cells

Monocytes were collected from human peripheral mononuclear cells byleukophoresis. Monocytes were then seeded at a density of 1×10⁶cells/well in a 96 well plate, using RPMI 1640 medium supplemented with10% fetal bovine serum and 2 in M L-glutamine (all from Invitrogen).Adherent cells were retained on the plate after overnight culture at 37°C. Adherent monocytes were then stimulated for 5-7 days with 100 ng/mlGM-CSF (#300-03, PeproTech) and 250 ng/ml IL-4 (#200-04, PeproTech),followed by activation with 5 μg/mL LPS from Salmonella typhimurium(#437650, Sigma) and 50 ng/mL IFN-γ (#285-IF, R&D Systems) foradditional 2 days to induce dendritic cell maturation.

After dendritic cell activation, the medium was replaced with completedRPMI 1640 supplemented with 100-200 U/mL IL-2 (#CYT-209, ProSpec-TanyTechnoGene) and 100 ng/mL anti-CD3 antibody (#555336, PharMingen), Tcells (2−3×10⁵ cells/well), and serial dilutions of IDO compounds. Afterincubation for 2 more days, T cell proliferation was measured by BrdUincorporation assay, using a colorimetric Cell Proliferation ELISA kitper manufacturer's instruction (#1647229, Roche Molecular Biochemicals).Cells were continuously cultured for 16-18 hrs in presence of 10 μM BrdUlabeling solution. Then, the labeling medium was removed, and 200 μLFixDenat per well was added to the cells and incubated for 30 minutes atroom temperature. The FixDenat solution was removed and 100 μL/wellanti-BrdU-POD antibody conjugate working solution was added. Thereaction was carried out for 90 minutes at room temperature. Theantibody conjugate was then removed, and cells were rinsed three timeswith 200 μL/well washing solution. Finally, 100 μL/well of substratesolution was added and the results were obtained using a microplatereader (Spectra Max PLUS, Molecular Devices) during color development.Multiple readings at various time points were obtained to ensure thedata was within the linear range. The data was routinely obtained fromreplicated experiments, and appropriate controls were included. See:Terness P, et al. (2002). Inhibition of allogeneic T cell proliferationby indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation ofsuppression by tryptophan metabolites. J. Exp. Med. 196(4):447-57; andHwu P, et al. (2000). Indoleamine 2,3-dioxygenase production by humandendritic cells results in the inhibition of T cell proliferation. J.Immunol. 164(7):3596-9. Compounds of the invention having an IC₅₀ lessthan about 100 μM were considered active.

Example D In Vivo Testing of IDO Inhibitors for Antitumor Activity

In vivo anti-tumor efficacy can be tested using modified tumorallograft/xenograft protocols. For instance, it has been described inthe literature that IDO inhibition can syngerize with cytotoxicchemotherapy in immune-competent mice (Muller, A. J., et al). Thissynergy was shown to be dependent on T-cells by comparison of thesynergistic effects of an investigational IDO inhibitor in murine tumorxenograft models (e.g. B16 and related variants, CT-26, LLC) grown inimmune competent syngenic mice to that observed in syngenic mice treatedwith neutralizing anti-CD4 antibodies, or the same tumors grown inimmune-compromised mice (e.g. nu/nu).

The concept of differential anti-tumor effects in immune-competentversus immune-compromised mice may also permit testing ofinvestigational IDO inhibitors as single agents. For instance, LLCtumors grow well in their syngeneic host strain, C57Bl/6. However, ifthese mice are treated with the IDO inhibitor 1-MT (versus placebo) theformation of tumors is markedly delayed, implying that IDO inhibitionwas growth inhibitory (Friberg, M., et al). Following this logic, onecan examine the efficacy of IDO inhibition in the LLC xenograft tumormodel grown in C57Bl/6 immune competent mice and compare that to theeffects of IDO inhibitors on LLC tumor growth in nude or SCID mice (orC57Bl/6 mice treated with antibodies that neutralize T-cell activity).As the effects of relieving the tumor-mediated immune suppressiveactivity of IDO will likely differ depending on the immunogenicpotential of different tumor models, genetic modifications can be madeto the tumor cells to increase their immunogenic potential. Forinstance, expression of GM-CSF in B16.F10 cells increases theirimmunogenic potential (Dranoff, G., et al). As such, in some tumormodels (e.g. B16.F10) one can generate [poly]clones that express immunestimulatory proteins such as GM-CSF and test the growth inhibitoryeffects of IDO inhibitors against tumors established from these tumorcells in both immune-competent and compromised mice.

A third avenue for assessing the efficacy of IDO inhibitors in vivoemploys ‘pre-immunization’ murine tumor allograft/xenograft models. Inthese models, immune-competent mice are sensitized to a specific tumorantigen or antigens to mimic a therapeutic anti-tumor vaccination. Thisprimes the mice for an anti-tumor response mediated by the immune systemwhen mice are subsequently challenged with murine tumor cell lines(possessing similar tumor antigens to those used for immunization) inxenograft experiments. Expression of IDO has been shown to blunt theanti-tumor response and allow xenografts to grow more rapidly.Importantly, the growth of tumors in this model is inhibited by the IDOinhibitor 1-MT (Uyttenhove, C., et al). This model is particularlyattractive as IDO activity is permissive for P815 tumor growth andspecific inhibition of IDO should therefore growth inhibitory.

Lastly, therapeutic immunization may be used to evaluate the impact ofIDO inhibitors in vivo. For example, it has been demonstrated using B16-BL6 cells that one can challenge Blk/6 mice with an intravenousinjection of tumor cells followed by treatment with a well characterizedimmunogenic peptide (e.g. TRP-2) expressed by the tumor cells (Ji, etal., J. Immunol, 2005, 175:1456-63). Importantly, immune systemmodifiers, such as anti-CTL-4 antibody, can improve responses to suchtherapeutic immunizations. The impact of IDO inhibitors may be evaluatedin a similar manner tumor peptide immunization with or without IDOinhibitor. Efficacy is assess by animal survival (time to morbidity) orby the measurement of tumor metastases to the lungs and/or other organsat defined timepoints.

In any/all of the above mentioned models, it may also be possible todirectly and/or indirectly measure the number and/or activity of tumorreactive immune cells. Methods for measuring the number and/or activityof tumor reactive immune cells are well established and can be performedusing techniques familiar to those schooled in the art (CurrentProtocols in Immunology, vol 4, Coligan, J. E., et al; Immunotherapy ofCancer, Human Press, 2006, Disis, M. L. and references therein).Conceptually, a reduction in the immune suppressive effects of IDO mayresult in increased numbers or reactivity of tumor specific immunecells. Further, IDO inhibition may further increase the number orreactivity of tumor reactive immune cells when combined with othertherapeutics, for example chemotherapeutics and/or immune modulators(e.g. anti-CTLA4 antibody).

All allograft/xenograft experiments can be performed using standardtumor techniques (reviewed by Corbett, et al). The cloning andintroduction of genes (e.g. IDO, GM-CSF) into tumor cell lines, can beperformed using techniques familiar to those schooled in the art(reviewed in Sambrook, J, et al). See: Corbett, T., Polin, L., et al. Invivo methods for screening and preclinical testing. Cancer DrugDiscovery and Development: Anticancer Drug Development Guide:Preclinical Screening, Clinical Trials, and Approval, 2n^(d) Ed.Teicher, B. A. and Andrews, P. A., Gumana Press Inc., Totowa, N. J.,2004; Dranoff, G., Jaffee, E., et al. Vaccination with irradiated tumorcells engineered to secrete murine granulocyte-macrophagecolony-stimulating factor stimulates potent, specific, and long-lastinganti-tumor immunity. Proc. Natl. Acad. Sci, USA, 90:3539-3543, 1993;Friberg, M., Jennings, R., et al. Indoleamine 2,3-dioxygenasecontributes to tumor cell evasion of T cell-mediated rejection. Int. J.Cancer: 101:151-155, 2002; Muller, A. J., DuHadaway, J. B., et al.Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target ofthe cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat.Med. 11:312-319, 2005; Sambrook, J, Russel, D. Molecular Cloning: Alaboratory Manual (3^(rd) edition). Cold Spring Harbor Laboratory Press.Cold Spring Harbor, N.Y., USA. 2001; and Uyttenhove, C., Pilotte, L., etal. Evidence for a tumoral immune resistance mechanism based ontryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med.9:1269-1274, 2003.

Example E In Vivo Testing of IDO Inhibitors in Human ImmunodeficiencyVirus-1 (HIV-1) Encephalitis Model 1. Cell Isolation and Viral Infection

Monocytes and PBL can be obtained by countercurrent centrifugalelutriation of leukopheresis packs from HIV-1, 2 and hepatitis Bseronegative donors. Monocytes are cultivated in suspension cultureusing Teflon flasks in Dulbecco's Modified Eagle's Medium (DMEM,Sigma-Aldrich) supplemented with 10% heat-inactivated pooled humanserum, 1% glutamine, 50 μg/mL gentamicin, 10 μg/mL ciprofloxacin(Sigma), and 1000 U/mL highly purified recombinant human macrophagecolony stimulating factor. After seven days in culture, MDM are infectedwith HIV-1_(ADA) at multiplicity of infection of 0.01.

2. Hu-PBL-NOD/SCID HIVE Mice

Four-wk old male NOD/C.B-17 SCID mice can be purchased (JacksonLaboratory). Animals are maintained in sterile microisolator cages underpathogen-free conditions. All animals are injected intraperitoneallywith rat anti-CD122 (0.25 mg/mouse) three days before PBLtransplantation and twice with rabbit asialo-GM1 antibodies (0.2mg/mouse) (Wako) one day before and three days after PBL injection(20×10⁶ cells/mouse). HIV-1_(ADA)-infected MDM (3×10⁵ cells in 10 μL)are injected intracranially (i.c.) eight days following PBLreconstitution generating hu-PBL-NOD/SCID HIVE mice. Immediatelyfollowing i.c. injection of HIV-1 infected MDM the hu-PBL-NOD/SCID HIVEmice are subcutaneously (s.c) implanted with control (vehicle) orcompound pellets (14 or 28 day slow release, Innovative Research).Initial experiments are designed to confirm the induction ofvirus-specific CTL in the hu PBL-NOD/SCID HIVE animals treated with IDOcompounds. This is confirmed by tetramer staining and neuropathologicanalyses of MDM elimination from the brain tissue. Then, the experimentis designed to analyze human lymphocyte reconstitution, humoral immuneresponses, and neuropathological alterations. In these experiments,animals are bled on day 7 and sacrificed at 14 and 21 days after i.c.injection of human MDM. Blood collected in EDTA-containing tubes is usedfor flow cytometry and plasma is used for detection of HIV-1 p24 usingELISA (Beckman Coulter™). HIV-1-specific antibodies are detected byWestern blot tests according to the manufacturer instructions (CambridgeBiotech HIV-1 Western blot kit, Calypte Biomedical). Similar amount ofvirus-specific antibodies are detected in control and compound-treatedanimals. A total of three independent experiments can be performed usingthree different human leukocyte donors.

3. FACScan of Peripheral Blood and Spleen in Hu PBL-NOD/SCID HIVE Mice

Two-color FACS analysis can be performed on peripheral blood at wk 1-3and splenocytes at wk 2 and 3 after i.c. injection of human MDM. Cellsare incubated with fluorochrome-conjugated monoclonal Abs (mAbs) tohuman CD4, CD8, CD56, CD3, IFN-γ (eBioscience) for 30 min at 4° C. Toevaluate the cellular immune response, IFN-γ intracellular staining isperformed in combination with anti-human CD8 and FITC-conjugatedanti-mouse CD45 to exclude murine cells. To determine the Ag-specificCTL, allophycocyanin-conjugated tetramer staining for HIV-1^(gag) (p17(aa77-85) SLYNTVATL, SL-9) and HIV-1^(pol) [(aa476-485) ILKEPVHGV, IL-9]is performed on phytohemaglutinin/interleukin-2 (PHA/IL-2)-stimulatedsplenocytes. Cells are stained following the recommendation of theNIH/National Institute of Allergy and Infections Disease, NationalTetramer Core Facilities. Data were analyzed with a FACS Calibur™ usingCellQuest software (Becton Dickinson Immunocytometry System).

4. Histopathology and Image Analyses

Brain tissue is collected at days 14 and 21 after i.c. injection of MDM,fixed in 4% phosphate-buffered paraformaldehyde and embedded in paraffinor frozen at 80° C. for later use. Coronal sections from the embeddedblocks are cut in order to identify the injection site. For each mouse,30-100 (5-μm-thick) serial sections are cut from the human MDM injectionsite and 3-7 slides (10 sections apart) are analyzed. Brain sections aredeparaffinized with xylene and hydrated in gradient alcohols.Immunohistochemical staining follows a basic indirect protocol, usingantigen retrieval by heating to 95° C. in 0.01 mol/L citrate buffer for30 min for antigen retrieval. To identify human cells in mouse brains,mAb to vimentin (1:50, clone 3B4, Dako Corporation), which identifiesall human leukocytes is used. Human MDM and CD8⁺ lymphocytes aredetected with CD68 (1:50 dilution, clone KP 1) and CD8 (1:50 dilution,clone 144B) antibodies, respectively. Virus-infected cells are labeledwith mAb to HIV-1 p24 (1:10, clone Kal-1, all from Dako). Reactivemurine microglial cells are detected with Iba-1 antibody (1:500, Wako).Expression of human IDO (huIDO) is visualized with Abs obtained from theDepartment of Cell Pharmacology, Central Research Institute, GraduateSchool of Medicine, Hokkaido University, Sapporo, Japan. Primaryantibodies are detected with the appropriate biotinylated secondaryantibodies and visualized with avidin-biotin complexes (Vectastain EliteABC kit, Vector Laboratories) and horseradish peroxidase (HRP) coupleddextran polymer (EnVision, Dako Corporation). Immunostained sections arecounterstained with Mayer's hematoxylin. Sections from which primaryantibody is deleted or irrelevant IgG isotype is incorporated served ascontrols. Two independent observers in a blinded fashion count thenumbers of CD8⁺lymphocytes, CD68⁺MDM and HIV-1 p24⁺cells in each sectionfrom each mouse. Light microscopic examination is performed with a NikonEclipse 800 microscope (Nikon Instruments Inc). Semi-quantitativeanalysis for Iba1 (percentage of area occupied by immunostaining) iscarried out by computer-assisted image analysis (Image-Pro®Plus, MediaCybernetics) as previously described.

5. Statistic Analysis

Data can be analyzed using Prism (Graph Pad) with Student t-test forcomparisons and ANOVA. P-values <0.05 were considered significant.

6. Reference

-   Poluektova L Y, Munn D H, Persidsky Y, and Gendelman H E (2002).    Generation of cytotoxic T cells against virus-infected human brain    macrophages in a murine model of HIV-1 encephalitis. J. Immunol.    168(8):3941-9.

Various modifications of the invention, in addition to those describedherein, will be apparent to those skilled in the art from the foregoingdescription. Such modifications are also intended to fall within thescope of the appended claims. Each reference, including all patent,patent applications, and publications, cited in the present applicationis incorporated herein by reference in its entirety.

1. A method of inhibiting immunosuppression or treating cancer, viralinfection, depression, a neurodegenerative disorder, trauma, age-relatedcataracts, organ transplant rejection, or an autoimmune disease in apatient comprising administering to said patient an effective amount ofa compound of Formula Ia:

or a pharmaceutically acceptable salt thereof, wherein: U is N, O, S,CR′, or NR″; V, and W are each, independently, N, O, S, CR², or NR³,wherein the five-membered ring containing U, V, and W is an aromaticheterocycle; A is aryl, cycloalkyl, heteroaryl, or heterocycloalkyl,each optionally substituted by 1, 2, 3, 4, or 5 substituentsindependently selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆ cyanoalkyl,halosulfanyl, Cy¹, CN, NO₂, OR^(a), SR^(a), C(O)R^(b), C(O)NR^(c)R^(d),C(O)OR^(a), OC(O)R^(b), OC(O)NR^(c)R^(d), NR^(c)R^(d), NR^(c)C(O)R^(b),NR^(c)C(O)NR^(c)R^(d), NR^(c)C(O)OR^(a), C(═NR^(i))NR^(c)R^(d),NR^(c)C(═NR^(i))NR^(c)R^(d), P(R^(f))₂, P(OR^(e))₂, P(O)R^(e)R^(f),P(O)OR^(e)OR^(f), S(O)R^(b), S(O)NR^(c)R^(d), S(O)₂R^(b),NR^(c)S(O)₂R^(b), and S(O)₂NR^(c)R^(d), wherein said C₁₋₆ alkyl, C₂₋₆alkenyl, and C₂₋₆ alkynyl is optionally substituted with 1, 2, or 3substitutents independently selected from Cy¹, CN, NO₂, OR^(a), SR^(a),C(O)R^(b), C(O)NR^(c)R^(d), C(O)OR^(a), OC(O)R^(b), OC(O)NR^(c)R^(d),NR^(c)R^(d), NR^(c)C(O)R^(b), NR^(c)C(O)NR^(c)R^(d), NR^(c)C(O)OR^(a),C(═NR^(i))NR^(c)R^(d), NR^(c)C(═NR^(i))NR^(c)R^(d), P(R^(f))₂,P(OR^(e))₂, P(O)R^(e)R^(f), P(O)OR^(e)OR^(f), S(O)R^(b),S(O)NR^(c)R^(d), S(O)₂R^(b), NR′S(O)₂R^(b), and S(O)₂NR^(c)R^(d); R isH, C(O)R⁵, C(O)OR⁶, or C(O)NR^(6a)R^(6b); R^(A) and R^(B) areindependently selected from H, F, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl,arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl,halosulfanyl, CN, NO₂, OR^(a1), SR^(a1), C(O)R^(b1), C(O)NR^(c1)R^(d1),C(O)OR^(a1), OC(O)R^(b1), OC(O)NR^(c1)R^(d1), NR^(c1)R^(d1),NR^(c1)C(O)R^(b1), NR^(c1)C(O)NR^(c1)R^(d1), NR^(c1)C(O)OR^(a1),C(═NR^(i))NR^(c1)R^(d1), NR^(c1)C(═NR^(i))NR^(c1)R^(d1), P(R^(f1))₂,P(OR^(e1))₂, P(O)R^(e1)R^(f1), P(O)OR^(e1)OR^(f1), S(O)R^(b1),S(O)NR^(c1)R^(d1), S(O)₂R^(b1), NR^(c1)S(O)₂R^(b1), andS(O)₂NR^(c1)R^(d1); wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl,cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl is optionallysubstituted by 1, 2, 3, 4, or 5 substituents independently selected fromhalo, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₁₋₄hydroxyalkyl, C₁₋₄ cyanoalkyl, halosulfanyl, CN, NO₂, OR^(a1), SR^(a1),C(O)R^(b1), C(O)NR^(c1)R^(d1), C(O)OR^(a1), OC(O)R^(b1),OC(O)NR^(c1)R^(d1), NR^(c1)R^(d1), NR^(c1)C(O)R^(b1),NR^(c1)C(O)NR^(c1)R^(d1), NR^(e1)C(O)OR^(a1), C(═NR^(i))NR^(c1)R^(d1),NR^(c1)C(═NR^(i))NR^(c1)R^(d1), P(R^(f1))₂, P(OR^(e1))₂,P(O)R^(e1)R^(f1), P(O)OR^(e1)OR^(f1), S(O)R^(b1), S(O)NR^(c1)R^(d1),S(O)₂R^(b1), NR^(c1)S(O)₂R^(b1), and S(O)₂NR^(c1)R^(d1); or R^(A) andR^(B) together with the carbon atom to which they are attached form a3-, 4-, 5-, 6-, or 7-membered cycloalkyl group or 3-, 4-, 5-, 6-, or7-membered heterocycloalkyl group, each optionally substituted with 1,2, or 3 substituents independently selected from halo, C₁₋₄ alkyl, C₂₋₄alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₁₋₄ hydroxyalkyl, C₁₋₄cyanoalkyl, halosulfanyl, CN, NO₂, OR^(a1), SR^(a1), C(O)R^(b1),C(O)NR^(c1)R^(d1), C(O)OR^(a1), OC(O)R^(b1), OC(O)NR^(c1)R^(dl),NR^(c1)R^(d1), NR^(c1)C(O)R^(d), NR^(c1)C(O)NR^(c1)R^(d1),NR^(c1)C(O)OR^(a1), C(═NR^(i))NR^(c1)R^(d1),NR^(c1)C(═NR^(i))NR^(c1)R^(d1), P(R^(f1))₂, P(OR^(e1))₂,P(O)R^(e1)R^(f1), P(O)OR^(e1)OR^(f1), S(O)R^(b1), S(O)NR^(c1)R^(d1),S(O)₂R^(b1), NR^(c1)S(O)₂R^(b1), and S(O)₂NR^(c1)R^(d1); or R^(A) andR^(B), together with the carbon atom to which they are attached, form aC═CH₂ group; Q is OR^(Q), OC(O)R^(Q), OC(O)NR⁴R^(Q), NR⁴R^(Q),NR⁴C(O)R^(Q), NR⁴C(O)NR⁴R^(Q), NR⁴C(O)OR^(Q), NR⁴S(O)R^(Q),NR⁴S(O)₂R^(Q), NR⁴C(═NR^(i))NR⁴R^(Q), SR^(Q), S(O)R^(Q), S(O)NR⁴R^(Q),S(O)₂R^(Q), S(O)₂NR⁴R^(Q), C(O)R^(Q), C(O)OR^(Q), C(O)NR⁴R^(Q), halo,cyano, azido, or nitro; or Q is H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, each optionallysubstituted by 1, 2, 3, 4, or 5 substituents independently selected fromhalo, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆hydroxyalkyl, C₁₋₆ cyanoalkyl, Cy, —(C₁₋₄ alkyl)-Cy, halosulfanyl, CN,NO₂, OR^(a2), —(C₁₋₄ alkyl)-OR^(a2), SR^(a2), —(C₁₋₄ alkyl)-SR^(a2),C(O)R^(b2), —(C₁₋₄ alkyl)-C(O)R^(b2), C(O)NR^(c2)R^(d2), —(C₁₋₄alkyl)-C(O)NR^(c2)R^(d2), C(O)OR^(a2), —(C₁₋₄ alkyl)-C(O)OR^(a2),OC(O)R^(b2), —(C₁₋₄ alkyl)-OC(O)R^(b2), OC(O)NR^(c2)R^(d2), —(C₁₋₄alkyl)-OC(O)NR^(c2)R^(d2), NR^(c2)R^(d2), —(C₁₋₄ alkyl)-NR^(c2)R^(d2),NR^(c2)C(O)R^(b2), —(C₁₋₄ alkyl)-NR^(c2)C(O)R^(b2),NR^(c2)C(O)NR^(c2)R^(d2), —(C₁₋₄ alkyl)-NR^(c2)C(O)NR^(c2)R^(d2),NR^(c2)C(O)OR^(a2), —(C₁₋₄ alkyl)-NR^(c2)C(O)OR^(a2),C(—NR^(i))NR^(c2)R^(d2), NR^(c2)C(═NR^(i))NR^(c2)R^(d2), P(R^(f2))₂,P(OR^(e2))₂, P(O)R^(e2)R^(f2), P(O)OR^(e2)OR^(f2), S(O)R^(b2), —(C₁₋₄alkyl)-S(O)R^(b2), S(O)NR^(c2)R^(d2), —(C₁₋₄ alkyl)-S(O)NR^(c2)R^(d2),S(O)₂R^(b2), —(C₁₋₄ alkyl)-S(O)₂R^(b2), NR^(c2)S(O)₂R^(b2), —(C₁₋₄alkyl)-NR^(c2)S(O)₂R^(b2), S(O)₂NR^(c2)R^(d2), and —(C₁₋₄alkyl)-S(O)₂NR^(c2)R^(d2); R^(Q) is H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl,arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl,wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, cycloalkyl,heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl,heteroarylalkyl, or heterocycloalkylalkyl is optionally substituted by1, 2, 3, 4, or 5 substituents independently selected from halo, C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl,C₁₋₆ cyanoalkyl, halosulfanyl, Cy, —(C₁₋₄ alkyl)-Cy, CN, NO₂, OR^(a2),SR^(a2), C(O)R^(b2), C(O)NR^(c2)R^(d2), C(O)OR^(a2), OC(O)R^(b2),OC(O)NR^(c2)R^(d2), NR^(c2)R^(d2), NR^(c2)C(O)R^(b2),NR^(c2)C(O)NR^(c2)R^(d2), NR^(c2)C(O)OR^(a2), C(═NR^(i))NR^(c2)R^(d2),NR^(c2)C═(NR^(i))NR^(c2)R^(d2), P(R^(f2))₂, P(OR^(e2))₂,P(O)R^(e2)R^(f2), P(O)OR^(e2)OR^(f2), S(O)R^(b2), S(O)NR^(c2)R^(d2),S(O)₂R^(b2), S(O)₂R^(b2), and S(O)₂NR^(c2)R^(d2); or R⁴ and R^(Q)together with the N atom to which they are attached form a 4-20 memberedheterocycloalkyl group or 5-20 membered heteroaryl group, eachoptionally substituted by 1, 2, 3, 4, or 5 substituents independentlyselected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆ cyanoalkyl, halosulfanyl, Cy, —(C₁₋₄alkyl)-Cy, CN, NO₂, OR^(a2), —(C₁₋₄ alkyl)-OR^(a2), SR^(a2), —(C₁₋₄alkyl)-SR^(a2), C(O)R^(b2), —(C₁₋₄ alkyl)-C(O)R^(b2), C(O)NR^(c2)R^(d2),—(C₁₋₄ alkyl)-C(O)NR^(c2)R^(d2), C(O)OR^(a2), —(C₁₋₄ alkyl)-C(O)OR^(a2),OC(O)R^(b2), —(C₁₋₄ alkyl)-OC(O)R^(b2), OC(O)NR^(c2)R^(d2), —(C₁₋₄alkyl)-OC(O)NR^(a)R^(d2), NR^(a)R^(d2), —(C₁₋₄ alkyl)-NR^(a)R^(d2),NR^(c2)C(O)R^(b2), —(C₁₋₄ alkyl)-NR^(c2)C(O)R^(b2),NR^(c2)C(O)NR^(c2)R^(d2), —(C₁₋₄ alkyl)-NR^(c2)C(O)NR^(c2)R^(d2),NR^(c2)C(O)OR^(a2), —(C₁₋₄ alkyl)-NR^(c2)C(O)OR^(a2),C(═NR^(i))NR^(c2)R^(d2), NR^(c2)C(═NR^(i))NR^(c2)R^(d2), P(R^(f2))₂,P(OR^(e2))₂, P(OR^(e2))₂, P(O)R^(e2)R^(f2), P(O)OR^(e2), OR^(f2),S(O)R^(b2), —(C₁₋₄ alkyl)-S(O)R^(b2), S(O)NR^(c2)R^(d2), —(C₁₋₄alkyl)-S(O)NR^(c2)R^(d2), S(O)₂R^(b2), —(C₁₋₄ alkyl)-S(O)₂R^(b2),NR^(c2)S(O)₂R^(b2), —(C₁₋₄ alkyl)-NR^(c2)S(O)₂R^(b2), S(O)₂NR^(a)R^(d2),and —(C₁₋₄ alkyl)-S(O)₂NR^(a)R^(d2); Cy, Cy¹, and Cy² are independentlyselected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, eachoptionally substituted by 1, 2, 3, 4 or 5 substituents independentlyselected from halo, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄haloalkyl, halosulfanyl, CN, NO₂, OR^(a3), SR^(a3), C(O)R^(b3),C(O)NR^(c3)R^(d3), C(O)OR^(a3), OC(O)R^(b3), OC(O)NR^(c3)R^(d3),NR^(c3)R^(d3), NR^(c3)C(O)R^(b3), NR^(c3)C(O)OR^(a3),C(═NR^(i))NR^(c3)R^(d3), NR^(c3)C(═NR^(i))NR^(c3)R^(d3), P(R^(f3))₂,P(OR^(e3))₂, P(O)R^(e3)R^(f3), P(O)OR^(e3)OR^(f3), S(O)R^(b3),S(O)NR^(c3)R^(d3), S(O)₂R^(b3), and S(O)₂NR^(c3)R^(d3); R¹ is H or C₁₋₄alkyl; R² is H, halo, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₂₋₄ alkenyl, C₂₋₄alkynyl, CN, NO₂, OH, C₁₋₄ alkoxy, amino, C₁₋₄ alkylamino, or C₂₋₈dialkylamino; R³ is H, C₁₋₄ alkyl, C₂₋₄ alkenyl, or C₂₋₄ alkynyl; R⁴ isH, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C(O)—R^(4a), SO₂—R^(4a),aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl,cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl, wherein saidC₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, aryl, cycloalkyl, heteroaryl,heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, orheterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4, or 5substituents independently selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆ cyanoalkyl, aryl,heteroaryl, cycloalkyl, heterocycloalkyl, halosulfanyl, CN, NO₂,OR^(a4), SR^(a4), C(O)R^(b4), C(O)NR^(c4)R^(d4), C(O)OR^(a4),OC(O)R^(b4), OC(O)NR^(c4)R^(d4), NR^(c4)R^(d4), NR^(c4)C(O)R^(b4),NR^(c4)C(O)NR^(c4)R^(d4), NR^(c4)C(O)OR^(a4), C(═NR^(i))NR^(c4)R^(d4),NR^(c4)C(═NR^(i))NR^(c4)R^(d4), P(R^(f4))₂, P(OR^(e4))₂,P(O)R^(e4)R^(f4), P(O)OR^(e4)OR^(f4), S(O)R^(b4), S(O)NR^(c4)R^(d4),S(O)₂R^(b4), NR^(c4)S(O)₂R^(b4), and S(O)₂NR^(c4)R^(d4); R^(4a) is H,C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, aryl, cycloalkyl, heteroaryl,heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, orheterocycloalkylalkyl; R⁵ and R⁶ are independently selected from H, C₁₋₈alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl,heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, eachoptionally substituted by one or more substituents independentlyselected from halo, CN, NO₂, OH, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, amino,C₁₋₄ alkylamino, C₂₋₈ dialkylamino, C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆alkynyl; R^(6a) and R^(6b) are independently selected from H, C₁₋₈alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl,heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, eachoptionally substituted by one or more substituents independentlyselected from halo, CN, NO₂, OH, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, amino,C₁₋₄ alkylamino, C₂₋₈ dialkylamino, C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆alkynyl; R^(a), R^(a1), R^(a3), R^(a4), and R^(a5) are independentlyselected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl,heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, whereinsaid C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl,cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl,cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted withOH, amino, halo, C₁₋₆ alkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, cycloalkyl, or heterocycloalkyl; R^(b), R^(b1), R^(b3),R^(b4), and R^(b5) are independently selected from H, C₁₋₆ alkyl, C₁₋₆haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, cycloalkyl, heteroaryl,heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, andheterocycloalkylalkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl,arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl isoptionally substituted with OH, amino, halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl,aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, orheterocycloalkyl; R^(a2) is H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, Cy², or Cy²-(C₁₋₆ alkyl)-, wherein said C₁₋₆ alkyl, C₁₋₆haloalkyl, C₂₋₆ alkenyl, or C₂₋₆ alkynyl, is optionally substituted with1, 2, 3, 4, or 5 substituents independently selected from halo, C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl,C₁₋₆ cyanoalkyl, halosulfanyl, Cy², CN, NO₂, OR^(a5), SR^(a5),C(O)R^(b5), C(O)NR^(c5)R^(d5), C(O)OR^(a5), OC(O)R^(b5),OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5), NR^(c5)C(O)R^(b5),NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5), C(═NR^(i))NR^(c5)R^(d5),NR^(c5)C(═NR^(i))NR^(c5)R^(d5), P(R^(f5))₂, P(OR^(e5))₂,P(O)R^(e5)R^(f5), P(O)OR^(e5)OR^(f5), S(O)R^(b5), S(O)NR^(c5)R^(d5),R^(b2), S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5), and S(O)₂NR^(c5)R^(d5); R^(b2)is H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, Cy²,or Cy²-(C₁₋₆ alkyl)-, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, or aryl is optionally substituted with 1, 2, 3,4, or 5 substituents independently selected from halo, C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆cyanoalkyl, halosulfanyl, Cy², CN, NO₂, OR^(a5), SR^(a5), C(O)R^(b5),C(O)NR^(c5)R^(d5), C(O)OR^(a5), OC(O)R^(b5), OC(O)NR^(c5)R^(d5),NR^(c5)R^(d5), NR^(c5)C(O)R^(b5), NR^(c5)C(O)NR^(c5)R^(d5),NR^(c5)C(O)OR^(a5), C(═NR^(i))NR^(c5)R^(d5),NR^(c5)C(═NR^(i))NR^(c5)R^(d5), P(R^(f5))₂, P(OR^(e5))₂,P(O)R^(e5)R^(f5), P(O)OR^(e5)OR^(f5), S(O)R^(b5), S(O)NR^(c5)R^(d5),S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5), and S(O)₂NR^(c5)R^(d5); R^(c) and R^(d)are independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl,arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl,wherein said C₁₋₁₀ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl,heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionallysubstituted with OH, amino, halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or heterocycloalkyl;or R^(c) and R^(d) together with the N atom to which they are attachedform a 4-, 5-, 6- or 7-membered heterocycloalkyl group; R^(c1) andR^(d1) are independently selected from H, C₁₋₁₀ alkyl, C₁₋₆ haloalkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, heteroaryl, cycloalkyl,heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, andheterocycloalkylalkyl, wherein said C₁₋₁₀ alkyl, C₁₋₆ haloalkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl,arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl isoptionally substituted with OH, amino, halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl,aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, orheterocycloalkyl; or R^(c1) and R^(d1) together with the N atom to whichthey are attached form a 4-, 5-, 6- or 7-membered heterocycloalkylgroup; R^(c2) and R^(d2) are independently selected from H, C₁₋₁₀ alkyl,C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, Cy² and Cy²-(C₁₋₆ alkyl)-,wherein said C₁₋₁₀ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, and C₂₋₆alkynyl, is optionally substituted with 1, 2, or 3, substitutentsindependently selected from halo, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄alkynyl, C₁₋₄ haloalkyl, halosulfanyl, CN, NO₂, OR^(a3), SR^(a3),C(O)R^(b3), C(O)NR^(e3)R^(d3), C(O)OR^(a3), OC(O)R^(b3),OC(O)NR^(c3)R^(d3), NR^(a3)R^(d3), NR^(b3)C(O)R^(b3),NR^(a3)C(O)OR^(a3), C(═NR^(i))NR^(c3)R^(d3),NR^(c3)C(═NR^(i))NR^(c3)R^(d3), P(R^(f3))₂, P(OR^(e3))₂,P(O)R^(e3)R^(f3), P(O)OR^(e3)OR^(f3), S(O)R^(b3), S(O)NR^(c3)R^(d3),S(O)₂R^(b3), and S(O)₂NR^(c3)R^(d3); or R^(c2) and R^(d2) together withthe N atom to which they are attached form a 4-, 5-, 6- or 7-memberedheterocycloalkyl group optionally substituted with 1, 2, or 3,substitutents independently selected from Cy², Cy²-(C₁₋₆ alkyl)-, halo,C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, halosulfanyl,CN, NO₂, OR^(a3), SR^(a3), C(O)R^(b3), C(O)NR^(c3)R^(d3), C(O)OR^(a3),OC(O)R^(b3), OC(O)NR^(c3)R^(d3), NR^(c3)R^(d3), NR^(c3)C(O)R^(b3),NR^(c3)C(O)OR^(a3), C(═NR^(i))NR^(c3)R^(d3),NR^(c3)C(═NR^(i))NR^(c3)R^(d3), P(R^(f3))₂, P(OR^(e3))₂,P(O)R^(e3)R^(f3), P(O)ORe^(e3)OR^(f3), S(O)R^(b3), S(O)NR^(c3)R^(d3),S(O)₂NR^(c3)R^(d3); R^(c3) and R^(d3) are independently selected from H,C₁₋₁₀ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl,heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl,cycloalkylalkyl, and heterocycloalkylalkyl, wherein said C₁₋₁₀ alkyl,C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, heteroaryl,cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl,cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted withOH, amino, halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, aryl, arylalkyl,heteroaryl, heteroarylalkyl, cycloalkyl, or heterocycloalkyl; or R^(c3)and R^(d3) together with the N atom to which they are attached form a4-, 5-, 6- or 7-membered heterocycloalkyl group; R^(c4) and R^(d4) areindependently selected from H, C₁₋₁₀ alkyl, C₁₋₆ haloalkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl,arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl,wherein said C₁₋₁₀ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl,heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl isoptionally substituted with OH, amino, halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl,aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, orheterocycloalkyl; or R^(c4) and R^(d4) together with the N atom to whichthey are attached form a 4-, 5-, 6- or 7-membered heterocycloalkylgroup; R^(c5) and R^(d5) are independently selected from H, C₁₋₁₀ alkyl,C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, heteroaryl,cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl,cycloalkylalkyl, and heterocycloalkylalkyl, wherein said C₁₋₁₀ alkyl,C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, heteroaryl,cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl,cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted withOH, amino, halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, aryl, arylalkyl,heteroaryl, heteroarylalkyl, cycloalkyl, or heterocycloalkyl; or R^(c5)and R^(d5) together with the N atom to which they are attached form a4-, 5-, 6- or 7-membered heterocycloalkyl group; R^(e), R^(e1), R^(e2),R^(e3), R^(e4), and R^(e5) are independently selected from H, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, (C₁₋₆ alkoxy)-C₁₋₆ alkyl, C₂₋₆alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl,cycloalkylalkyl, heteroarylalkyl, and heterocycloalkylalkyl; R^(f),R^(f1), R^(f2), R^(f3), R^(f4), and R^(f5) are independently selectedfrom H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl,cycloalkyl, heteroaryl, and heterocycloalkyl; R^(i) is H, CN, C(O)NH₂,or NO₂; R′ is H, halo, C₁₋₁₀ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, Cy,Cy-(C₁₋₆ alkyl)-, CN, NO₂, OR^(a3), SR^(a3), C(O)R^(b3),C(O)NR^(c3)R^(d3), C(O)OR^(a3), OC(O)R^(b3), OC(O)NR^(e3)R^(d3),NR^(c3)R^(d3), NR^(a3)C(O)R^(b3), NR^(a3)C(O)OR^(a3), S(O)R^(b3),S(O)NR^(c3)R^(d3), S(O)₂R^(b3), or S(O)₂NR^(c3)R^(d3); wherein saidC₁₋₁₀ alkyl, C₂₋₆ alkenyl, or C₂₋₆ alkynyl is optionally substitutedwith 1, 2, 3, 4, or 5 substituents independently selected from CN, NO₂,Cy, Cy-(C₁₋₆ alkyl)-, OR^(a3), SR^(a3), C(O)R^(b3), C(O)NR^(c3)R^(d3),C(O)OR^(a3), OC(O)R^(b3), OC(O)NR^(c3)R^(d3), NR^(c3)R^(d3),NR^(c3)C(O)R^(b3), NR^(c3)C(O)OR^(a3), C(═NR^(i))NR^(c3)R^(d3),NR^(c3)C(═NR^(i))NR^(c3)R^(d3), P(R^(f3))₂, P(OR^(e3))₂,P(O)R^(e3)R^(f3), P(O)ORe³OR^(f3), S(O)R^(b3), S(O)NR^(c3)R^(d3),S(O)₂R^(b3), and S(O)₂NR^(c3)R^(d3); R″ is H, C₁₋₁₀ alkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, Cy, Cy-(C₁₋₆ alkyl)-, C(O)R^(b3), C(O)NR^(c3)R^(d3),C(O)OR^(a3), S(O)R^(b3), S(O)NR^(c3)R^(d3), S(O)₂R^(b3), orS(O)₂NR^(c3)R^(d3); wherein said C₁₋₁₀ alkyl, C₂₋₆ alkenyl, or C₂₋₆alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituentsindependently selected from CN, NO₂, Cy, —(C₁₋₆ alkyl)-Cy, OR^(a3),SR^(a3), C(O)R^(b3), C(O)NR^(c3)R^(d3), C(O)OR^(a3), OC(O)R^(b3),OC(O)NR^(c3)R^(d3), NR^(c3)R^(d3), NR^(c3)C(O)R^(b3),NR^(c3)C(O)OR^(a3), C(═NR^(i))NR^(c3)R^(d3),NR^(c3)C(═NR^(i))NR^(c3)R^(d3), P(R^(f3))₂, P(OR^(e3))₂,P(O)R^(e3)R^(f3), P(O)OR^(e3)OR^(f3), S(O)R^(b3), S(O)NR^(c3)R^(d3),S(O)₂R^(b3), and S(O)₂NR^(c3)R^(d3); and p is 1, 2, 3, 4, 5, 6, 7, 8, 9or
 10. 2-5. (canceled)
 6. The method of claim 1, wherein U and W areboth N and V is O. 7-8. (canceled)
 9. The method of claim 1, wherein Ais aryl or heteroaryl, each optionally substituted by 1, 2, 3, 4, or 5substituents selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆ cyanoalkyl, Cy¹, CN, NO₂,OR^(a), SR^(a), C(O)R^(b), C(O)NR^(c)R^(d), C(O)OR^(a), OC(O)R^(b),OC(O)NR^(c)R^(d), NR^(c)R^(d), NR^(c)C(O)R^(b), NR^(c)C(O)NR^(c)R^(d),NR^(c)C(O)OR^(a), C(═NR^(i))NR^(c)R^(d), NR^(c)C(═NR^(i))NR^(c)R^(d),P(R^(f))₂, P(OR^(e))₂, P(O)R^(e)R^(f), P(O)OR^(e)R^(f), S(O)R^(b),S(O)NR^(c)R^(d), S(O)₂R^(b), NR^(c)S(O)₂R^(b), and S(O)₂NR^(c)R^(d),wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl is optionallysubstituted with 1, 2, or 3 substitutents selected from Cy¹, CN, NO₂,OR^(a), SR^(a), C(O)R^(b), C(O)NR^(c)R^(d), C(O)OR^(a), OC(O)R^(b),OC(O)NR^(c)R^(d), NR^(c)R^(d), NR^(c)C(O)R^(b), NR^(c)C(O)NR^(c)R^(d),NR^(c)C(O)OR^(a), C(═NR^(i))NR^(c)R^(d), NR^(c)C(═NR^(i))NR^(c)R^(d),P(R^(f))₂, P(OR^(e))₂, P(O)R^(e)R^(f), P(O)OR^(e)OR^(f), S(O)R^(b),S(O)NR^(c)R^(d), S(O)₂R^(b), NR^(c)S(O)₂R^(b), and S(O)₂NR^(c)R^(d). 10.(canceled)
 11. The method of claim 1, wherein A is phenyl optionallysubstituted by 1, 2, 3, 4, or 5 substituents selected from halo, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆ cyanoalkyl, CN, NO₂,OR^(a), SR^(a), C(O)R^(b), C(O)NR^(c)R^(d), C(O)OR^(a), OC(O)R^(b),OC(O)NR^(c)R^(d), NR^(c)R^(d), NR^(c)C(O)R^(b), NR^(c)C(O)NR^(c)R^(d),NR^(e)C(O)OR^(a), S(O)R^(b), S(O)NR^(c)R^(d), S(O)₂R^(b),NR^(c)S(O)₂R^(b), and S(O)₂NR^(c)R^(d).
 12. The method of claim 1,wherein A is phenyl optionally substituted by 1, 2, 3, 4, or 5substituents selected from halo, C₁₋₆ alkyl, and C₁₋₆ haloalkyl. 13-14.(canceled)
 15. The method of claim 1, wherein Q is OR^(Q).
 16. Themethod of claim 1, wherein Q is NR⁴R^(Q). 17-23. (canceled)
 24. Themethod of claim 1, wherein R^(Q) is C₁₋₆ alkyl optionally substituted by1, 2, 3, 4, or 5 substituents selected from halo, C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, hydroxyalkyl, C₁₋₆ cyanoalkyl,Cy, —(C₁₋₄ alkyl)-Cy, CN, NO₂, OR^(a2), SR^(a2), C(O)R^(b2),C(O)NR^(c2)R^(d2), C(O)OR^(a2), OC(O)R^(b2), OC(O)NR^(c2)R^(d2),NR^(C2)R^(d2), NR^(c2)C(O)R^(b2), NR^(c2)C(O)NR^(c2)R^(d2),NR^(c2)C(O)OR^(a2), C(═NR^(i))NR^(c2)R^(d2),NR^(c2)C(═NR^(i))NR^(c2)R^(d2), P(R^(f2))₂, P(OR^(e2))₂,P(O)R^(e2)R^(f2), P(O)OR^(e2)OR^(f2), S(O)R^(b2), S(O)NR^(c2)R^(d2),S(O)₂R^(b2), NR^(c2)S(O)₂R^(b2), and S(O)₂NR^(c2)R^(d2).
 25. The methodof claim 1, wherein R^(Q) is aryl, heteroaryl, arylalkyl, orheteroarylalkyl, each optionally substituted by 1, 2, 3, 4, or 5substituents selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆ cyanoalkyl, Cy, —(C₁₋₄alkyl)-Cy, CN, NO₂, OR^(a2), SR^(a2), C(O)R^(b2), C(O)NR^(c2)R^(d3),C(O)OR^(a2), OC(O)R^(b2), OC(O)NR^(c2)R^(d2), NR^(c2)R^(d2),NR^(c2)C(O)R^(b2), NR^(c2)C(O)NR^(c2)R^(d2), NR^(c2)C(O)OR^(a2),C(═NR^(i))NR^(c2)R^(d2), NR²C(═NR^(i))NR^(c2)R^(d2), P(R^(f2))₂,P(OR^(e2))₂, P(O)R^(e2)R^(f2), P(O)OR^(e2)OR^(f2), S(O)R^(b2),S(O)NR^(c2)R^(d2), S(O)₂R^(b2), NR^(c2)S(O)₂R^(b2), andS(O)₂NR^(c2)R^(d2).
 26. (canceled)
 27. The method of claim 1, wherein R⁴is H.
 28. (canceled)
 29. The method of claim 1, or pharmaceuticallyacceptable salt thereof, wherein R^(A) and R^(B) are both H.
 30. Themethod of claim 1, wherein R¹ is H.
 31. The method of claim 1, wherein Ris H. 32-37. (canceled)
 38. The method of claim 1, wherein the compoundis a compound having Formula IIa:

or pharmaceutically acceptable salt thereof.
 39. The method of claim 1,wherein the compound is a compound having Formula II:

or pharmaceutically acceptable salt thereof.
 40. The method of claim 1,wherein the compound is a compound having Formula III:

or pharmaceutically acceptable salt thereof.
 41. The method of claim 1,wherein the compound is selected from:N-(3-chloro-4-fluoro-phenyl)-N′-hydroxy-4-hydroxymethyl-furazan-3-carboxamidine;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-(phenoxymethyl)-1,2,5-oxadiazole-3-carboximidamide;4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-ylmethylphenylcarbamate;4-[(benzylamino)methyl]-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-[(2-chlorophenoxy)methyl]-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-[(3-chlorophenoxy)methyl]-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-[(4-chlorophenoxy)methyl]-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[(2-methoxyphenoxy)methyl]-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[(3-methoxyphenoxy)methyl]-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[(4-methoxyphenoxy)methyl]-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-[(3-cyanophenoxy)methyl]-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-[(4-chloro-2-methoxyphenoxy)methyl]-N′-hydroxy-1,2,5-oxa-diazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-[(3,4-dimethoxyphenoxy)methyl]-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;{4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}methylphenylcarbamate;{4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}methylisopropylcarbamate;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-(piperidin-1-ylmethyl)-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-[(dimethylamino)methyl]-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[(4-phenylpiperazin-1-yl)methyl]-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[(isoxazol-3-ylamino)methyl]-1,2,5-oxadiazole-3-carboximidamide;4-{[(1-benzylpiperidin-4-yl)amino]methyl}-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxa-diazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{[4-(2-methoxyphenyl)piperazin-1-yl]methyl}-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{[(pyridin-2-ylmethyl)amino]methyl}-1,2,5-oxa-diazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{[(2-phenylethyl)amino]methyl}-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{[(3-phenylpropyl)amino]methyl}-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-({[(1R)-1-phenylethyl]amino}methyl)-1,2,5-oxa-diazole-3-carboximidamide;4-{[(2-chlorobenzyl)amino]methyl}-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{[(4-phenylbutyl)amino]methyl}-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-(3,4-dihydroisoquinolin-2(1H)-ylmethyl)-N-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-(2,3-dihydro-1H-indol-1-ylmethyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N-hydroxy-4-(morpholin-4-ylmethyl)-1,2,5-oxadiazole-3-carboximidamide;3-(4-[(2-morpholin-4-ylethyl)amino]methyl-1,2,5-oxadiazol-3-yl)-4-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5(4H)-one;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[(methylsulfonyl)(2-morpholin-4-ylethyl)amino]-methyl-1,2,5-oxadiazole-3-carboximidamide;N-{4-[N-(3-chloro-4-fluoro-phenyl)-N′-hydroxy-carbamimidoyl]-furazan-3-ylmethyl}-benzamide;N-(3-chloro-4-fluoro-phenyl)-N′-hydroxy-4-[(3-phenyl-ureido)-methyl]-furazan-3-carboxamidine;4-(benzenesulfonylamino-methyl)-N-(3-chloro-4-fluoro-phenyl)-N′-hydroxy-furazan-3-carboxamidine;benzyl({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}methyl)carbamate;N-(3-cyanophenyl)-N′-hydroxy-4-methyl-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-methyl-1,2,3-thiadiazole-5-carboximidamide;4-[(5-amino-1H-tetrazol-1-yl)methyl]-N-(3-chloro-4-fluorophenyl)-N-hydroxy-1,2,5-oxadiazole-3-carboximidamide;4-[(5-amino-2H-tetrazol-2-yl)methyl]-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[(1H-tetrazol-5-ylamino)methyl]-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-({[3-(1H-imidazol-1-yl)propyl]amino}methyl)-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{[(2-morpholin-4-ylethyl)amino]methyl}-1,2,5-oxadiazole-3-carboximidamide;{4-[({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}-methyl)amino]phenyl}aceticacid;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[(4-hydroxyppiperidin-1-yl)methyl]-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{[4-(2-hydroxyethyl)piperazin-1-yl]methyl}-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-({[(1R)-2-hydroxy-1-phenylethyl]amino}methyl)-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{[(2-hydroxyethyl)amino]methyl}-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{[(2-pyridin-4-ylethyl)amino]methyl}-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{[(tetrahydrofuran-2-ylmethyl)amino]methyl}-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{[(1,3-thiazol-2-ylmethyl)amino]methyl}-1,2,5-oxadiazole-3-carboximidamide;4-({[4-(aminosulfonyl)benzyl]amino}methyl)-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;{4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}methyldimethylcarbamate;4-{[4-(aminosulfonyl)phenoxy]methyl}-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{[4-(methylsulfonyl)phenoxy]methyl}-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-(1H-imidazol-1-ylmethyl)-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4(1H-1,2,4-triazol-1-ylmethyl)-1,2,5-oxadiazole-3-carboximidamide;4-[({2-[4-(aminosulfonyl)phenyl]ethyl}amino)methyl]-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-(2H-tetrazol-2-ylmethyl)-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-(1H-tetrazol-1-ylmethyl)-1,2,5-oxadiazole-3-carboximidamide;{4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}methylmorpholine-4-carboxylate;2-[4-({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}-methoxy)phenyl]acetamide;4-(aminomethyl)-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;4-[(5-amino-1H-tetrazol-1-yl)methyl]-N-[3-(trifluoromethyl)phenyl]-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;4-[(5-benzyl-1H-tetrazol-1-yl)methyl]-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;4-[(5-benzyl-2H-tetrazol-2-yl)methyl]-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;[2-({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}-methyl)-2H-tetrazol-5-yl]aceticacid;N-(3-chloro-4-fluorophenyl)-4-(cyanomethyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[(2-oxo-1,3-oxazolidin-3-yl)methyl]-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-({[2-(dimethylamino)ethyl]amino}methyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{[(3-morpholin-4-ylpropyl)amino]methyl}-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[(5-pyridin-4-yl-2H-tetrazol-2-yl)methyl]-1,2,5-oxadiazole-3-carboximidamide;4-({[4-(aminosulfonyl)benzyl]amino}methyl)-N-[3-(trifluoromethyl)phenyl]-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-[3-(trifluoromethyl)phenyl]-N′-hydroxy-4-(1H-tetrazol-1-ylmethyl)-1,2,5-oxadiazole-3-carboximidamide;N-[3-(trifluoromethyl)phenyl]-N′-hydroxy-4-(2H-tetrazol-2-ylmethyl)-1,2,5-oxadiazole-3-carboximidamide;N-[3-(trifluoromethyl)phenyl]-N′-hydroxy-4-{[(2-morpholin-4-ylethyl)amino]methyl}-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{[(pyridin-3-ylmethyl)amino]methyl}-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{[(2-pyrrolidin-1-ylethyl)amino]methyl}-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-({[2-(1H-imidazol-4-yl)ethyl]amino}methyl)-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-({[2-(2-oxopyrrolidin-1-yl)ethyl]amino}methyl)-1,2,5-oxadiazole-3-carboximidamide;N-(3-choro-4-fluorophenyl)-N′-hydroxy-4-[(5-methyl-1H-tetrazol-1-yl)methyl]-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[(5-methyl-2H-tetrazol-2-yl)methyl]-1,2,5-oxadiazole-3-carboximidamide;N-({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}-methyl)-N-(2-morpholin-4-ylethyl)acetamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{[5-(methylthio)-2H-tetrazol-2-yl]methyl}-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{[5-(methylthio)-1H-tetrazol-1-yl]methyl}-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[(5-phenyl-1H-tetrazol-1-yl)methyl]-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[(5-phenyl-2H-tetrazol-2-yl)methyl]-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-({5-[3-(trifluoromethoxy)phenyl]-2H-tetrazol-2-yl}methyl)-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[(5-pyridin-3-yl-2H-tetrazol-2-yl)methyl]-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[(5-pyrrolidin-1-yl-2H-tetrazol-2-yl)methyl]-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-({5-[3-(trifluoromethoxy)phenyl]-1H-tetrazol-1-yl}-methyl)-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[(5-pyridin-2-yl-1H-tetrazol-1-yl)methyl]-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[(5-pyrrolidin-1-yl-1H-tetrazol-1-yl)methyl]-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-{[5-(4-fluorophenyl)-1H-tetrazol-1-yl]methyl}-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-({5-[2-(dimethylamino)ethyl]-1H-tetrazol-1-yl}methyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamideN-(3-chloro-4-fluorophenyl)-4-{[5-(4-fluorophenyl)-2H-tetrazol-2-yl]methyl}-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-({5-[2-(4-chlorophenoxy)ethyl]-2H-tetrazol-2-yl}methyl)-N-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-({5-[5-(trifluoromethyl)pyridin-2-yl]-2H-tetrazol-2-yl}methyl)-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-({5-[2-(4-chlorophenoxy)ethyl]-1H-tetrazol-1-yl}methyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-[({2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]ethyl}amino)methyl]-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-({[2-(2-methylpiperidin-1-yl)ethyl]amino}methyl)-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-{[(1,1-dimethyl-2-morpholin-4-ylethyl)amino]methyl}-N-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{[(2-piperazin-1-ylethyl)amino]methyl}-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-({[(1-ethylpyrrolidin-2-yl)methyl]amino}methyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-({[2-(dimethylamino)propyl]amino}methyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{[(2-methyl-2-morpholin-4-ylpropyl)amino]methyl}-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{[(2-methyl-2-piperidin-1-ylpropyl)amino]methyl}-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{[(piperidin-2-ylmethyl)amino]methyl}-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-({[2-(1,1-dioxidothiomorpholin-4-yl)ethyl]-amino}-methyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[(piperidin-3-ylamino)methyl]-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{[(pyrrolidin-3-ylmethyl)amino]methyl}-1,2,5-oxadiazole-3-carboximidamide;N-({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}-methyl)-2-methylpropanamide;N-({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}-methyl)-2,2-dimethylpropanamide;N-({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}-methyl)-2-phenylacetamide;N-({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}-methyl)-3-phenylpropanamide;N-({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}-methyl)-1,3-thiazole-5-carboxamide;N-({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}-methyl)cyclopentanecarboxamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{[(methylsulfonyl)amino]methyl}-1,2,5-oxadiazole-3-carboximidamide;4-({[(benzylamino)carbonyl]amino}methyl)-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[({[(2-phenylethyl)-amino]carbonyl}-amino)methyl]-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-({[(isopropylamino)-carbonyl]amino}-methyl)-1,2,5-oxadiazole-3-carboximidamide;N-({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}-methyl)morpholine-4-carboxamide;N-(3-chloro-4-fluorophenyl)-4-({[(dimethylamino)carbonyl]amino}methyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}methyl)acetamide;methyl({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}methyl)carbamate;isobutyl({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}methyl)carbamate;benzyl({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}methyl)carbamate;N-(3-chloro-4-fluorophenyl)-4-[(ethylsulfonyl)amino]methyl1-N-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(5-{[({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}methyl)amino]sulfonyl}-4-methyl-1,3-thiazol-2-yl)acetamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{[({5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-2-thienyl}sulfonyl)amino]methyl}-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-({[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino}-methyl)-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-({[(2,4-dimethyl-1,3-thiazol-5-yl)sulfonyl]amino}methyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-({[(3,5-dimethylisoxazol-4-yl)sulfonyl]amino}methyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-({[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfonyl]amino}-methyl)-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-({[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]amino}methyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{[(propylsulfonyl)amino]methyl}-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-{[(cyclopropylsulfonyl)amino]methyl}-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{[(3-methylisothiazol-5-yl)amino]methyl}-1,2,5-oxadiazole-3-carboximidamide;ethyl3-4-[(Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-ylpropanoate;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-(3-morpholin-4-ylpropyl)-1,2,5-oxadiazole-3-carboximidamide;5-[(5-amino-1H-tetrazol-1-yl)methyl]-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,3-thiadiazole-4-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-5-(hydroxymethyl)-1,2,3-thiadiazole-4-carboximidamide;4-[(aminosulfonyl)amino]methyl-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-([(E/Z)-(cyanoimino)(methylamino)methyl]aminomethyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-([(methylamino)-sulfonyl]aminomethyl)-1,2,5-oxadiazole-3-carboximidamide;4-[(aminocarbonyl)amino]methyl-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;4-([(tert-butylamino)carbonyl]aminomethyl)-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-([(3-morpholin-4-ylpropyl)sulfonyl]aminomethyl)-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[(piperidin-4-ylsulfonyl)amino]methyl-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate;4-[([1-(aminosulfonyl)piperidin-4-yl]sulfonylamino)methyl]-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;4-([(1-acetylpiperidin-4-yl)sulfonyl]aminomethyl)-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[5-(morpholin-4-ylmethyl)-2H-tetrazol-2-yl]methyl-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[5-(morpholin-4-ylmethyl)-1H-tetrazol-1-yl]methyl-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate;4-[(5-amino-1,3,4-thiadiazol-2-yl)thio]methyl-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;4-[(5-amino-4H-1,2,4-triazol-3-yl)thio]methyl-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;4-[(5-amino-4H-1,2,4-triazol-3-yl)sulfonyl]methyl-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-[({(E/Z)-(cyanoimino)[(4-methoxybenzyl)amino]methyl}amino)-methyl]-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate;4-[({(E/Z)-[(aminocarbonyl)imino][(4-methoxybenzyl)amino]methyl}amino)methyl]-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;4-({[(E/Z)-amino(nitroimino)methyl]amino}methyl)-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate;4-({[amino(imino)methyl]amino}methyl)-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-(4H-1,2,4-triazol-4-ylmethyl)-1,2,5-oxadiazole-3-carboximidamide;4-[2-(5-amino-1H-tetrazol-1-yl)ethyl]-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;4-[2-(5-amino-2H-tetrazol-2-yl)ethyl]-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[2-(1H-imidazol-1-yl)ethyl]-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-(2-morpholin-4-ylethyl)-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[2-(4-methylpiperazin-1-yl)ethyl]-1,2,5-oxadiazole-3-carboximidamidebis(trifluoroacetate);N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[2-(4H-1,2,4-triazol-4-yl)ethyl]-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[2-(1H-1,2,4-triazol-1-yl)ethyl]-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[2-(1H-tetrazol-1-yl)ethyl]-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[2-(2H-tetrazol-2-yl)ethyl]-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-vinyl-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-[2-(dimethylamino)ethyl]-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-(2-thiomorpholin-4-ylethyl)-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-(2-pyrrolidin-1-ylethyl)-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{2-[isopropyl(methyl)amino]ethyl}-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-{2-[(methylsulfonyl)amino]ethyl}-1,2,5-oxadiazole-3-carboximidamide;4-{2-[(aminosulfonyl)amino]ethyl}-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;4-{[(aminosulfonyl)amino]methyl}-N-(3-bromo-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;4-{[(aminosulfonyl)amino]methyl}-N′-hydroxy-N-[3-(trifluoromethyl)phenyl]-1,2,5-oxadiazole-3-carboximidamide;N-({4-[(E/Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}-methyl)-N′-cyanomorpholine-4-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-[({(E/Z)-(cyanoimino)[(2-morpholin-4-ylethyl)amino]methyl}amino)methyl]-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;4-[({(E/Z)-[(aminocarbonyl)imino][(2-morpholin-4-ylethyl)amino]methyl}amino)methyl]-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-{[((E/Z)-(cyanoimino){[2-(dimethylamino)ethyl]amino}methyl)-amino]methyl}-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-{[((E/Z)-(cyanoimino){[2-(1H-imidazol-5-yl)ethyl]amino}-methyl)amino]methyl}-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;4-{[((E/Z)-[(aminocarbonyl)imino]{[2-(1H-imidazol-5-yl)ethyl]amino}methyl)amino]methyl}N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-[({(E/Z)-(cyanoimino)[(2-hydroxy-1-methylethyl)amino]methyl}-amino)methyl]-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-({[(E/Z)-(cyanoimino)(isopropylamino)methyl]amino}methyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate;N-(3-chloro-4-fluorophenyl)-4-[({(E/Z)-(cyanoimino)[(2-methoxy-1-methylethyl)amino]-methyl}amino)methyl]-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate;N-(3-chloro-4-fluorophenyl)-4-[({(E/Z)-(cyanoimino)[(2-methoxyethyl)amino]methyl}amino)-methyl]-N-hydroxy-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate;N-(3-chloro-4-fluorophenyl)-4-({[(E/Z)-(cyanoimino)(tetrahydro-2H-pyran-4-ylamino)methyl]-amino}methyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate;N-(3-chloro-4-fluorophenyl)-4-{[((E/Z)-(cyanoimino){[(1-ethylpyrrolidin-2-yl)methyl]amino}-methyl)amino]methyl}-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamidebis(trifluoroacetate);4-({[(E/Z)-amino(cyanoimino)methyl]amino}methyl)-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate;N-(3-chloro-4-fluorophenyl)-4-[({(E/Z)-(cyanoimino)[(2-hydroxyethyl)amino]methyl}amino)-methyl]-N-hydroxy-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate;N-(3-chloro-4-fluorophenyl)-4-({[(E/Z)-(cyanoimino)(dimethylamino)methyl]amino}methyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-({[(E/Z)-(cyanoimino)(ethylamino)methyl]amino}methyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-bromo-4-fluorophenyl)-4-({[(E/Z)-(cyanoimino)(ethylamino)methyl]amino}methyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;4-({[(E/Z)-(cyanoimino)(dimethylamino)methyl]amino}methyl)-N′-hydroxy-N-[3-(trifluoro-methyl)phenyl]-1,2,5-oxadiazole-3-carboximidamide;4-({[(E/Z)-(cyanoimino)(ethylamino)methyl]amino}methyl)-N′-hydroxy-N-[3-(trifluoromethyl)-phenyl]-1,2,5-oxadiazole-3-carboximidamide;N-(3-bromo-4-fluorophenyl)-4-({[(E/Z)-(cyanoimino)(dimethylamino)methyl]amino}methyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;4-({[(E/Z)-(cyanoimino)(methylamino)methyl]amino}methyl)-N′-hydroxy-N-[3-(trifluoro-methyl)phenyl]-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate;N-(3-bromo-4-fluorophenyl)-4-({[(E/Z)-(cyanoimino)(methylamino)methyl]amino}methyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;4-({[(E/Z)-amino(cyanoimino)methyl]amino}methyl)-N-(3-bromo-4-fluorophenyl)-N-hydroxy-1,2,5-oxadiazole-3-carboximidamide;4-({[(E/Z)-amino(cyanoimino)methyl]amino}methyl)-N′-hydroxy-N-[3-(trifluoromethyl)phenyl]-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-({[(isopropylamino)sulfonyl]amino}methyl)-1,2,5-oxadiazole-3-carboximidamide;N-(3-bromo-4-fluorophenyl)-N′-hydroxy-4-({[(methylamino)sulfonyl]amino}methyl)-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-({[(ethylamino)sulfonyl]amino}methyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-({[(dimethylamino)sulfonyl]amino}methyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-[3-(difluoromethyl)phenyl]-N′-hydroxy-4-(1H-tetrazol-1-ylmethyl)-1,2,5-oxadiazole-3-carboximidamide;N-[3-(difluoromethyl)phenyl]-N′-hydroxy-4-(2H-tetrazol-2-ylmethyl)-1,2,5-oxadiazole-3-carboximidamide;N′-hydroxy-4-(4H-1,2,4-triazol-4-ylmethyl)-N-[3-(trifluoromethyl)phenyl]-1,2,5-oxadiazole-3-carboximidamide;N-(3-bromo-4-fluorophenyl)-N′-hydroxy-4-(4H-1,2,4-triazol-4-ylmethyl)-1,2,5-oxadiazole-3-carboximidamide;4-[(5-amino-1H-tetrazol-1-yl)methyl]-N-(3-bromo-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;4-[(5-amino-2H-tetrazol-2-yl)methyl]-N-(3-bromo-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-({4-[(Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}-methyl)-1H-imidazole-2-carboxamidetrifluoroacetate;N-({4-[(Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}-methyl)-1H-pyrazole-4-carboxamidetrifluoroacetate;N-({4-[(Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}-methyl)-4-methyl-1,2,3-thiadiazole-5-carboxamide;N-({4-[(Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}-methyl)-1H-imidazole-4-carboxamidetrifluoroacetate;N-({4-[(Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}-methyl)-1,2,3-thiadiazole-4-carboxamide;5-amino-N-({4-[(Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}methyl)-1,3,4-thiadiazole-2-carboxamide;5-amino-N-({4-[(Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}methyl)-1H-pyrazole-4-carboxamide;4-(aminomethyl)-N-(3-bromo-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate;N-(3-bromo-4-fluorophenyl)-N′-hydroxy-4-{[(methylsulfonyl)amino]methyl}-1,2,5-oxadiazole-3-carboximidamide;4-(aminomethyl)-N′-hydroxy-N-[3-(trifluoromethyl)phenyl]-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate;N′-hydroxy-4-{[(methylsulfonyl)amino]methyl}-N-[3-(trifluoromethyl)phenyl]-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-({[(2,2,2-trifluoroethyl)sulfonyl]amino}methyl)-1,2,5-oxadiazole-3-carboximidamide;N-(3-bromo-4-fluorophenyl)-N′-hydroxy-4-(1H-tetrazol-1-ylmethyl)-1,2,5-oxadiazole-3-carboximidamide;[1-({4-[(Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}-methyl)-1H-tetrazol-5-yl]aceticacid;N-(3-chloro-4-fluorophenyl)-4-({[(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)sulfonyl]amino}-methyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-({[(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-sulfonyl]amino}methyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[3-(1H-tetrazol-1-yl)propyl]-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[3-(2H-tetrazol-2-yl)propyl]-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[3-(4H-1,2,4-triazol-4-yl)propyl]-1,2,5-oxadiazole-3-carboximidamide;4-{3-[(aminosulfonyl)amino]propyl}-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-4-(3-{[(E/Z)-(cyanoimino)(methylamino)methyl]amino}propyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate;4-[(3-amino-4H-1,2,4-triazol-4-yl)methyl]-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;4-[(5-amino-1H-1,2,4-triazol-1-yl)methyl]-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-[(1,3,4-thiadiazol-2-ylamino)methyl]-1,2,5-oxadiazole-3-carboximidamidetrifluoroacetate;N-[3-(difluoromethyl)phenyl]-N′-hydroxy-4-({[(methylamino)sulfonyl]amino}methyl)-1,2,5-oxadiazole-3-carboximidamide;4-[(5-amino-1H-tetrazol-1-yl)methyl]-N-[3-(difluoromethyl)phenyl]-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;4-[(5-amino-2H-tetrazol-2-yl)methyl]-N-(4-fluoro-3-methylphenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-[3-(difluoromethyl)phenyl]-N′-hydroxy-4-(1H-tetrazol-1-ylmethyl)-1,2,5-oxadiazole-3-carboximidamide;N-[3-(difluoromethyl)phenyl]-N′-hydroxy-4-(2H-tetrazol-2-ylmethyl)-1,2,5-oxadiazole-3-carboximidamide;N-[3-(difluoromethyl)phenyl]-N′-hydroxy-4-{[(methylsulfonyl)amino]methyl}-1,2,5-oxadiazole-3-carboximidamide;4-{[(aminosulfonyl)amino]methyl}-N-[3-(difluoromethyl)phenyl]-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-[3-(difluoromethyl)phenyl]-N′-hydroxy-4-({[(trifluoromethyl)sulfonyl]amino}methyl)-1,2,5-oxadiazole-3-carboximidamide;4-{[bis(methylsulfonyl)amino]methyl}-N-[3-(difluoromethyl)phenyl]-N-hydroxy-1,2,5-oxadiazole-3-carboximidamide;4-[(5-amino-1H-tetrazol-1-yl)methyl]-N-(4-fluoro-3-methylphenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;4-{[(6-aminohexyl)amino]methyl}-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;5-[({6-[({4-[(Z)-[(3-chloro-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl}-methyl)amino]hexyl}amino)carbonyl]-2-(7-hydroxy-3-oxo-3H-xanthen-9-yl)benzoicacid;N-(4-fluoro-3-methylphenyl)-N′-hydroxy-4-{[(methylsulfonyl)amino]methyl}-1,2,5-oxadiazole-3-carboximidamide;4-[2-(5-amino-1H-tetrazol-1-yl)ethyl]-N-(3-bromo-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-bromo-4-fluorophenyl)-N′-hydroxy-4-{2-[(methylsulfonyl)amino]ethyl}-1,2,5-oxadiazole-3-carboximidamide;4-{2-[(aminosulfonyl)amino]ethyl}-N-(3-bromo-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;and pharmaceutically acceptable salts thereof. 42-46. (canceled)
 47. Themethod of claim 1 further comprising administering an anti-viral agent,a chemotherapeutic, an immunosuppressant, radiation, an anti-tumorvaccine, an anti-viral vaccine, cytokine therapy, or a tyrosine kinaseinhibitor.
 48. The method of claim 1, wherein the cancer is melanoma.49. The method of claim 48 further comprising administering achemotherapeutic, radiation, an anti-tumor vaccine, or cytokine therapy.